CUMULATIVE
SUPPLEMENT 12

JAN'92-DEC'92

APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

12TH EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION

Prepared By
Division of Drug Information Resources
Office of Management
Center for Drug Evaluation and Research, FDA

APPROVED DRUG PRODUCTS with THERAPEUTIC EQUIVALENCE EVALUATIONS

12TH EDITION

Cumulative Supplement 12

December 1992

CONTENTS

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

12TH EDITION

CUMULATIVE SUPPLEMENT 12

DECEMBER 1992

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 12th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Additions new to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >ADD> to the left of the line on which new information exists. The >ADD> symbol is then dropped in subsequent Cumulative Supplements for that item. A newly approved product is also identified by a lozenge (◆) to the right of its strength which remains throughout all Cumulative Supplements for this edition.

Deletions new to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >DLT> (DELETE) to the left of the line containing overstruck print. The >DLT> symbol is dropped in subsequent Cumulative Supplements for that item. The overstruck print remains in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements for this edition. However, the overstruck print in the Patent and Exclusivity Data is dropped in subsequent Cumulative Supplements.

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the " ∂ " symbol to designate their non-marketed status. All products having a " ∂ " symbol in the 12th Cumulative Supplement of the 12th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 13th Edition.

1.2 CEFADROXIL/CEFADROXIL HEMIHYDRATE ACTIVE INGREDIENT HEADING

The active ingredient heading Cefadroxil/Cefadroxil Hemihydrate replaces the active ingredient heading Cefadroxil which is currently listed in the Approved Drug Products with Therapeutic Equivalence Evaluations, 12th Edition. All products which are listed under Cefadroxil (which is understood to be the monohydrate form) in the 12th Edition will now be listed along with the newly approved duplicate drug products under the new active ingredient, Cefadroxil/Cefadroxil Hemihydrate.

1.3 PRODUCTS REQUIRING REVISED LABELING FOR FULL APPROVAL

Drug products in this category (1) initially received approval only on the basis of safety before effectiveness studies were required, or (2) were conditionally approved under the temporary exemption that allowed these products to be marketed while effectiveness studies were being conducted. Listed below are those drugs which are now required to revise their labeling and provide additional information necessary for full approval on the basis of requirements listed in the Federal Register. As approval is granted by the Agency for a specific product, based on additional information submitted by the applicant, the product will be included in the appropriate Drug Product List.

Products	Federal Register Reference
Nitroglycerin (capsule, controlled release;oral)	SEP 7, 1984 (49 FR 35428)
Nitroglycerin (tablet, controlled release;oral)	SEP 7, 1984 (49 FR 35428)
Nitroglycerin (tablet, controlled release;buccal)	JUL 5, 1985 (50 FR 27688)
Tranylcypromine Sulfate	MAR 22, 1984 (49 FR 10708)

1.4 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant; or when an applicant changes its name; or when an applicant name is changed to meet internal publication standards. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial approved product lines are transferred between applicants, each approved product involved will appear as an applicant name change in the Cumulative Supplement.

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
BARNES HIND PHARMACEUTICALS INC (BARNES HIND)	SOLA BARNES HIND (SOLA BARNES HIND)

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
BEECHAM LABORATORIES DIV OF BEECHAM INC (BEECHAM)	SMITHKLINE BEECHAM PHARMACEUTICALS (SMITHKLINE BEECHAM)
DELMED INC (DELMED)	FRESENIUS USA INC (FRESENIUS)
MERCK SHARP AND DOHME RESEARCH LABS DIV MERCK AND CO INC (MSD)	MERCK RESEARCH LABORATORIES DIV MERCK AND CO INC (MERCK)
NORWICH EATON PHARMS INC SUB PROCTOR & GAMBLE CO (NORWICH EATON)	PROCTER & GAMBLE PHARMACEUTICALS INC (P&G)
OFFICE SURGEON GENERAL DEPT ARMY (DEPT ARMY)	OFFICE SURGEON GENERAL DEPT ARMY (US ARMY)
RECKITT AND COLMAN PHARMACEUTICALS INC (R & C)	RECKITT AND COLMAN PHARMACEUTICALS INC (RECKITT AND COLMAN)
SCHWARZ PHARMACEUTICALS INC (SCHWARZ)	SCHWARZ PHARMACEUTICALS INC (SCHWARZ PHARMA)
SMITH KLINE AND FRENCH LABS DIV SMITHKLINE BECKMAN CORP (SKF)	SMITHKLINE BEECHAM PHARMACEUTICALS (SMITHKLINE BEECHAM)
SOLOPAK LABORATORIES (SOLOPAK)	SMITH AND NEPHEW SOLOPAK DIVISION OF SMITH AND NEPHEW (SMITH NEPHEW SOLOPAK)
VICKS HEALTH CARE DIV RICHARDSON VICKS INC (VICKS HLTH CARE)	VICKS HEALTH CARE DIV RICHARDSON VICKS INC (VICKS HEALTH CARE)
WHITBY PHARMACEUTICALS INC (WHITBY PHARMS)	WHITBY PHARMACEUTICALS INC (WHITBY)
US CHEMICAL MARKETING GROUP INC (US CHEM MKTG)	US CHEMICAL MARKETING GROUP INC (US CHEM)

1.5 USP MONOGRAPH TITLE ADDITIONS OR CHANGES

The U.S. Pharmacopeia (USP) periodically makes additions to or changes in monograph titles. Some of these additions or changes may affect dosage form terms listed in *Approved Drug Products with Therapeutic Equivalence Evaluations* (ADP). Instead of making the change in each affected product, the Cumulative Supplement (CS) will list applicable monograph title and dosage form additions or changes in this section. These will appear as soon as the modified USP monograph title is official. It is possible for these additions or changes to be listed in this section before all applicant holders have made labeling modifications.

The monograph title additions or changes shown below will remain in this section in each succeeding supplement of this edition. Once the next edition of the ADP is published, the products affected by the title additions or changes will be displayed with the new dosage form in the appropriate drug list. As notification to the reader, these monograph title additions or changes will also be listed in a special section of the ADP.

USP MONOGRAPH TITLE ADDITIONS OR CHANGES

FORMER USP MONOGRAPH TITLE (FORMER ADP DOSAGE FORM; ROUTE)	NEW USP MONOGRAPH TITLE (NEW ADP DOSAGE FORM; ROUTE)
ACETAMINOPHEN AND CODEINE PHOSPHATE ELIXIR (ELIXIR; ORAL)	ACETAMINOPHEN AND CODEINE PHOSPHATE SOLUTION (SOLUTION; ORAL)
LACTULOSE SYRUP (SYRUP; ORAL)	LACTULOSE SOLUTION (SOLUTION; ORAL)
LACTULOSE SYRUP (SYRUP; ORAL, RECTAL)	LACTULOSE SOLUTION (SOLUTION; ORAL, RECTAL)
NONE (SYRUP; ORAL)	METOCLOPRAMIDE ORAL SOLUTION (SOLUTION; ORAL)
OXTRIPHYLLINE ELIXIR (ELIXIR; ORAL)	OXTRIPHYLLINE SOLUTION (SOLUTION; ORAL)

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1991) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 1991	JUN 1992	SEP 1992	DEC 1992
DRUG PRODUCTS LISTED	9584	9476	9501	9488
SINGLE SOURCE	2187 (22.8%)	2227 (23.5%)	2227 (23.4%)	2245 (23.7%)
MULTISOURCE	7397 (77.2%)	7249 (76.5%)	7274 (76.6%)	7243 (76.3%)
THERAPEUTICALLY EQUIVALENT	6580 (68.7%)	6494 (68.5%)	6518 (68.6%)	6516 (68.6%)
NOT THERAPEUTICALLY EQUIVALENT	664 (6.9%)	595 (6.3%)	590 (6.2%)	577 (6.1%)
EXCEPTIONS[1]	153 (1.6%)	160 (1.7%)	166 (1.8%)	150 (1.6%)
NEW MOLECULAR ENTITIES APPROVED	--	2	8	10
NUMBER OF APPLICANTS	430	455	471	477

[1]Amino acid-containing products of varying composition (see Introduction, page xvi of the List).

ACETAMINOPHEN; BUTALBITAL

CAPSULE; ORAL

> DLT >		/BANCAP/			
> DLT >	/AA/	/FOREST PHARMS/	/325MG;50MG/	/N88889/001/	
> DLT >				/JAN/16,/1986/	
> ADD >		∂ FOREST PHARMS	325MG;50MG	N88889 001	
> ADD >				JAN 16, 1986	

TABLE; ORAL

BUTAPAP

AB	MIKART	325MG;50MG¤	N89987 001	
			OCT 26, 1992	
AB		650MG;50MG¤	N89988 001	
			OCT 26, 1992	

SEDAPAP

AB	+ MAYRAND	650MG;50MG	N88944 001	
			OCT 17, 1985	

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

FIORICET W/ CODEINE

+ SANDOZ	325MG;50MG;40MG;30MG¤	N20232 001	
		JUL 30, 1992	

ACETAMINOPHEN; CODEINE PHOSPHATE

ELIXIR; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA	MIKART	120MG/5ML;12MG/5ML¤	N89450 001	
			OCT 27, 1992	

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA	PHARM BASICS	120MG/5ML;12MG/5ML	N87006 001	
	/TYLENOL AND CODEINE/			
/AA/	/PHARM BASICS/	/120MG/5ML;12MG/5ML/	/N87006/001/	

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

/AA/	/CHARLOTTE/	/300MG;15MG/	/N89990/001/	
			/SEP/30,/1988/	
/AA/		/300MG;30MG/	/N89805/001/	
			/SEP/30,/1988/	
/AA/		/300MG;60MG/	/N89828/001/	
			/SEP/30,/1988/	
	∂ EON LABS	300MG;15MG	N87433 001	
	∂	300MG;30MG	N85917 001	
	∂	300MG;60MG	N87423 001	

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA	GENEVA	300MG;30MG¤	N81250 001	
			JUL 16, 1992	
AA		300MG;60MG¤	N81249 001	
			JUL 16, 1992	
> DLT >	/∂/PARKE/DAVIS/	/300MG;15MG/	/N85992/001/	
> DLT >	/∂/	/300MG;30MG/	/N85218/002/	
AA	VINTAGE	300MG;15MG	N89990 001	
			SEP 30, 1988	
AA		300MG;30MG	N89805 001	
			SEP 30, 1988	
AA		300MG;60MG	N89828 001	
			SEP 30, 1988	
	/∂/VITARINE/	/300MG;15MG/	/N87433/001/	
	/∂/	/300MG;30MG/	/N85917/001/	
	/∂/	/300MG;60MG/	/N87423/001/	
> ADD >	∂ WARNER CHILCOTT	300MG;15MG	N85992 001	
> ADD >	∂	300MG;30MG	N85218 002	

ACETAMINOPHEN W/ CODEINE PHOSPHATE

/AA/	/CHELSEA/	/300MG;15MG/	/N87277/001/	
			/MAY/26,/1982/	
/AA/		/300MG;30MG/	/N87276/001/	
			/MAY/26,/1982/	
/AA/		/300MG;60MG/	/N87275/001/	
			/MAY/26,/1982/	
	∂ CHELSEA	300MG;15MG	N87277 001	
			MAY 26, 1982	
	∂	300MG;30MG	N87276 001	
			MAY 26, 1982	
	∂	300MG;60MG	N87275 001	
			MAY 26, 1982	

ACETAMINOPHEN; HYDROCODONE BITARTRATE

ELIXIR; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

MIKART	500MG/15ML;5MG/15ML¤	N81226 001	
		OCT 27, 1992	
	500MG/15ML;5MG/15ML¤	N89557 001	
		APR 29, 1992	
	500MG/15ML;7.5MG/15ML¤	N81051 001	
		AUG 28, 1992	

TABLET; ORAL

/HYCODAN/

/AA/	/CHARLOTTE/	/500MG;5MG/	/N89971/001/	
			/DEC/02,/1988/	

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

/AA/	/CHARLOTTE/	/500MG;5MG/	/N89831/001/	/SEP/07,/1988/
AA	MIKART	500MG;5MG¤	N89697 001	JAN 28, 1992
		650MG;10MG¤	N81223 001	MAY 29, 1992
/B¤/	/PHARM/BASICS/	/500MG;5MG/	/N89291/001/	/MAY/29,/1987/
	∂ PHARM BASICS	500MG;5MG	N89291 001	MAY 29, 1987

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	VINTAGE	500MG;5MG	N89831 001	SEP 07, 1988
AA		500MG;5MG	N89971 001	DEC 02, 1988

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL

PROPOXYPHENE HCL AND ACETAMINOPHEN

AA	MYLAN	650MG;65MG	N83978 001	
	∂	325MG;32MG	N83689 001	
	/PROPOXYPHENE HCL W/ APAP/			
/AA/	/MYLAN/	/650MG;65MG/	/N83978/001/	
		/325MG;32MG/	/N83689/001/	

ACETIC ACID, GLACIAL

SOLUTION/DROPS; OTIC

	/BOROFAIR/			
/AT/	/PHARMAFAIR/	/2%/	/N88606/001/	/AUG/21,/1985/

ACETIC ACID, GLACIAL; ALUMINUM ACETATE

SOLUTION/DROPS; OTIC

BOROFAIR

AT	PHARMAFAIR	2%;0.79%	N88606 001	AUG 21, 1985

DOMEBORO

AT	MILES	2%;0.79%	N84476 001	
	/2%;0.79%/		/N84476/001/	

ACETOHEXAMIDE

TABLET; ORAL

ACETOHEXAMIDE

/B¤/	/PHARM/BASICS/	/250MG/	/N70753/001/	/NOV/03,/1986/
/B¤/		/500MG/	/N70754/001/	/NOV/03,/1986/
	∂ PHARM BASICS	250MG	N70753 001	NOV 03, 1986
	∂	500MG	N70754 001	NOV 03, 1986

ACETYLCYSTEINE

SOLUTION; INHALATION, ORAL

ACETYLCYSTEINE

AN	CETUS BEN VENUE	10%¤	N72323 001	APR 30, 1992
AN		20%¤	N72324 001	APR 30, 1992
AN	ROXANE	10%¤	N72621 001	SEP 30, 1992
AN		20%¤	N72622 001	SEP 30, 1992

MUCOMYST

AN	APOTHECON	10%	N13601 002	
AN		20%	N13601 001	
/AN/	/HEAD/JOHNSON/	/10%/	/N13601/002/	
/AN/		/20%/	/N13601/001/	

MUCOSIL-10

AN	DEY	10%	N70575 001	OCT 14, 1986

MUCOSIL-20

AN	DEY	20%	N70576 001	OCT 14, 1986
/AN/	/MUCOSOL-10/ /DEY/	/10%/	/N70575/001/	/OCT/14,/1986/
/AN/	/MUCOSOL-20/ /DEY/	/20%/	/N70576/001/	/OCT/14,/1986/

ALBUTEROL SULFATE

SOLUTION; INHALATION

ALBUTEROL SULFATE

AN	DEY	EQ 0.083% BASE¤	N72652 001	FEB 21, 1992

ALBUTEROL SULFATE

SOLUTION; INHALATION

PROVENTIL

AN	SCHERING	EQ 0.083% BASE	N19243 002	JAN 14, 1987

VENTOLIN

AN	GLAXO	EQ 0.083% BASE*	N19773 001	APR 23, 1992

SYRUP; ORAL

ALBUTEROL SULFATE

AA	LEMMON	EQ 2MG BASE/5ML*	N73419 001	MAR 30, 1992

TABLET; ORAL

ALBUTEROL SULFATE

AB	MD PHARM	EQ 2MG BASE*	N73120 001	SEP 29, 1992
AB		EQ 4MG BASE*	N73121 001	SEP 29, 1992

TABLET, EXTENDED RELEASE; ORAL

PROVENTIL

> ADD >	AB	+ SCHERING	EQ 4MG BASE	N19383 001	JUL 13, 1987

VOLMAX

> ADD >	AB	GLAXO	EQ 4MG BASE*	N19604 002	DEC 23, 1992
> ADD >		+	EQ 8MG BASE*	N19604 001	DEC 23, 1992

ALGLUCERASE

INJECTABLE; INJECTION

CEREDASE

GENZYME	10 UNITS/ML*	N20057 004	MAY 08, 1992

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

/AB/	/BOLAR/	/100MG/	/N18241/001/	/NOV/16,/1984/
	∂ BOLAR	100MG	N18241 001	NOV 16, 1984

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN

AP	ELKINS SINN	EQ 50MG BASE/ML*	N63274 001	MAY 18, 1992
AP		EQ 250MG BASE/ML*	N63275 001	MAY 18, 1992

AMIKIN

AP	BRISTOL	EQ 50MG BASE/ML	N50495 001	
AP		EQ 50MG BASE/ML	N62562 001	SEP 20, 1984
AP		EQ 250MG BASE/ML	N50495 002	
AP		EQ 250MG BASE/ML	N62562 002	SEP 20, 1984

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

/AMINOSYN/4.25%/W//DEXTROSE/25%/IN/PLASTIC/CONTAINER/			
/ABBOTT/	/4.25%;25GM/100ML/	/N19119/001/	/OCT/11,/1984/
∂ ABBOTT	4.25%;25GM/100ML	N19119 001	OCT 11, 1984

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

/INJECTABLE;/INJECTION/			
/AMINOSYN/3.5%/N/			
/ABBOTT/	/3.5%;21MG/100ML;128MG/100ML;/ 234MG/100ML/	/N17789/001/	
∂ ABBOTT	3.5%;21MG/100ML;128MG/100ML; 234MG/100ML	N17789 001	

AMINOPHYLLINE

INJECTABLE; INJECTION

AMINOPHYLLINE

> ADD > AP	FUJISAWA	25MG/ML	N87200 001	
> ADD > AP		25MG/ML	N87886 001	AUG 30, 1983
> DLT > /AP/	/LYPHOMED/	/25MG/ML/	/N87200/001/	
/AP/		/25MG/ML/	/N87250/001/	/JAN/06,/1982/
> DLT > /AP/		/25MG/ML/	/N87886/001/	/AUG/30,/1983/
∂ LYPHOMED		25MG/ML	N87250 001	JAN 06, 1982

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AB	WARNER CHILCOTT	10MG	N83939 001	
		25MG	N83937 001	
		50MG	N83938 002	
		75MG	N84957 001	
		100MG	N85093 001	
		150MG	N86295 001	
BP	PAR	10MG	N88697 001	SEP 25, 1984
		25MG	N88698 001	SEP 25, 1984
		50MG	N88699 001	SEP 25, 1984
		75MG	N88700 001	SEP 25, 1984
		100MG	N88701 001	SEP 25, 1984
		150MG	N88702 001	SEP 25, 1984

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HCL

B*	PHARM BASICS	EQ 12.5MG BASE;5MG	N70477 001	JAN 12, 1988
B*		EQ 25MG BASE;10MG	N70478 001	JAN 12, 1988

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

PERPHENAZINE AND AMITRIPTYLINE HCL

	SCHEIN	4MG;10MG	N71556 001	MAR 02, 1987

AMLODIPINE BESYLATE

TABLET; ORAL

NORVASC

+	PFIZER	EQ 10MG BASE*	N19787 003	JUL 31, 1992
		EQ 2.5MG BASE*	N19787 001	JUL 31, 1992
		EQ 5MG BASE*	N19787 002	JUL 31, 1992

AMOXAPINE

TABLET; ORAL

AMOXAPINE

AB	DANBURY	25MG*	N72688 001	AUG 28, 1992
AB		50MG*	N72689 001	AUG 28, 1992
AB		100MG*	N72690 001	AUG 28, 1992
AB		150MG*	N72691 001	AUG 28, 1992

AMOXICILLIN

CAPSULE; ORAL

POLYMOX

AB	BRISTOL MYERS	250MG*	N63099 001	MAR 20, 1992
AB		500MG*	N63099 002	MAR 20, 1992
/AB/	/UTIMOX/ PARKE/DAVIS/	/250MG/	/N62107/001/	
/AB/		/500MG/	/N62107/002/	
	∂ PARKE DAVIS	250MG	N62107 001	
	∂	500MG	N62107 002	

POWDER FOR RECONSTITUTION; ORAL

AMOXICILLIN

/AB/	/CLONMEL/	/125MG/5ML/	/N62927/001/	/NOV/25,/1988/
/AB/		/250MG/5ML/	/N62927/002/	/NOV/25,/1988/
BX	CLONMEL	125MG/5ML	N62927 001	NOV 25, 1988
BX		250MG/5ML	N62927 002	NOV 25, 1988
/AB/	/UTIMOX/ PARKE/DAVIS/	/125MG/5ML/	/N62127/001/	
/AB/		/250MG/5ML/	/N62127/002/	
	∂ PARKE DAVIS	125MG/5ML	N62127 001	
	∂	250MG/5ML	N62127 002	

TABLET, CHEWABLE; ORAL

AMOXICILLIN

> ADD > AB	BIOCRAFT	250MG*	N64013 001	DEC 22, 1992

AMOXIL

> ADD > AB	+ SMITHKLINE BEECHAM	250MG	N50542 001	

AMPHETAMINE RESIN COMPLEX; DEXTROAMPHETAMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL

> DLT >	/DIPHETAMINE/T/S/			
> DLT >	/FISONS/	/EQ/3.75MG/BASE;/		
> DLT >		/EQ/3.75MG/BASE/	/N10093/009/	
> ADD >	∂ FISONS	EQ 3.75MG BASE;		
> ADD >		EQ 3.75MG BASE	N10093 009	

AMPHOTERICIN B

INJECTABLE; INJECTION

AMPHOTERICIN B

> ADD > AP	FUJISAWA	50MG/VIAL	N62728 001	APR 13, 1987
> ADD >				/N62728/001/
> DLT > /AP/	/LYPHOMED/	/50MG/VIAL/		/APR/13,/1987/
> DLT >				
AP	PHARMA TEK	50MG/VIAL*	N63206 001	APR 29, 1992

AMPICILLIN SODIUM

INJECTABLE; INJECTION

POLYCILLIN-N

/AP/	/BRISTOL/	/EQ/125MG/BASE/VIAL/	/N50309/001/	
/AP/		/EQ/250MG/BASE/VIAL/	/N50309/002/	
/AP/		/EQ/500MG/BASE/VIAL/	/N50309/003/	
/AP/		/EQ/1GM/BASE/VIAL/	/N50309/004/	
/AP/		/EQ/2GM/BASE/VIAL/	/N50309/005/	
	∂ BRISTOL	EQ 125MG BASE/VIAL	N50309 001	
	∂	EQ 250MG BASE/VIAL	N50309 002	
	∂	EQ 500MG BASE/VIAL	N50309 003	
	∂	EQ 1GM BASE/VIAL	N50309 004	
	∂	EQ 2GM BASE/VIAL	N50309 005	

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

/AMCILL/

/AB/	/PARKE/DAVIS/	/EQ/250MG/BASE/	/N62041/001/	
/AB/		/EQ/500MG/BASE/	/N62041/002/	
	∂ PARKE DAVIS	EQ 250MG BASE	N62041 001	
	∂	EQ 500MG BASE	N62041 002	

POLYCILLIN

/AB/	/BRISTOL/	/EQ/250MG/BASE/	/N50310/001/	
/AB/		/EQ/250MG/BASE/	/N61392/001/	
AB	+ BRISTOL	EQ 250MG BASE	N61392 001	
/AB/		/EQ/500MG/BASE/	/N50310/002/	
	∂	EQ 250MG BASE	N50310 001	
	∂	EQ 500MG BASE	N50310 002	

POWDER FOR RECONSTITUTION; ORAL

/AMCILL/

/AB/	/PARKE/DAVIS/	/EQ/125MG/BASE/5ML/	/N62030/001/	
/AB/		/EQ/250MG/BASE/5ML/	/N62030/002/	
	∂ PARKE DAVIS	EQ 125MG BASE/5ML	N62030 001	
	∂	EQ 250MG BASE/5ML	N62030 002	

AMPICILLIN/AMPICILLIN TRIHYDRATE

POWDER FOR RECONSTITUTION; ORAL

	POLYCILLIN			
/AB/	/BRISTOL/	/EQ 100MG BASE/ML/	/N50308/004/	
/AB/		/EQ 100MG BASE/ML/	/N61394/001/	
	∂ BRISTOL	EQ 100MG BASE/ML	N50308 004	
		EQ 100MG BASE/ML	N61394 001	

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

POWDER FOR RECONSTITUTION; ORAL

	POLYCILLIN-PRB			
/AB/	/+/BRISTOL/	/EQ 3.5GM BASE/BOT;/ 1GM/BOT/	/N50457/001/	
/AB/		/EQ 3.5GM BASE/BOT;/ 1GM/BOT/	/N61898/001/	
AB	+ BRISTOL	EQ 3.5GM BASE/BOT; 1GM/BOT	N61898 001	
	∂	EQ 3.5GM BASE/BOT; 1GM/BOT	N50457 001	

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

	BUTALBITAL, ASPIRIN AND CAFFEINE			
/AB/	/CHELSEA/	/325MG;50MG;40MG/	/N86231/002/ /FEB/12,/1985/	
	∂ CHELSEA	325MG;50MG;40MG	N86231 002 FEB 12, 1985	

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

>DLT>	/ORPHENADRINE/COMPOUND/			
>DLT>	/∂/EON/LABS/	/385MG;30MG;25MG/	/N71564/001/ /JUN/23,/1988/	
>DLT>				
>DLT>	/ORPHENADRINE/COMPOUND/DOUBLE/STRENGTH/			
>DLT>	/∂/EON/LABS/	/770MG;60MG;50MG/	/N71565/001/ /JUN/23,/1988/	
>DLT>				

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

	PROPOXYPHENE COMPOUND 65			
AA	EON LABS	389MG;32.4MG;65MG	N80044 002 SEP 16, 1983	
/AA/	/VITARINE/	/389MG;32.4MG;65MG/	/N80044/002/ /SEP/16,/1983/	

ASPIRIN; MEPROBAMATE

TABLET; ORAL

	MEPRO-ASPIRIN			
	∂ EON LABS	325MG;200MG	N89127 001 MAR 02, 1987	
	/∂/VITARINE/	/325MG;200MG/	/N89127/001/ /MAR/02,/1987/	

ATENOLOL

TABLET; ORAL

	ATENOLOL			
AB	APOTHECON	50MG*	N73317 001 MAR 20, 1992	
AB		100MG*	N73318 001 MAR 20, 1992	
AB	GENEVA	25MG*	N74052 001 MAY 01, 1992	
AB	IPR	25MG*	N73646 001 JUL 31, 1992	
AB	LEDERLE	25MG*	N74099 001 APR 28, 1992	
AB	MYLAN	50MG*	N73456 001 JAN 24, 1992	
AB		100MG*	N73457 001 JAN 24, 1992	
AB	SCHIAPPARELLI SEARLE	50MG*	N73676 001 OCT 30, 1992	
AB		100MG*	N73676 002 OCT 30, 1992	
	TENORMIN			
AB	ICI	25MG	N18240 004 APR 09, 1990	

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL

	ATENOLOL AND CHLORTHALIDONE			
AB	DANBURY	50MG;25MG*	N73665 001 JUL 02, 1992	
AB		100MG;25MG*	N73665 002 JUL 02, 1992	
	TENORETIC 100			
AB	+ ICI	100MG;25MG	N18760 001 JUN 08, 1984	
/AB/	/+/STUART/	/100MG;25MG/	/N18760/001/ /JUN/08,/1984/	
	TENORETIC 50			
AB	ICI	50MG;25MG	N18760 002 JUN 08, 1984	

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL
TENORETIC 50
AB STUART 50MG;25MG N18760 002 JUN 08, 1984

ATOVAQUONE

TABLET; ORAL
MEPRON
+ BURROUGHS WELLCOME 250MG* N20259 001 NOV 25, 1992

ATROPINE SULFATE

AEROSOL;METERED;INHALATION
ATROPINE SULFATE
US ARMY EQ 0.36MG BASE/INH N20056 001 SEP 19, 1990

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

SOLUTION; ORAL
> DLT > COLONAID
> DLT > AB WALLACE 0.025MG/5ML;2.5MG/5ML N85735 001
> ADD > ∂ WALLACE
LOMANATE
AB BARRE 0.025MG/5ML;2.5MG/5ML N85746 001
∂ BARRE

TABLET; ORAL
> DLT > COLONAID
> DLT > AB WALLACE 0.025MG;2.5MG N85737 001
> ADD > ∂ WALLACE

DIPHENOXYLATE HCL AND ATROPINE SULFATE
AB CHELSEA 0.025MG;2.5MG N85876 001
∂ CHELSEA
DIPHENOXYLATE HCL W/ ATROPINE SULFATE N86173 001
∂ EON LABS 0.025MG;2.5MG
∂ VITARINE

AZITHROMYCIN

CAPSULE;ORAL
ZITHROMAX
+ PFIZER 250MG N50670 001 NOV 01, 1991

AZITHROMYCIN DIHYDRATE

CAPSULE; ORAL
ZITHROMAX
+ PFIZER EQ 250MG BASE N50670 001 NOV 01, 1991

AZLOCILLIN SODIUM

INJECTABLE; INJECTION
AZLIN
MILES EQ 3GM/BASE/VIAL N62388 002 SEP 08, 1982
∂ MILES EQ 3GM BASE/VIAL
EQ 3GM/BASE/VIAL N62417 002 OCT 12, 1982
∂ EQ 3GM BASE/VIAL

BACLOFEN

INJECTABLE; INJECTION
LIORESAL
MEDTRONIC 0.5MG/ML* N20075 001 JUN 17, 1992
2MG/ML* N20075 002 JUN 17, 1992

TABLET; ORAL
BACLOFEN
AB BIOCRAFT 10MG* N73043 001 FEB 27, 1992
AB 20MG* N73044 001 FEB 27, 1992
> DLT > ∂ EON LABS 10MG N71901 001 APR 13, 1988
> DLT > ∂ 20MG N71902 001 APR 13, 1988
> DLT >
> DLT >

BACLOFEN

TABLET; ORAL
BACLOFEN

/B*/	/PHARM/BASICS/	/10MG/	/N71260/001/ /MAY/06,/1988/	
/B*/		/20MG/	/N71261/001/ /MAY/06,/1988/	
	∂ PHARM BASICS	10MG	N71260 001 MAY 06, 1988	
	∂	20MG	N71261 001 MAY 06, 1988	

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
LOTENSIN HCT

+	CIBA	20MG;25MG¤	N20033 003 MAY 19, 1992
		5MG;6.25MG¤	N20033 001 MAY 19, 1992
		10MG;12.5MG¤	N20033 002 MAY 19, 1992
		20MG;12.5MG¤	N20033 004 MAY 19, 1992

BENZTROPINE MESYLATE

TABLET; ORAL
BENZTROPINE MESYLATE

AA	MUTUAL PHARM	1MG¤	N81264 001 JAN 23, 1992
AA		2MG¤	N81265 001 JAN 23, 1992
/B*/	/PHARM/BASICS/	/0.5MG/	/N89211/001/ /JUN/14,/1988/
/B*/		/1MG/	/N89212/001/ /JUN/14,/1988/
/B*/		/2MG/	/N89213/001/ /JUN/14,/1988/
	∂ PHARM BASICS	0.5MG	N89211 001 JUN 14, 1988
	∂	1MG	N89212 001 JUN 14, 1988
	∂	2MG	N89213 001 JUN 14, 1988

BETAMETHASONE BENZOATE

> DLT >	/OINTMENT;/TOPICAL/			
> DLT >	/UTICORT/			
> DLT >	/*//PARKE/DAVIS/	/0.025%/		/N18089/001/
> ADD >	∂ PARKE DAVIS	0.025%		N18089 001

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL
BETAMETHASONE DIPROPIONATE

> DLT > /B*/	/CLAY/PARK/	/EQ/0.05%/BASE/		/N72536/001/ /JAN/31,/1990/
> DLT >				
> ADD >	∂ CLAY PARK	EQ 0.05% BASE		N72536 001 JAN 31, 1990
> ADD > AB	TARO	EQ 0.05% BASE¤		N73552 001 APR 30, 1992

OINTMENT; TOPICAL
BETAMETHASONE DIPROPIONATE

> DLT > /B*/	/CLAY/PARK/	/EQ/0.05%/BASE/		/N72526/001/ /JAN/31,/1990/
> DLT >				
> ADD >	∂ CLAY PARK	EQ 0.05% BASE		N72526 001 JAN 31, 1990

BETAMETHASONE VALERATE

CREAM; TOPICAL
BETAMETHASONE VALERATE

/AB/	/PHARMAFAIR/	/EQ 0.12 BASE/		/N70485/001/ /MAY/29,/1987/
	∂ PHARMAFAIR	EQ 0.1% BASE		N70485 001 MAY 29, 1987

OINTMENT; TOPICAL
BETAMETHASONE VALERATE

/AB/	/CLAY/PARK/	/EQ 0.12 BASE/		/N71478/001/ /DEC/23,/1987/
B*	CLAY PARK	EQ 0.1% BASE		N71478 001 DEC 23, 1987
/AB/	/PHARMAFAIR/	/EQ 0.12 BASE/		/N70486/001/ /MAY/29,/1987/
	∂ PHARMAFAIR	EQ 0.1% BASE		N70486 001 MAY 29, 1987

BETAXOLOL HYDROCHLORIDE; CHLORTHALIDONE

TABLET; ORAL
KERLEDEX
+ LOREX

10MG;12.5MG*	N19807 002	OCT 30, 1992
5MG;12.5MG*	N19807 001	OCT 30, 1992

BETHANECHOL CHLORIDE

TABLET; ORAL
BETHANECHOL CHLORIDE

	∂ EON LABS	5MG	N84353 001
	∂	10MG	N84378 001
	∂	10MG	N84379 001
> ADD >	∂	25MG	N84383 001
	∂	25MG	N84384 001
	/∂/VITARINE/	/5MG/	/N84353/001/
	/∂/	/10MG/	/N84378/001/
	/∂/	/10MG/	/N84379/001/
> DLT >	/∂/	/25MG/	/N84383/001/
	/∂/	/25MG/	/N84384/001/

BISOPROLOL FUMARATE

TABLET; ORAL
ZEBETA
+ LEDERLE

10MG*	N19982 001	JUL 31, 1992
5MG*	N19982 002	JUL 31, 1992

BITOLTEROL MESYLATE

SOLUTION; INHALATION
TORNALATE

/STERLING/	/0.2%/	/N19548/001/ /FEB/19/1992/
STERLING MINTHROP	0.2%*	N19548 001 FEB 19, 1992

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION
BRETYLIUM TOSYLATE

/AP/	/LYPHOMED/	/50MG/ML/	/N70134/001/ /FEB/12/1986/
	∂ LYPHOMED	50MG/ML	N70134 001 FEB 12, 1986

BROMPHENIRAMINE MALEATE

INJECTABLE; INJECTION
BROMPHENIRAMINE MALEATE

> DLT >/AP/	/STERIS/	/10MG/ML/	/N83821/001/
> ADD >	STERIS	10MG/ML	N83821 001
	/DIMETANE-TEN/		
> DLT >/AP/	/ROBINS/	/10MG/ML/	/N11418/002/
> ADD >	∂ WYETH AYERST	10MG/ML	N11418 002

TABLET; ORAL
BROMPHENIRAMINE MALEATE

/AA/	/PIONEER/PHARMS/	/4MG/	/N88604/001/ /JUL/13/1984/
	∂ PIONEER PHARMS	4MG	N88604 001 JUL 13, 1984

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION
BUPIVACAINE HCL KIT
ABBOTT

0.075%*	N19978 001	SEP 03, 1992
0.114%*	N19978 002	SEP 03, 1992
0.23%*	N19978 003	SEP 03, 1992

BUTABARBITAL SODIUM

> DLT >	/CAPSULE;ORAL/			
> DLT >	/BUTICAPS/			
> DLT >	/WALLACE/	/15MG/	/N85381/001/
> DLT >		/30MG/	/N85381/002/
> DLT >		/50MG/	/N85381/003/
> DLT >		/100MG/	/N85381/004/
> ADD >	∂ WALLACE	15MG	N85381 001
> ADD >	∂	30MG	N85381 002
> ADD >	∂	50MG	N85381 003
> ADD >	∂	100MG	N85381 004

BUTABARBITAL SODIUM

TABLET; ORAL
BUTABARBITAL SODIUM
ə EON LABS 15MG N85938 001
ə 30MG N85934 001
/ə/VITARINE/ /15MG/ /N85938/001/
/ə/ /30MG/ /N85934/001/
SODIUM BUTABARBITAL
/AA/ /WEST/WARD/ /15MG/ /N85418/001/
/AA/ /30MG/ /N85432/001/
ə WEST WARD 15MG N85418 001
ə 30MG N85432 001

BUTORPHANOL TARTRATE

SPRAY, METERED; NASAL
STADOL
+ BRISTOL MYERS SQUIBB 1MG/INH N19890 001
DEC 12, 1991
/1MG/INH/ /N19890/001/
/DEC/12/1991/

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER
FRESENIUS 18.4MG/100ML;1.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML¤ N20171 001
AUG 19, 1992

DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER
FRESENIUS 18.4MG/100ML;2.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML¤ N20171 002
AUG 19, 1992

DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER
FRESENIUS 18.4MG/100ML;4.25GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML¤ N20171 003
AUG 19, 1992

> ADD > DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER
> ADD > BAXTER 18.3MG/100ML;1.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML¤ N20183 001
> ADD > DEC 04, 1992
> ADD >
> ADD >

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL
> ADD > DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER
> ADD > BAXTER 18.3MG/100ML;2.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML¤ N20183 002
> ADD > DEC 04, 1992
> ADD >
> ADD > DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER
> ADD > BAXTER 18.3MG/100ML;3.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML¤ N20183 003
> ADD > DEC 04, 1992
> ADD >
> ADD > DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER
> ADD > BAXTER 18.3MG/100ML;4.25GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML¤ N20183 004
> ADD > DEC 04, 1992
> ADD >
> ADD > AT DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER
> ADD > BAXTER 25.7MG/100ML;1.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML¤ N20163 001
> ADD > DEC 04, 1992
> ADD >
> ADD > AT DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER
> ADD > BAXTER 25.7MG/100ML;2.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML¤ N20163 002
> ADD > DEC 04, 1992
> ADD >
> ADD > AT DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER
> ADD > BAXTER 25.7MG/100ML;4.25GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML¤ N20163 003
> ADD > DEC 04, 1992
> ADD >

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION
DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER
AP MCGAW 33MG/100ML;5GM/100ML;30MG/100ML; 860MG/100ML¤ N20000 001
APR 17, 1992

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION
RINGER'S IN PLASTIC CONTAINER
AP MCGAW 33MG/100ML;30MG/100ML; 860MG/100ML¤ N20002 001
APR 17, 1992

CARBAMAZEPINE

TABLET; ORAL

CARBAMAZEPINE

/AB/	/PARKE/DAVIS/	/200MG/	/N70429/001/ /JAN/02,/1987/
/B*/	/PHARM/BASICS/	/200MG/	/N70300/001/ /MAY/15,/1986/
	∂ PHARM BASICS	200MG	N70300 001 MAY 15, 1986
	∂ WARNER CHILCOTT	200MG	N70429 001 JAN 02, 1987

TABLET, CHEWABLE; ORAL

EPITOL

AB	LEMMON	100MG*	N73524 001 JUL 29, 1992

CARBIDOPA; LEVODOPA

TABLET; ORAL

CARBIDOPA AND LEVODOPA

AB	LEMMON	10MG;100MG*	N73618 001 AUG 28, 1992
AB		25MG;100MG*	N73589 001 AUG 28, 1992
AB		25MG;250MG*	N73607 001 AUG 28, 1992

SINEMET

AB	MSD	10MG;100MG	N17555 001
AB		25MG;100MG	N17555 003
AB	+	25MG;250MG	N17555 002

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

	∂ EON LABS	350MG	N89566 001 AUG 30, 1988
/B*/	/VITARINE/	/350MG/	/N89566/001/ /AUG/30,/1988/

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL

CEFADROXIL

AB	ZENITH	EQ 500MG BASE	N62766 001 MAR 03, 1987
/∂/		/EQ/500MG/BASE/	/N62766/001/ /MAR/03,/1987/

TABLET; ORAL

CEFADROXIL

AB	ZENITH	EQ 1GM BASE	N62774 001 APR 08, 1987
/∂/		/EQ/1GM/BASE/	/N62774/001/ /APR/08,/1987/

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

ZOLICEF

>ADD >	AP	APOTHECON	EQ 500MG BASE/VIAL	N62831 001 DEC 09, 1988
>ADD >	AP		EQ 1GM BASE/VIAL	N62831 002 DEC 09, 1988
>ADD >	AP		EQ 10GM BASE/VIAL*	N62831 003 SEP 25, 1992
>DLT >/AP/		/BRISTOL/MYERS/	/EQ 500MG BASE/VIAL/	/N62831/001/ /DEC/09,/1988/
>DLT >/AP/			/EQ 1GM BASE/VIAL/	/N62831/002/ /DEC/09,/1988/

CEFMETAZOLE SODIUM

INJECTABLE; INJECTION

ZEFAZONE IN PLASTIC CONTAINER

>ADD >	UPJOHN	EQ 20MG BASE/ML*	N50683 001 DEC 29, 1992
>ADD >		EQ 40MG BASE/ML*	N50683 002 DEC 29, 1992

CEFPODOXIME PROXETIL

GRANULE, FOR RECONSTITUTION; ORAL

/BANAN/

>DLT >/AB/	/SANKYO/	/EQ 50MG BASE/5ML*/	/N50688/002/ /AUG/07,/1992/
>DLT >/AB/		/EQ 100MG BASE/5ML*/	/N50688/001/ /AUG/07,/1992/

CEFPODOXIME PROXETIL

GRANULE, FOR RECONSTITUTION; ORAL

> DLT >	/BANAN/			
> ADD >	∂ SANKYO	EQ 50MG BASE/5ML*	N50688 002	AUG 07, 1992
> ADD >				
> ADD >	∂	EQ 100MG BASE/5ML*	N50688 001	AUG 07, 1992
> ADD >				
	VANTIN			
> DLT >	/AB/ /UPJOHN/	/EQ 50MG BASE/5ML□/	/N50675/001/	/AUG/07,/1992/
> DLT >				
> DLT >	/AB//+/	/EQ 100MG BASE/5ML□/	/N50675/002/	/AUG/07,/1992/
> DLT >				
> ADD >	+ UPJOHN	EQ 100MG BASE/5ML*	N50675 002	AUG 07, 1992
> ADD >				
> ADD >		EQ 50MG BASE/5ML*	N50675 001	AUG 07, 1992
> ADD >				

TABLET; ORAL

	BANAN			
> DLT >	/AB/ /SANKYO/	/EQ 100MG BASE□/	/N50687/001/	/AUG/07,/1992/
> DLT >				
> DLT >	/AB/	/EQ 200MG BASE□/	/N50687/002/	/AUG/07,/1992/
> DLT >				
> ADD >	∂ SANKYO	EQ 100MG BASE*	N50687 001	AUG 07, 1992
> ADD >				
> ADD >	∂	EQ 200MG BASE*	N50687 002	AUG 07, 1992
> ADD >				
	VANTIN			
> DLT >	/AB/ /UPJOHN/	/EQ 100MG BASE□/	/N50674/001/	/AUG/07,/1992/
> DLT >				
> DLT >	/AB//+/	/EQ 200MG BASE□/	/N50674/002/	/AUG/07,/1992/
> DLT >				
> ADD >	+ UPJOHN	EQ 200MG BASE*	N50674 002	AUG 07, 1992
> ADD >				
> ADD >		EQ 100MG BASE*	N50674 001	AUG 07, 1992
> ADD >				

CEFPROZIL

PONDER FOR RECONSTITUTION; ORAL

CEFZIL			
+ BRISTOL MYERS SQUIBB 250MG/5ML		N50665 002	DEC 23, 1991
	/250MG/5ML/	/N50665/002/	/DEC/23,/1991/

CEFPROZIL

TABLET; ORAL

CEFZIL			
+ BRISTOL MYERS SQUIBB 500MG		N50664 002	DEC 23, 1991
	/500MG/	/N50664/002/	/DEC/23,/1991/

CEFTAZIDIME

INJECTABLE; INJECTION

/CEPTAZ/				
/GLAXO/	/500MG/VIAL/	/N50646/001/	/SEP/27,/1990/
	/1GM/VIAL/	/N50646/002/	/SEP/27,/1990/
	/2GM/VIAL/	/N50646/003/	/SEP/27,/1990/
	/10GM/VIAL/	/N50646/004/	/SEP/27,/1990/

CEFTAZIDIME (ARGININE FORMULATION)

INJECTABLE; INJECTION

	CEPTAZ			
AP	GLAXO	1GM/VIAL	N50646 002	SEP 27, 1990
AP		2GM/VIAL	N50646 003	SEP 27, 1990
AP		10GM/VIAL	N50646 004	SEP 27, 1990
		500MG/VIAL	N50646 001	SEP 27, 1990
	PENTACEF			
AP	SMITHKLINE BEECHAM	1GM/VIAL*	N64006 001	MAR 31, 1992
AP		2GM/VIAL*	N64006 002	MAR 31, 1992
AP		10GM/VIAL*	N64008 002	MAR 31, 1992
		6GM/VIAL*	N64008 001	MAR 31, 1992

CEFTIZOXIME SODIUM

INJECTABLE; INJECTION

CEFIZOX

>ADD>	FUJISAWA	EQ 1GM BASE/VIAL	N50560 002 SEP 15, 1983
>ADD>		EQ 2GM BASE/VIAL	N50560 003 SEP 15, 1983
>DLT>	/SKF/	/EQ 1GM BASE/VIAL/	/N50560/002/ /SEP/15,/1983/
>DLT>		/EQ 2GM BASE/VIAL/	/N50560/003/ /SEP/15,/1983/

CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER

>ADD>	FUJISAWA	EQ 20MG BASE/ML	N50589 001 OCT 03, 1984
>ADD>		EQ 40MG BASE/ML	N50589 002 OCT 03, 1984
>DLT>	/SKF/	/EQ 20MG BASE/ML/	/N50589/001/ /OCT/03,/1984/
>DLT>		/EQ 40MG BASE/ML/	/N50589/002/ /OCT/03,/1984/

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION

ROCEPHIN

	/ROCHE/	/EQ 250MG BASE/VIAL/	/N62510/001/ /MAR/12,/1985/
	∂ ROCHE	EQ 250MG BASE/VIAL	N62510 001 MAR 12, 1985
		/EQ 500MG BASE/VIAL/	/N62510/002/ /MAR/12,/1985/
	∂	EQ 500MG BASE/VIAL	N62510 002 MAR 12, 1985
		/EQ 1GM BASE/VIAL/	/N62510/003/ /MAR/12,/1985/
	∂	EQ 1GM BASE/VIAL	N62510 003 MAR 12, 1985

CEPHALEXIN

CAPSULE; ORAL

>DLT>	/CEPHALEXIN MONOHYDRATE/		
>DLT>	/∂/EON LABS/	/EQ 250MG BASE/	/N62159/001/
>DLT>	/∂/	/EQ 500MG BASE/	/N62159/002/

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION

CEFADYL

/AP/	/BRISTOL/	/EQ 20GM BASE/VIAL/	/N50446/004/
	BRISTOL	EQ 20GM BASE/VIAL	N50446 004

CEPHAPIRIN SODIUM

/AP/	/ELKINS SINN/	/EQ 500MG BASE/VIAL/	/N62720/001/ /JUL/02,/1987/
/AP/		/EQ 1GM BASE/VIAL/	/N62720/002/ /JUL/02,/1987/
/AP/		/EQ 2GM BASE/VIAL/	/N62720/003/ /JUL/02,/1987/
/AP/		/EQ 20GM BASE/VIAL/	/N62720/004/ /JUL/02,/1987/
	∂ ELKINS SINN	EQ 500MG BASE/VIAL	N62720 001 JUL 02, 1987
	∂	EQ 1GM BASE/VIAL	N62720 002 JUL 02, 1987
	∂	EQ 2GM BASE/VIAL	N62720 003 JUL 02, 1987
	∂	EQ 20GM BASE/VIAL	N62720 004 JUL 02, 1987

CEPHRADINE

>DLT>	/TABLET;ORAL/			
>DLT>	/VELOSEF/			
>DLT>	/+//SQUIBB/	/1GM/		/N50530/001/
>ADD>	∂ SQUIBB	1GM		N50530 001

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE; INJECTION

CHLORAMPHENICOL SODIUM SUCCINATE

>ADD>	AP	FUJISAWA	EQ 1GM BASE/VIAL	N62365 001 AUG 25, 1982
>ADD>				
>DLT>	/AP/	/LYPHOMED/	/EQ 1GM BASE/VIAL/	/N62365/001/ /AUG/25,/1982/
>DLT>				

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

CHLORDIAZEPOXIDE HCL

∂ EON LABS	5MG	N84919 001
∂	10MG	N84920 001
∂	25MG	N84823 001

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

	CHLORDIAZEPOXIDE HCL			
/AB/	/PARKE/DAVIS/	/5MG/		/N85163/001/
/AB/		/10MG/		/N84598/001/
/AB/		/25MG/		/N85164/001/
	∂ PARKE DAVIS	5MG		N85163 001
	∂	10MG		N84598 001
	∂	25MG		N85164 001
>DLT >/AB/	/PIONEER/PHARMS/	/10MG/		/N89533/001/
>DLT >				/JUL/15,/1988/
>ADD >	∂ PIONEER PHARMS	10MG		N89533 001
>ADD >				JUL 15, 1988
/AB/	/VITARINE/	/5MG/		/N84919/001/
/AB/		/10MG/		/N84920/001/
/AB/		/25MG/		/N84823/001/
/AB/	/WEST/WARD/	/5MG/		/N85014/001/
/AB/		/10MG/		/N85000/001/
/AB/		/25MG/		/N85294/001/
	∂ WEST WARD	5MG		N85014 001
	∂	10MG		N85000 001
	∂	25MG		N85294 001

CHLOROQUINE PHOSPHATE

TABLET; ORAL

	CHLOROQUINE PHOSPHATE		
/AA/	/WEST/WARD/	/EQ 150MG BASE/	/N83082/001/
	∂ WEST WARD	EQ 150MG BASE	N83082 001

CHLOROTHIAZIDE

TABLET; ORAL

	CHLOROTHIAZIDE		
	∂ EON LABS	250MG	N85485 001
/S/	/VITARINE/	/250MG/	/N85485/001/

CHLORPHENIRAMINE MALEATE

TABLET; ORAL

	CHLORPHENIRAMINE MALEATE			
/AA/	/PIONEER/PHARMS/	/4MG/		/N88556/001/
				/JUL/13,/1984/
	∂ PIONEER PHARMS	4MG		N88556 001
				JUL 13, 1984

CHLORPROPAMIDE

TABLET; ORAL

	CHLORPROPAMIDE			
	∂ EON LABS	250MG		N84669 001
/B*/	/PHARM/BASICS/	/100MG/		/N88708/001/
				/AUG/30,/1984/
/B*/		/250MG/		/N88709/001/
				/AUG/30,/1984/
	∂ PHARM BASICS	100MG		N88708 001
				AUG 30, 1984
	∂	250MG		N88709 001
				AUG 30, 1984
/S/	/VITARINE/	/250MG/		/N84669/001/

CHLORTHALIDONE

TABLET; ORAL

	CHLORTHALIDONE			
AB	EON LABS	50MG		N87118 001
/AB/	/PIONEER/PHARMS/	/50MG/		/N89591/001/
				/JUL/21,/1988/
	∂ PIONEER PHARMS	50MG		N89591 001
				JUL 21, 1988
/AB/	/VITARINE/	/50MG/		/N87118/001/
/AB/	/WARNER/CHILCOTT/	/25MG/		/N87515/001/
				/JAN/24,/1983/
/AB/		/50MG/		/N87516/001/
				/FEB/09,/1983/
	∂ WARNER CHILCOTT	25MG		N87515 001
				JAN 24, 1983
	∂	50MG		N87516 001
				FEB 09, 1983
	THALITONE			
/AB/	/BOEHRINGER/INGELHEIM/	/25MG/		/N88051/001/
				/NOV/12,/1982/
		/15MG/		/N19574/001/
				/DEC/20,/1988/
BX	HORUS	25MG		N88051 001
				NOV 12, 1982
		15MG		N19574 001
				DEC 20, 1988

CHYMOTRYPSIN

POWDER FOR RECONSTITUTION; OPHTHALMIC

	ALPHA CHYMAR			
/AT/	/BARNES/HIND/	/750 UNITS/VIAL/		/N11837/001/
	∂ SOLA BARNES HIND	750 UNITS/VIAL		N11837 001

CHYMOTRYPSIN

POWDER FOR RECONSTITUTION; OPHTHALMIC

ZOLYSE

AT	ALCON	750 UNITS/VIAL	N11903 001

CINOXACIN

CAPSULE; ORAL

CINOBAC

AB	LILLY	250MG	N18067 001
AB	+	500MG	N18067 002

CINOXACIN

AB	BIOCRAFT	250MG*	N73005 001 FEB 28, 1992
AB		500MG*	N73006 001 FEB 28, 1992

CITRIC ACID; GLUCONOLACTONE; MAGNESIUM CARBONATE

SOLUTION; IRRIGATION

RENACIDIN

GUARDIAN LABS	6.602GM/100ML;198MG/100ML; 3.177GM/100ML	N19481 001 OCT 02, 1990

CLEMASTINE FUMARATE

SYRUP; ORAL

CLEMASTINE FUMARATE

AA	COPLEY	EQ 0.5MG BASE/5ML*	N73095 001 APR 21, 1992

TAVIST

AA	SANDOZ	EQ 0.5MG BASE/5ML	N18675 001 JUN 28, 1985

CLEMASTINE FUMARATE

TABLET; ORAL

CLEMASTINE FUMARATE

AB	LEMMON	2.68MG*	N73283 001 JAN 31, 1992
> DLT >		1.34MG*	
> DLT >			
> ADD >	∂	1.34MG*	N73282 001 JAN 31, 1992
> ADD >			

TAVIST

AB	+ SANDOZ	2.68MG	N17661 001

TAVIST-1

AB	∂ SANDOZ	1.34MG	N17661 002

CLEMASTINE FUMARATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

TABLET,EXTENDED RELEASE;ORAL

TAVIST D

+ SANDOZ	EQ 1MG BASE;75MG	N18298 001 DEC 15, 1982

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLINDAMYCIN HCL

> DLT >	∂ ECN LABS	EQ 75MG BASE	N62916 001 JUL 05, 1988
> DLT >			
> DLT >	∂	EQ 150MG BASE	N62916 002 JUL 05, 1988
> DLT >			

CLINDAMYCIN PALMITATE HYDROCHLORIDE

POWDER FOR RECONSTITUTION; ORAL

CLEOCIN

> DLT > AA	UPJOHN	EQ 75MG BASE/5ML	N61827 001
> DLT > AA		EQ 75MG BASE/5ML	N62644 001 APR 07, 1986
> DLT >			
> ADD >	∂ UPJOHN	EQ 75MG BASE/5ML	N61827 001
> ADD >		EQ 75MG BASE/5ML	N62644 001
> ADD >			APR 07, 1986

CLINDAMYCIN PHOSPHATE

CREAM; VAGINAL
CLEOCIN
+ UPJOHN — EQ 2% BASE* — N50680 001 AUG 11, 1992

INJECTABLE; INJECTION
CLEOCIN PHOSPHATE
> DLT > /AP/ /UPJOHN/ /EQ 150MG BASE/ML/ /N61839/001/
> ADD > @ UPJOHN — EQ 150MG BASE/ML — N61839 001

CLINDAMYCIN PHOSPHATE
AP GENSIA — EQ 150MG BASE/ML* — N63282 001 MAY 29, 1992

> DLT > /AP/ /SMITH/NEPHEW/SOLOPAK/ EQ 150MG BASE/ML/ /N62819/001/ /MAR/15,/1988/
> DLT >
> ADD > AP SOLOPAK — EQ 150MG BASE/ML — N62819 001 MAR 15, 1988
> ADD >

> DLT > /AP/ /SMITH/NEPHEW/SOLOPAK/ EQ 150MG BASE/ML/ /N62852/001/ /MAR/17,/1988/
> DLT >
> ADD > AP SOLOPAK — EQ 150MG BASE/ML — N62852 001 MAR 17, 1988
> ADD >

SOLUTION; TOPICAL
CLINDA-DERM
AT PADDOCK — EQ 1% BASE* — N63329 001 SEP 30, 1992

CLIOQUINOL; HYDROCORTISONE

/CREAM;TOPICAL/
/VIOFORM-HYDROCORTISONE/
/CIBA/ /3%;0.5%/ /N16412/002/
/3%;1%/ /N16412/001/

/OINTMENT;TOPICAL/
/VIOFORM-HYDROCORTISONE/
/@/CIBA/ /3%;0.5%/ /N16412/004/
/3%;1%/ /N16412/003/

CLIOQUINOL; NYSTATIN

/OINTMENT;TOPICAL/
/NYSTAFORM/
/MILES/ /10MG/GM;/ /100,000/UNITS/GM/ /N50235/001/
@ MILES — 10MG/GM; 100,000 UNITS/GM — N50235 001

CLOFIBRATE

CAPSULE; ORAL
CLOFIBRATE
AB PHARMACAPS — 500MG* — N73396 001 MAR 20, 1992

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL
CLORAZEPATE DIPOTASSIUM
/B*/ /PHARM/BASICS/ /3.75MG/ /N71242/001/ /MAY/20,/1987/
/B*/ /7.5MG/ /N71243/001/ /MAY/20,/1987/
/B*/ /15MG/ /N71244/001/ /MAY/20,/1987/
@ PHARM BASICS — 3.75MG — N71242 001 MAY 20, 1987
@ — 7.5MG — N71243 001 MAY 20, 1987
@ — 15MG — N71244 001 MAY 20, 1987

TABLET; ORAL
CLORAZEPATE DIPOTASSIUM
/AB/ /WARNER/CHILCOTT/ /3.75MG/ /N71828/001/ /MAR/03,/1988/
/AB/ /7.5MG/ /N71829/001/ /MAR/03,/1988/
/AB/ /15MG/ /N71830/001/ /MAR/03,/1988/
@ WARNER CHILCOTT — 3.75MG — N71828 001 MAR 03, 1988
@ — 7.5MG — N71829 001 MAR 03, 1988
@ — 15MG — N71830 001 MAR 03, 1988

CLOTRIMAZOLE

CREAM; TOPICAL
LOTRIMIN
/AT/;/SCHERING/ /1%/ /N17619/001/
BX + SCHERING — 1% — N17619 001
MYCELEX
/AT/ /MILES/ /1%/ /N18183/001/
BX MILES — 1% — N18183 001

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL

/AA/	/HISTAFED C/			
	/CENCI/	/10MG/5ML;30MG/5ML;1.25MG/5ML/	/N89018/001/	/JUL/23,/1986/
AA	CENCI	10MG/5ML;30MG/5ML;1.25MG/5ML	N89018 001	JUL 23, 1986

TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES W/ CODEINE

COLCHICINE; PROBENECID

TABLET; ORAL

/BP/	/PROBEN-C/			
	/CHELSEA/	/0.5MG;500MG/	/N85552/001/	
	∂ CHELSEA	0.5MG;500MG	N85552 001	

PROBENECID AND COLCHICINE

/BP/	/EON/LABS/	/0.5MG;500MG/	/N86130/001/	
	∂ EON LABS	0.5MG;500MG	N86130 001	

CYANOCOBALAMIN

INJECTABLE; INJECTION

CYANOCOBALAMIN

> ADD >	AP	FUJISAWA	1MG/ML	N83075 001	
	/AP/	/LUITPOLD/	/0.03MG/ML/	/N80668/001/	
		∂ LUITPOLD	0.03MG/ML	N80668 001	
> DLT >	/AP/	/LYPHOMED/	/1MG/ML/	/N83075/001/	
> DLT >	/AP/	/SMITH/NEPHEW/SOLOPAK/	1MG/ML/	/N87551/001/	/FEB/29,/1984/
> DLT >					
> ADD >	AP	SOLOPAK MEDCL	1MG/ML	N87551 001	FEB 29, 1984
> ADD >					

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CYCLOPENTOLATE HCL

/AT/	/BARNES/HIND/	/1%/	/N84863/001/	
	∂ SOLA BARNES HIND	1%	N84863 001	

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL

CYPROHEPTADINE HCL

/AA/	/PIONEER/PHARMS/	/4MG/	/N87839/001/	/FEB/08,/1984/
	∂ PIONEER PHARMS	4MG	N87839 001	FEB 08, 1984

DACARBAZINE

INJECTABLE; INJECTION

DACARBAZINE

/AP/	/LYPHOMED/	/100MG/VIAL/	/N70962/001/	/AUG/28,/1986/
/AP/		/200MG/VIAL/	/N70990/001/	/AUG/28,/1986/
	∂ LYPHOMED	100MG/VIAL	N70962 001	AUG 28, 1986
	∂	200MG/VIAL	N70990 001	AUG 28, 1986

DTIC-DOME

/AP/	/MILES/	/100MG/VIAL/	/N17575/001/	
/AP/		/200MG/VIAL/	/N17575/002/	
	MILES	100MG/VIAL	N17575 001	
		200MG/VIAL	N17575 002	

DESFLURANE

LIQUID; INHALATION

SUPRANE

+	ANAQUEST	99.9%	N20118 001 SEP 18, 1992

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

	DESIPRAMINE HCL			
AB	EON LABS	25MG	N71601 001	JUN 05, 1987
AB		50MG	N71588 001	JUN 05, 1987
AB		75MG	N71602 001	OCT 05, 1987
AB		100MG	N71766 001	OCT 05, 1987
> DLT >	/#/	/10MG/	/N72167/001/	/FEB/03,/1988/
> DLT >	/#/	/150MG/	/N72254/001/	/FEB/03,/1988/
> DLT >	/B*/ /PHARM/BASICS/	/25MG/	/N71864/001/	/SEP/09,/1987/
	/B*/	/50MG/	/N71865/001/	/SEP/09,/1987/
	/B*/	/75MG/	/N71866/001/	/SEP/09,/1987/
	/B*/	/100MG/	/N71867/001/	/SEP/09,/1987/
	ə PHARM BASICS	25MG	N71864 001	SEP 09, 1987
	ə	50MG	N71865 001	SEP 09, 1987
	ə	75MG	N71866 001	SEP 09, 1987
	ə	100MG	N71867 001	SEP 09, 1987
	/AA/ /VITARINE/	/25MG/	/N71601/001/	/JUN/05,/1987/
	/AA/	/50MG/	/N71588/001/	/JUN/05,/1987/
	/AA/	/75MG/	/N71602/001/	/OCT/05,/1987/
	/AA/	/100MG/	/N71766/001/	/OCT/05,/1987/

DESOGESTREL; ETHINYL ESTRADIOL

> ADD > TABLET; ORAL-21

> ADD >	**DESOGEN**			
> ADD > AB	+ ORGANON	0.15MG;0.03MG㋮	N20071 001	DEC 10, 1992
> ADD >	**ORTHO-CEPT**			
> ADD > AB	JOHNSON RW	0.15MG;0.03MG㋮	N20301 001	DEC 14, 1992

DESOGESTREL; ETHINYL ESTRADIOL

> ADD > TABLET; ORAL-28

> ADD >	**DESOGEN**			
> ADD > AB	ORGANON	0.15MG;0.03MG㋮	N20071 002	DEC 10, 1992
> ADD >	**ORTHO-CEPT**			
> ADD > AB	JOHNSON RW	0.15MG;0.03MG㋮	N20301 002	DEC 14, 1992

DESONIDE

CREAM; TOPICAL

	DESONIDE			
AB	COPLEY	0.05%㋮	N74027 001	SEP 28, 1992
AB	TARO	0.05%㋮	N73548 001	JUN 30, 1992

LOTION; TOPICAL

	DESOWEN			
	OWEN GALDERMA	0.05%㋮	N72354 001	JAN 24, 1992

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

	DEXAMETHASONE SODIUM PHOSPHATE			
> ADD > AP	FUJISAWA	EQ 4MG PHOSPHATE/ML	N84916 001	
> DLT >/AP/	/LYPHOMED/	/EQ 4MG PHOSPHATE/ML/	/N84916/001/	

SOLUTION/DROPS; OPHTHALMIC

	DEXAIR			
	/BAUSCH/AND/LOMB/	/EQ/0.1%/PHOSPHATE/	/N88433/001/	/DEC/15,/1983/
	PHARMAFAIR	EQ 0.1% PHOSPHATE	N88433 001	DEC 15, 1983

DEXTROSE

INJECTABLE; INJECTION

	DEXTROSE 5% IN PLASTIC CONTAINER			
> ADD > AP	BAXTER	5GM/100ML㋮	N20179 001	DEC 07, 1992
> ADD > AP		50MG/ML㋮	N20179 002	DEC 07, 1992

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
MCGAW 3.3GM/100ML;75MG/100ML; 300MG/100ML N19630 049 MAY 07, 1992

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
MCGAW 3.3GM/100ML;110MG/100ML; 300MG/100ML N19630 050 MAY 07, 1992

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
MCGAW 3.3GM/100ML;150MG/100ML; 300MG/100ML N19630 051 MAY 07, 1992

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
MCGAW 3.3GM/100ML;220MG/100ML; 300MG/100ML N19630 052 MAY 07, 1992

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
MCGAW 3.3GM/100ML;300MG/100ML; 300MG/100ML N19630 053 MAY 07, 1992

DIAZEPAM

INJECTABLE; INJECTION

DIAZEPAM

> DLT >	/AP/	/LEDERLE/	/5MG/ML/	/N71308/001/ /JUL/17,/1987/
> DLT >				
> ADD >		ə LEDERLE	5MG/ML	N71308 001 JUL 17, 1987
> ADD >				
> DLT >		/S/PARKE/DAVIS/	/5MG/ML/	/N71613/001/ /OCT/22,/1987/
> DLT >				
> DLT >		/S/	/5MG/ML/	/N71614/001/ /OCT/22,/1987/
> DLT >				
> ADD >		ə WARNER CHILCOTT	5MG/ML	N71613 001 OCT 22, 1987
> ADD >				
> ADD >		ə	5MG/ML	N71614 001 OCT 22, 1987
> ADD >				

DIAZEPAM

TABLET; ORAL

DIAZEPAM

/AB/	/PARKE/DAVIS/	/2MG/	/N70269/001/ /SEP/04,/1985/
/AB/		/5MG/	/N70210/001/ /SEP/04,/1985/
/AB/		/10MG/	/N70222/001/ /SEP/04,/1985/
/AB/	/PIONEER/PHARMS/	/2MG/	/N70787/001/ /AUG/02,/1988/
/AB/		/5MG/	/N70788/001/ /AUG/02,/1988/
/AB/		/10MG/	/N70776/001/ /AUG/02,/1988/
	ə PIONEER PHARMS	2MG	N70787 001 AUG 02, 1988
	ə	5MG	N70788 001 AUG 02, 1988
	ə	10MG	N70776 001 AUG 02, 1988
	ə WARNER CHILCOTT	2MG	N70209 001 SEP 04, 1985
	ə	5MG	N70210 001 SEP 04, 1985
	ə	10MG	N70222 001 SEP 04, 1985

DIAZOXIDE

INJECTABLE; INJECTION

DIAZOXIDE

/AP/	/LYPHOMED/	/15MG/ML/	/N71519/001/ /AUG/26,/1987/
	ə LYPHOMED	15MG/ML	N71519 001 AUG 26, 1987

DICLOFENAC SODIUM

TABLET, DELAYED RELEASE; ORAL

VOLTAREN

+	GEIGY	25MG	N19201 001 JUL 28, 1988
+		50MG	N19201 002 JUL 28, 1988
		/25MG/	/N19201/001/ /JUL/28,/1988/
		/50MG/	/N19201/002/ /JUL/28,/1988/

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL
DIETHYLPROPION HCL
∂ EON LABS 25MG N85916 001
/∂/VITARINE/ /25MG/ /N85916/001/

DIFLORASONE DIACETATE

CREAM; TOPICAL
FLORONE
BX + UPJOHN 0.05% N17741 001
PSORCON
BX DERMIK 0.05%ⓡ N20205 001
NOV 20, 1992

DIFLUNISAL

TABLET; ORAL
DIFLUNISAL
AB LEMMON 250MGⓡ N73679 001
JUL 31, 1992
AB 500MGⓡ N73673 001
JUL 31, 1992
AB ROXANE 250MGⓡ N73562 001
NOV 27, 1992
AB 500MGⓡ N73563 001
NOV 27, 1992
DOLOBID
AB MSD 250MG N18445 001
APR 19, 1982
AB + 500MG N18445 002
APR 19, 1982

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
CARDIZEM CD
BC + MARION MERRELL DOW 180MG N20062 002
DEC 27, 1991
BC + 240MG N20062 003
DEC 27, 1991
+ 120MGⓡ N20062 001
AUG 10, 1992
+ 300MG N20062 004
DEC 27, 1991
/300MG/ /N20062/004/
/DEC/27,/1991/

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
CARDIZEM SR
+ MARION MERRELL DOW 60MG N19471 001
JAN 23, 1989
+ 90MG N19471 002
JAN 23, 1989
/60MG/ /N19471/001/
/JAN/23,/1989/
/90MG/ /N19471/002/
/JAN/23,/1989/
DILACOR XR
BC RHONE POULENC RORER 180MGⓡ N20092 002
MAY 29, 1992
BC 240MGⓡ N20092 003
MAY 29, 1992
∂ 120MGⓡ N20092 001
MAY 29, 1992

INJECTABLE; INJECTION
CARDIZEM
MARION MERRELL DOW 5MG/ML N20027 001
OCT 24, 1991
/25MG/VIAL/ /N20027/001/
/OCT/24,/1991/
/50MG/VIAL/ /N20027/002/
/OCT/24,/1991/

TABLET; ORAL
CARDIZEM
AB MARION MERRELL DOW 30MG N18602 001
NOV 05, 1982
AB 60MG N18602 002
NOV 05, 1982
AB 90MG N18602 003
DEC 08, 1986
AB + 120MG N18602 004
DEC 08, 1986
DILTIAZEM HCL
AB COPLEY 30MGⓡ N74067 001
NOV 05, 1992
AB 60MGⓡ N74067 002
NOV 05, 1992
AB 90MGⓡ N74067 003
NOV 05, 1992
AB 120MGⓡ N74067 004
NOV 05, 1992

DILTIAZEM HYDROCHLORIDE

TABLET; ORAL
DILTIAZEM HCL

AB	LEDERLE	30MG	N74093 001	NOV 05, 1992
AB		60MG	N74093 002	NOV 05, 1992
AB		90MG	N74093 003	NOV 05, 1992
AB		120MG	N74093 004	NOV 05, 1992
AB	MYLAN	30MG	N73185 001	NOV 05, 1992
AB		60MG	N73186 001	NOV 05, 1992
AB		90MG	N72837 001	NOV 05, 1992
AB		120MG	N72838 001	NOV 05, 1992

DINOPROSTONE

GEL; ENDOCERVICAL
PREPIDIL

>ADD>	+ UPJOHN	0.5MG/3GM	N19617 001	DEC 09, 1992

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL
DIPHENHYDRAMINE HCL

AA	EON LABS	25MG	N80845 002	
AA		50MG	N80845 001	
/AA/	/PIONEER/PHARMS/	/25MG/	/N89101/001/	/DEC/20,/1985/
/AA/		/50MG/	/N88880/001/	/DEC/20,/1985/
	∂ PIONEER PHARMS	25MG	N89101 001	DEC 20, 1985
	∂	50MG	N88880 001	DEC 20, 1985
/AA/	/VITARINE/	/25MG/	/N80845/002/	
/AA/		/50MG/	/N80845/001/	

DIPYRIDAMOLE

TABLET; ORAL
DIPYRIDAMOLE

AB	GENEVA	50MG	N87562 001	FEB 25, 1992
AB		75MG	N87561 001	FEB 25, 1992

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL
DISOPYRAMIDE PHOSPHATE

/B*/	/CHELSEA/	/EQ/100MG/BASE/	/N71020/001/	/DEC/01,/1986/
/B*/		/EQ/150MG/BASE/	/N71021/001/	/DEC/01,/1986/
/B*/	/INTERPHARM/	/EQ/100MG/BASE/	/N71190/001/	/JAN/15,/1987/
/B*/		/EQ/150MG/BASE/	/N71191/001/	/JAN/15,/1987/
	∂ INTERPHARM	EQ 100MG BASE	N71190 001	JAN 15, 1987
	∂	EQ 150MG BASE	N71191 001	JAN 15, 1987

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOPAMINE HCL

/AP/	/LYPHOMED/	/40MG/ML/	/N70058/001/	/MAR/20,/1985/
/AP/		/80MG/ML/	/N70059/001/	/MAR/20,/1985/
/AP/		/160MG/ML/	/N70364/001/	/DEC/04,/1985/
	∂ LYPHOMED	40MG/ML	N70058 001	MAR 20, 1985
	∂	80MG/ML	N70059 001	MAR 20, 1985
	∂	160MG/ML	N70364 001	DEC 04, 1985
>DLT>/AP/	/WARNER/CHILCOTT/	/40MG/ML/	/N18138/001/	
>DLT>/AP/		/40MG/ML/	/N70558/001/	/SEP/20,/1985/
>ADD>	∂ WARNER CHILCOTT	40MG/ML	N18138 001	
>ADD>	∂	40MG/ML	N70558 001	SEP 20, 1985

DOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION

DOPRAM

AP	ROBINS	20MG/ML	N14879 001

DOXAPRAM HCL

AP	STERIS	20MG/ML*	N73529 001 JAN 30, 1992

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

DOXYCYCLINE HYCLATE

> DLT >	/3/EON/LABS/	/EQ/50MG/BASE/	/N62766/001/ /APR/12,/1988/
> DLT >			
> DLT >	/3/	/EQ/100MG/BASE/	/N62227/001/
> DLT >/AB/	/HEATHER/	/EQ 50MG BASE/	/N62463/001/ /DEC/07,/1983/
> DLT >			
> DLT >/AB/		/EQ 100MG BASE/	/N62463/002/ /DEC/07,/1983/
> DLT >			
> ADD >	∂ HEATHER	EQ 50MG BASE	N62463 001 DEC 07, 1983
> ADD >			
> ADD >	∂	EQ 100MG BASE	N62463 002 DEC 07, 1983
> ADD >			
/B*/	/INTERPHARM/	/EQ/50MG/BASE/	/N62763/001/ /SEP/02,/1988/
/B*/		/EQ/100MG/BASE/	/N62763/002/ /SEP/02,/1988/
	∂ INTERPHARM	EQ 50MG BASE	N62763 001 SEP 02, 1988
	∂	EQ 100MG BASE	N62763 002 SEP 02, 1988
/AB/	/PARKE/DAVIS/	/EQ 50MG BASE/	/N62594/001/ /DEC/05,/1985/
/AB/		/EQ 100MG BASE/	/N62594/002/ /DEC/05,/1985/
	∂ WARNER CHILCOTT	EQ 50MG BASE	N62594 001 DEC 05, 1985
	∂	EQ 100MG BASE	N62594 002 DEC 05, 1985

CAPSULE, COATED PELLETS; ORAL

DOXYCYCLINE HYCLATE

AB	SIDMAK	EQ 100MG BASE*	N63187 001 JUN 30, 1992

DOXYCYCLINE HYCLATE

TABLET; ORAL

DOXYCYCLINE HYCLATE

/B*/	/INTERPHARM/	/EQ/100MG/BASE/	/N62764/001/ /SEP/02,/1988/
	∂ INTERPHARM	EQ 100MG BASE	N62764 001 SEP 02, 1988
/AB/	/MEDICOPHARMA/	/EQ 100MG BASE/	/N62536/001/ /APR/07,/1986/
/AB/	/PARKE/DAVIS/	/EQ 100MG BASE/	/N62593/001/ /AUG/28,/1985/
AB	VINTAGE	EQ 100MG BASE	N62538 001 APR 07, 1986
	∂ WARNER CHILCOTT	EQ 100MG BASE	N62593 001 AUG 28, 1985

DROPERIDOL

INJECTABLE; INJECTION

DROPERIDOL

/AP/	/LYPHOMED/	/2.5MG/ML/	/N70992/001/ /NOV/17,/1986/
/AP/		/2.5MG/ML/	/N70993/001/ /NOV/17,/1986/
	∂ LYPHOMED	2.5MG/ML	N70992 001 NOV 17, 1986
	∂	2.5MG/ML	N70993 001 NOV 17, 1986
/AP/	/SOLOPAK/	/2.5MG/ML/	/N71750/001/ /SEP/06,/1988/
	∂ SOLOPAK	2.5MG/ML	N71750 001 SEP 06, 1988

ENOXACIN

TABLET; ORAL

PENETREX

+	PARKE DAVIS	400MG	N19616 005 DEC 31, 1991
		/400MG/	/N19616/005/ /DEC/31,/1991/

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HCL AND EPINEPHRINE

AP	GRAHAM CHEM	0.01MG/ML;2%	N80504 004	OCT 19, 1983
AP		0.02MG/ML;2%	N80504 005	OCT 19, 1983

/LIDOCAINE HCL W// EPINEPHRINE/

/AP/	/GRAHAM CHEM/	/0.01MG/ML;2%/	/N80504/004/	/OCT 19, 1983/
/AP/		/0.02MG/ML;2%/	/N80504/005/	/OCT 19, 1983/

ERGOLOID MESYLATES

TABLET; SUBLINGUAL

ALKERGOT

∂ EON LABS	0.5MG	N85153 001	
∂	1MG	N87417 001	

/∂/VITARINE/

/∂/	/0.5MG/	/N85153/001/
/∂/	/1MG/	/N87417/001/

ERGOTAMINE TARTRATE

TABLET; SUBLINGUAL

/ERGOMAR/

/AA/	/FISONS/	/2MG/	/N87693/001/	/FEB 24, 1983/
	∂ FISONS	2MG	N87693 001	FEB 24, 1983

ERYTHROMYCIN

SOLUTION; TOPICAL

/C-SOLVE 2/

/AT/	/SYOSSET/	/2%/	/N62468/001/	/JUL 03, 1985/

C-SOLVE-2

AT	SYOSSET	2%	N62468 001	JUL 03, 1985

ERYTHROMYCIN

AT	PHARM BASICS	2%	N62825 001	OCT 23, 1987

/ERYTHROMYCIN/

/AT/	/PHARM BASICS/	/2%/	/N62825/001/	/OCT 23, 1987/

SANSAC

AT	OWEN GALDERMA	2%	N62522 001	JAN 24, 1985

ERYTHROMYCIN

SOLUTION; TOPICAL

/SANSACNE/

/AT/	/OWEN GALDERMA/	/2%/	/N62522/001/	/JAN 24, 1985/

SWAB; TOPICAL

ERYCETTE

>DLT>	/AT/	/JOHNSON RW/	/2%/	/N50594/001/	/FEB 15, 1985/
>DLT>					
>ADD>	AT	+ JOHNSON RW	2%	N50594 001	FEB 15, 1985
>ADD>					

TABLET, COATED PARTICLES; ORAL

PCE

ABBOTT	500MG	N50611 002	AUG 22, 1990

ERYTHROMYCIN ESTOLATE; SULFISOXAZOLE ACETYL

>DLT>	/SUSPENSION;ORAL/			
>DLT>	/ILOSONE/SULFA/			
>DLT>	/+//LILLY/	/EQ/125MG/BASE/5ML;/ /EQ/600MG/BASE/5ML/	/N50599/001/	/SEP 29, 1989/
>DLT>				
>DLT>				
>ADD>	∂ LILLY	EQ 125MG BASE/5ML; EQ 600MG BASE/5ML	N50599 001	SEP 29, 1989
>ADD>				
>ADD>				

ERYTHROMYCIN ETHYLSUCCINATE

SUSPENSION; ORAL

/E-MYCIN E/

/AB/	/UPJOHN/	/EQ 200MG BASE/5ML/	/N62198/001/	
/AB/		/EQ 400MG BASE/5ML/	/N62198/002/	
	∂ UPJOHN	EQ 200MG BASE/5ML	N62198 001	
	∂	EQ 400MG BASE/5ML	N62198 002	

ERYTHROMYCIN ETHYLSUCCINATE

/AB/	/PARKE/DAVIS/	/EQ 200MG BASE/5ML/	/N62231/001/	
/AB/		/EQ 400MG BASE/5ML/	/N62231/002/	
	∂ PARKE DAVIS	EQ 200MG BASE/5ML	N62231 001	
	∂	EQ 400MG BASE/5ML	N62231 002	

ESTRADIOL

CREAM; VAGINAL

ESTRACE

> ADD > + BRISTOL MYERS SQUIBB 0.01% N86069 001 JAN 31, 1984
> ADD >
> DLT > /+//MEAD/JOHNSON/ /0.01%/ /N86069/001/ /JAN/31,/1984/
> DLT >

TABLET; ORAL

ESTRACE

> ADD > + BRISTOL MYERS SQUIBB 2MG N84500 001
> ADD > 1MG N84499 001
> DLT > /+//MEAD/JOHNSON/ /2MG/ /N84500/001/
> DLT > /1MG/ /N84499/001/

ESTROPIPATE

TABLET; ORAL

/OGEN/

/AB/ /ABBOTT/ /0.75MG/ /N83220/001/
/AB//+/ /1.5MG/ /N83220/002/
/3MG/ /N83220/003/
/6MG/ /N83220/004/

OGEN .625
AB ABBOTT 0.75MG N83220 001

OGEN 1.25
AB + ABBOTT 1.5MG N83220 002

OGEN 2.5
ABBOTT 3MG N83220 003

OGEN 5
ABBOTT 6MG N83220 004

ETHINYL ESTRADIOL

TABLET; ORAL

ESTINYL

/BP/ /SCHERING/ /0.05MG/ /N05292/002/
SCHERING 0.05MG N05292 002

/FEMINONE/

/BP/ /UPJOHN/ /0.05MG/ /N16649/001/
∂ UPJOHN 0.05MG N16649 001

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

GENCEPT 0.5/35-21

AB GENCON 0.035MG;0.5MG* N72692 001 FEB 28, 1992

GENCEPT 1/35-21

AB GENCON 0.035MG;1MG* N72693 001 FEB 28, 1992

GENCEPT 10/11-21

AB GENCON 0.035MG;0.5MG AND 1MG* N72694 001 FEB 28, 1992

/N.E.E.1/35-21/

/AB/ /METRONED/ /0.035MG;1MG/ /N71541/001/ /DEC/14,/1987/

∂ LPI 0.035MG;1MG N71541 001 DEC 14, 1987

TABLET; ORAL-28

GENCEPT 0.5/35-28

AB GENCON 0.035MG;0.5MG* N72695 001 FEB 28, 1992

GENCEPT 1/35-28

AB GENCON 0.035MG;1MG* N72696 001 FEB 28, 1992

GENCEPT 10/11-28

AB GENCON 0.035MG;0.5MG AND 1MG* N72697 001 FEB 28, 1992

/N.E.E.1/35-28/

/AB/ /METRONED/ /0.035MG;1MG/ /N71542/001/ /DEC/14,/1987/

∂ LPI 0.035MG;1MG N71542 001 DEC 14, 1987

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-21

ORTHO TRI-CYCLEN

+ JOHNSON RW 0.035MG; 0.18MG,0.215MG,0.25MG* N19697 002 JUL 03, 1992

TABLET; ORAL-28

ORTHO TRI-CYCLEN

JOHNSON RW 0.035MG; 0.18MG,0.215MG,0.25MG* N19697 001 JUL 03, 1992

TABLET; ORAL-21

GENCEPT 0.5/35-21

AB	GENCON	0.035MG;0.5MG	N72692 001 FEB 28, 1992	

FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

PLENDIL

/MERCK/		/5MG/	/N19834/001/ /JUL/26,/1991/	
MERCK		5MG	N19834 001 JUL 25, 1991	
		/10MG/	/N19834/002/ /JUL/26,/1991/	
		10MG	N19834 002 JUL 25, 1991	

FENOPROFEN CALCIUM

CAPSULE; ORAL

FENOPROFEN CALCIUM

/AB/	/HALSEY/	/EQ 200MG BASE/	/N72355/001/ /JUL/05,/1988/	
/AB/		/EQ 300MG BASE/	/N72356/001/ /JUL/05,/1988/	
	∂ HALSEY	EQ 200MG BASE	N72355 001 JUL 05, 1988	
	∂	EQ 300MG BASE	N72356 001 JUL 05, 1988	
/AB/	/WARNER/CHILCOTT/	/EQ 200MG BASE/	/N72946/001/ /APR/30,/1991/	
>DLT>/AB/		/EQ 300MG BASE/	/N72472/001/ /APR/30,/1991/	
>DLT>	∂ WARNER CHILCOTT	EQ 200MG BASE	N72946 001 APR 30, 1991	
>ADD>	∂	EQ 300MG BASE	N72472 001 APR 30, 1991	

>ADD>

TABLET; ORAL

FENOPROFEN CALCIUM

/AB/	/HALSEY/	/EQ 600MG BASE/	/N72357/001/ /JUL/05,/1988/	
	∂ HALSEY	EQ 600MG BASE	N72357 001 JUL 05, 1988	

FENTANYL CITRATE

INJECTABLE; INJECTION

FENTANYL CITRATE

AP	STERIS	EQ 0.05MG BASE/ML	N73488 001 JUN 30, 1992	

FINASTERIDE

TABLET; ORAL

PROSCAR

+	MSD	5MG	N20180 001 JUN 19, 1992	

>ADD> FLOSEQUINAN

TABLET; ORAL

MANOPLAX

+	BOOTS	100MG	N19960 003 DEC 30, 1992	
		50MG	N19960 001 DEC 30, 1992	
		75MG	N19960 002 DEC 30, 1992	
	∂	125MG	N19960 004 DEC 30, 1992	

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

FLUONID

AT	ALLERGAN HERBERT	0.025%	N87156 002 SEP 06, 1984	
/AT/	/HERBERT/	/0.025%/	/N87156/002/ /SEP/06,/1984/	

FLUOCINONIDE

CREAM; TOPICAL

FLUOCINONIDE

/AB/	/CLAY/PARK/	/0.05%/	/N71790/001/ /APR/25,/1988/	
B*	CLAY PARK	0.05%	N71790 001 APR 25, 1988	
AB	NMC	0.05%	N73085 001 FEB 14, 1992	

FLUOROURACIL

INJECTABLE; INJECTION

FLUOROURACIL

/AP/	/ABIC/	/50MG/ML/	/N88929/001/ /MAR/04,/1986/	
	∂ ABIC	50MG/ML	N88929 001 MAR 04, 1986	

FLUOROURACIL

INJECTABLE; INJECTION

FLUOROURACIL

/AP/	/LYPHOMED/	/50MG/ML/	/N89152/001/	/MAR/21,/1986/
/AP/		/50MG/ML/	/N89428/001/	/JAN/12,/1987/
/AP/		/50MG/ML/	/N89519/001/	/MAR/12,/1987/
	∂ LYPHOMED	50MG/ML	N89152 001	MAR 21, 1986
	∂	50MG/ML	N89428 001	JAN 12, 1987
	∂	50MG/ML	N89519 001	MAR 12, 1987

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION

FLUPHENAZINE DECANOATE

>ADD > AO	FUJISAWA	25MG/ML	N71413 001	JUL 14, 1987
>ADD >				
>DLT >/AP/	/LYPHOMED/	/25MG/ML/	/N71413/001/	/JUL/14,/1987/
>DLT >				

FLUPHENAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

FLUPHENAZINE HCL

>ADD > AP	FUJISAWA	2.5MG/ML	N89556 001	APR 16, 1987
>ADD >				
>DLT >/AP/	/LYPHOMED/	/2.5MG/ML/	/N89556/001/	/APR/16,/1987/
>DLT >				

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

FLURAZEPAM HCL

/B*/	/PHARM/BASICS/	/15MG/	/N70562/001/	/JUL/09,/1987/
/B*/		/30MG/	/N70563/001/	/JUL/09,/1987/
	∂ PHARM BASICS	15MG	N70562 001	JUL 09, 1987
	∂	30MG	N70563 001	JUL 09, 1987

FOLIC ACID

INJECTABLE; INJECTION

FOLIC ACID

>ADD > AP	FUJISAWA	5MG/ML	N89202 001	FEB 18, 1986
>ADD >				
>DLT >/AP/	/LYPHOMED/	/5MG/ML/	/N89202/001/	/FEB/18,/1986/
>DLT >				

TABLET; ORAL

FOLIC ACID

	∂ EON LABS	1MG	N84472 001	
/AA/	/LILLY/	/1MG/	/N86135/003/	
	∂ LILLY	1MG	N06135 003	
/AA/	/PHOENIX/LABS/	/1MG/	/N86296/001/	
AA	VINTAGE	1MG	N86296 001	
	/∂/VITARINE/	/1MG/	/N84472/001/	

FURAZOLIDONE

SUSPENSION; ORAL

FUROXONE

+	ROBERTS	50MG/15ML	N11323 002
		/50MG/15ML/	/N11323/002/

TABLET; ORAL

FUROXONE

+	ROBERTS	100MG	N11270 002
		/100MG/	/N11270/002/

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

>ADD > AP	FUJISAWA	10MG/ML	N18902 001	MAY 22, 1984
>ADD >				
/AP/	/LYPHOMED/	/10MG/ML/	/N18507/001/	/JUL/30,/1982/
>DLT >/AP/		/10MG/ML/	/N18902/001/	/MAY/22,/1984/
>DLT >				
	∂ LYPHOMED	10MG/ML	N18507 001	JUL 30, 1982

FUROSEMIDE

TABLET; ORAL

FUROSEMIDE

/AB/	/CHELSEA/	/20MG/	/N18369/001/	
			/MAY/14,/1982/	
/AB/		/40MG/	/N18369/002/	
			/MAY/14,/1982/	
	∂ CHELSEA	20MG	N18369 001	
			MAY 14, 1982	
	∂	40MG	N18369 002	
			MAY 14, 1982	
	∂ EON LABS	40MG	N18750 002	
			JUL 30, 1984	
	/∂/VITARINE/	/40MG/	/N18750/002/	
			/JUL/30,/1984/	

GADOTERIDOL

INJECTABLE; INJECTION

PROHANCE

	SQUIBB	279.3MG/ML¤	N20131 001
			NOV 16, 1992

GALLIUM CITRATE, GA-67

INJECTABLE; INJECTION

GALLIUM CITRATE GA 67

/BS/	/DUPONT/	/2MCI/ML/	/N17478/001/
BS	DUPONT MERCK	2MCI/ML	N17478 001

GENTAMICIN SULFATE

CREAM; TOPICAL

GENTAMICIN

>DLT>/AT/	/THAMES/	/EQ 1MG BASE/GM/	/N62427/001/	
>DLT>			/MAY/26,/1983/	

GENTAMICIN SULFATE

>ADD> AT	THAMES	EQ 1MG BASE/GM	N62427 001
>ADD>			MAY 26, 1983

INJECTABLE; INJECTION

GENTAMICIN SULFATE

>ADD> AP	FUJISAWA	EQ 10MG BASE/ML	N62356 001
>ADD>			MAR 04, 1982
>ADD> AP		EQ 40MG BASE/ML	N62356 002
>ADD>			MAR 04, 1982

GENTAMICIN SULFATE

INJECTABLE; INJECTION

GENTAMICIN SULFATE

>DLT>/AP/	/LYPHOMED/	/EQ 10MG BASE/ML/	/N62356/001/	
>DLT>			/MAR/04,/1982/	
>DLT>/AP/		/EQ 40MG BASE/ML/	/N62356/002/	
>DLT>			/MAR/04,/1982/	
>DLT>/AP/	/SMITH/NEPHEW/SOLOPAK	/EQ 10MG BASE/ML/	/N62507/001/	
>DLT>			/JUN/06,/1985/	
>ADD> AP	SOLOPAK	EQ 10MG BASE/ML	N62507 001	
>ADD>			JUN 06, 1985	
>DLT>/AP/	/SMITH/NEPHEW/SOLOPAK	/EQ 40MG BASE/ML/	/N62507/002/	
>DLT>			/JUN/06,/1985/	
>ADD> AP	SOLOPAK	EQ 40MG BASE/ML	N62507 002	
>ADD>			JUN 06, 1985	

GLYBURIDE

TABLET; ORAL

GLUBATE

BX	HOECHST ROUSSEL	1.5MG¤	N20055 001
			APR 17, 1992
BX		3MG¤	N20055 002
			APR 17, 1992

GLYNASE

BX	UPJOHN	1.5MG	N20051 001
			MAR 04, 1992
BX +		3MG	N20051 002
			MAR 04, 1992

GLYCOPYRROLATE

INJECTABLE; INJECTION

GLYCOPYRROLATE

>ADD> AP	FUJISAWA	0.2MG/ML	N88475 001	
>ADD>			JUN 12, 1984	
>DLT>/AP/	/LYPHOMED/	/0.2MG/ML/	/N88475/001/	
>DLT>			/JUN/12,/1984/	

GONADORELIN ACETATE

INJECTABLE; INJECTION

LUTREPULSE PUMP KIT

	FERRING	0.8MG/VIAL	N19687 001
			OCT 10, 1989
		3.2MG/VIAL	N19687 002
			OCT 10, 1989

GONADORELIN ACETATE

INJECTABLE; INJECTION
LUTREPULSE PUMP KIT
/JOHNSON/RW/ /0.8MG/VIAL/ /N19687/001/ /OCT/16/1989/
/3.2MG/VIAL/ /N19687/002/ /OCT/16/1989/

GONADOTROPIN, CHORIONIC

INJECTABLE; INJECTION
A.P.L.
> DLT >/AP/ /WYETH/AYERST/ /5,000 UNITS/VIAL/ /N17055/001/
> ADD > AP + WYETH AYERST 5,000 UNITS/VIAL N17055 001
> DLT >/AP/ /10,000 UNITS/VIAL/ /N17055/002/
> ADD > AP + 10,000 UNITS/VIAL N17055 002
> DLT >/AP/ /20,000 UNITS/VIAL/ /N17055/003/
> ADD > AP + 20,000 UNITS/VIAL N17055 003

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET; ORAL
ULTRAGRIS-165
AB SIDMAK 165MG* N62645 001 JUN 30, 1992

ULTRAGRIS-330
AB SIDMAK 330MG* N62646 001 JUN 30, 1992

HALOFANTRINE HYDROCHLORIDE

TABLET; ORAL
HALFAN
+ SMITHKLINE BEECHAM 250MG* N20250 001 JUL 24, 1992

HALOPERIDOL

TABLET; ORAL
HALOPERIDOL
/AB/ /ROYCE/ /0.5MG/ /N71722/001/ /DEC/24/1987/
/AB/ /1MG/ /N71723/001/ /DEC/24/1987/
/AB/ /2MG/ /N71724/001/ /DEC/24/1987/
/AB/ /5MG/ /N71725/001/ /DEC/24/1987/
/AB/ /10MG/ /N72121/001/ /DEC/24/1987/
/AB/ /20MG/ /N72122/001/ /DEC/24/1987/
∂ ROYCE 0.5MG N71722 001 DEC 24, 1987
∂ 1MG N71723 001 DEC 24, 1987
∂ 2MG N71724 001 DEC 24, 1987
∂ 5MG N71725 001 DEC 24, 1987
∂ 10MG N72121 001 DEC 24, 1987
∂ 20MG N72122 001 DEC 24, 1987

HALOPERIDOL LACTATE

INJECTABLE; INJECTION
HALOPERIDOL
/AP/ /LYPHOMED/ /EQ 5MG BASE/ML/ /N71187/001/ /JAN/20/1987/
∂ LYPHOMED EQ 5MG BASE/ML N71187 001 JAN 20, 1987
> DLT >/AP/ /SMITH/NEPHEW/SOLOPAK/ /EQ 5MG BASE/ML/ /N70800/001/ /DEC/14/1987/
> DLT >
> ADD > AP SOLOPAK MEDCL EQ 5MG BASE/ML N70800 001 DEC 14, 1987
> ADD >

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN LOCK FLUSH

/AP/	/LUITPOLD/	/10 UNITS/ML/	/N89063/001/	/OCT/09,/1985/
/AP/		/100 UNITS/ML/	/N89064/001/	/OCT/09,/1985/
	@ LUITPOLD	10 UNITS/ML	N89063 001	OCT 09, 1985
	@	100 UNITS/ML	N89064 001	OCT 09, 1985
>DLT >/AP/	/SMITH/NEPHEW/SOLOPAK/	/10 UNITS/ML/	/N87903/001/	/APR/20,/1983/
>DLT >				
>DLT >/AP/		/10 UNITS/ML/	/N88457/001/	/OCT/25,/1984/
>DLT >				
>DLT >/AP/		/100 UNITS/ML/	/N87905/001/	/APR/20,/1983/
>DLT >				
>DLT >/AP/		/100 UNITS/ML/	/N88459/001/	/JUL/26,/1984/
>DLT >				
>ADD > AP	SOLOPAK MEDCL	10 UNITS/ML	N87903 001	APR 20, 1983
>ADD >				
>ADD > AP		10 UNITS/ML	N88457 001	OCT 25, 1984
>ADD >				
>ADD > AP		100 UNITS/ML	N87905 001	APR 20, 1983
>ADD >				
>ADD > AP		100 UNITS/ML	N88459 001	JUL 26, 1984
>ADD >				

HEPARIN LOCK FLUSH PRESERVATIVE FREE

/AP/	/LYPHOMED/	/10 UNITS/ML/	/N17029/011/	/SEP/22,/1987/
/AP/		/100 UNITS/ML/	/N17029/012/	/SEP/22,/1987/
	@ LYPHOMED	10 UNITS/ML	N17029 011	SEP 22, 1987
	@	100 UNITS/ML	N17029 012	SEP 22, 1987

HEPARIN LOCK FLUSH PRESERVATIVE FREE IN PLASTIC CONTAINER

/AP/	/LYPHOMED/	/10 UNITS/ML/	/N17029/008/	/SEP/22,/1987/
/AP/		/100 UNITS/ML/	/N17029/009/	/SEP/22,/1987/
	@ LYPHOMED	10 UNITS/ML	N17029 008	SEP 22, 1987
	@	100 UNITS/ML	N17029 009	SEP 22, 1987

HEPARIN SODIUM

/AP/	/LUITPOLD/	/1,000 UNITS/ML/	/N87452/001/	/OCT/31,/1983/
	@ LUITPOLD	1,000 UNITS/ML	N87452 001	OCT 31, 1983

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

>DLT >/AP/	/SMITH/NEPHEW/SOLOPAK/	/1,000 UNITS/ML/	/N87043/001/	
>DLT >/AP/		/5,000 UNITS/ML/	/N87077/001/	
>DLT >/AP/		/10,000 UNITS/ML/	/N87107/001/	
>DLT >/AP/		/5,000 UNITS/0.5ML/	/N87395/001/	
>DLT >/AP/		/10,000 UNITS/0.5ML/	/N87363/001/	
>ADD > AP	SOLOPAK MEDCL	1,000 UNITS/ML	N87043 001	
>ADD > AP		5,000 UNITS/ML	N87077 001	
>ADD > AP		10,000 UNITS/ML	N87107 001	
>ADD > AP		5,000 UNITS/0.5ML	N87395 001	
>ADD > AP		10,000 UNITS/0.5ML	N87363 001	

HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5%

/3/ABBOTT/		/10,000/UNITS/100ML/	/N18911/006/	/JAN/30,/1985/
AP	ABBOTT	10,000 UNITS/100ML	N18911 006	JAN 30, 1985

HEPARIN SODIUM 1000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	MCGAW	200 UNITS/100ML*	N19953 001	JUL 20, 1992

HEPARIN SODIUM 12500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	MCGAW	5,000 UNITS/100ML*	N19802 001	JUL 20, 1992

HEPARIN SODIUM 20000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	MCGAW	4,000 UNITS/100ML*	N19952 001	JUL 20, 1992

HEPARIN SODIUM 25000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	MCGAW	5,000 UNITS/100ML*	N19952 004	JUL 20, 1992
AP		10,000 UNITS/100ML*	N19952 005	JUL 20, 1992

HEPARIN SODIUM 25000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	MCGAW	5,000 UNITS/100ML*	N19802 005	JUL 20, 1992
AP		10,000 UNITS/100ML*	N19802 002	JUL 20, 1992

HEPARIN SODIUM 25000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	MCGAW	5,000 UNITS/100ML*	N19802 003	JUL 20, 1992

HISTRELIN ACETATE

INJECTABLE; INJECTION
SUPPRELIN

/JOHNSON/RW/	/EQ/0.2MG/BASE/ML/	/N19836/001/ /DEC/24,/1991/	
	/EQ/0.5MG/BASE/ML/	/N19836/002/ /DEC/24,/1991/	
	/EQ/1MG/BASE/ML/	/N19836/003/ /DEC/24,/1991/	
ROBERTS	EQ 0.2MG BASE/ML	N19836 001 DEC 24, 1991	
	EQ 0.5MG BASE/ML	N19836 002 DEC 24, 1991	
	EQ 1MG BASE/ML	N19836 003 DEC 24, 1991	

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
APRESOLINE

/BP/ /CIBA/	/20MG/ML/	/N083303/003/	
CIBA	20MG/ML	N08303 003	

/HYDRALAZINE HCL/

/BP/ /LYPHOMED/	/20MG/ML/	/N089532/001/ /AUG/11,/1987/	
∂ LYPHOMED	20MG/ML	N89532 001 AUG 11, 1987	

TABLET; ORAL
HYDRALAZINE HCL

∂ EON LABS	50MG	N85088 001	
/AB/ /VANGARD/	/25MG/	/N087712/001/	
∂ VANGARD	25MG	N87712 001	
/∂/VITARINE/	/50MG/	/N085088/001/	

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE; ORAL
/HYDRAL/

/AB/ /SOLVAY/	/25MG;25MG/	/N087608/001/ /FEB/08,/1982/	
/AB/	/50MG;50MG/	/N087213/001/ /FEB/08,/1982/	
/AB/	/100MG;50MG/	/N087609/001/ /FEB/08,/1982/	

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE; ORAL
HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE

AB SOLVAY	25MG;25MG	N87608 001 FEB 08, 1982	
AB	50MG;50MG	N87213 001 FEB 08, 1982	
∂	100MG;50MG	N87609 001 FEB 08, 1982	

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL
HYDRAP-ES

∂ EON LABS	25MG;15MG;0.1MG	N84876 001	
/∂/VITARINE/	/25MG;15MG;0.1MG/	/N084876/001/	

/RESERPINE/HYDRALAZINE/HCL/HYDROCHLOROTHIAZIDE/

/BP/ /DANBURY/	/25MG;15MG;0.1MG/	/N085549/001/	
/BP/	/25MG;15MG;0.1MG/	/N087556/001/	

RESERPINE, HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE

BP DANBURY	25MG;15MG;0.1MG	N85549 001	
BP	25MG;15MG;0.1MG	N87556 001	

HYDRALAZINE HYDROCHLORIDE; RESERPINE

TABLET; ORAL
DRALSERP

∂ EON LABS	25MG;0.1MG	N84617 001	
/∂/VITARINE/	/25MG;0.1MG/	/N084617/001/	

SERPASIL-APRESOLINE

/BP/ /CIBA/	/25MG;0.1MG/	/N009296/004/	
CIBA	25MG;0.1MG	N09296 004	

HYDROCHLOROTHIAZIDE

SOLUTION; ORAL
/HYDROCHLOROTHIAZIDE/INTENSOL/

/ROXANE/	/100MG/ML/	/N088588/001/ /JUL/02,/1984/	
∂ ROXANE	100MG/ML	N88588 001 JUL 02, 1984	

TABLET; ORAL
HYDROCHLOROTHIAZIDE

AB DANBURY	25MG	N81189 001 JAN 24, 1992	
AB	100MG	N81190 001 JAN 24, 1992	

HYDROCHLOROTHIAZIDE

TABLET; ORAL

	HYDROCHLOROTHIAZIDE		
/AB/	/EON LABS/	/25MG/	/N83899/001/
AB	EON LABS	50MG	N85219 001
		25MG	N83899 001
	∂		/N84135/001/
/AB/	/HEATHER/	/50MG/	N84135 001
	∂ HEATHER	50MG	/N85219/001/
/AB/	/VITARINE/	/50MG/	/N87586/001/
/AB/	/WARNER/CHILCOTT/	/25MG/	/MAY/03,/1982/
			/N87587/001/
/AB/		/50MG/	/MAY/03,/1982/
	∂ WARNER CHILCOTT	25MG	N87586 001
			MAY 03, 1982
	∂	50MG	N87587 001
			MAY 03, 1982

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

	HYDRO-SERP 25		
	∂ EON LABS	25MG;0.125MG	N84827 001
	/∂/VITARINE/	/25MG;0.125MG/	/N84827/001/
	HYDRO-SERP 50		
	∂ EON LABS	50MG;0.125MG	N85213 001
	/∂/VITARINE/	/50MG;0.125MG/	/N85213/001/
	/SERPASIL-ESIDRIX/#1/		
/BP/	/CIBA/	/25MG;0.1MG/	/N11878/003/
	∂ CIBA	25MG;0.1MG	N11878 003
	/SERPASIL-ESIDRIX/#2/		
/BP/	/CIBA/	/50MG;0.1MG/	/N11878/005/
	∂ CIBA	50MG;0.1MG	N11878 005

HYDROCHLOROTHIAZIDE; TRIAMTERENE

TABLET; ORAL

	MAXZIDE-25		
AB	MYLAN	25MG;37.5MG	N19129 003
			MAY 13, 1988
	TRIAMTERENE AND HYDROCHLOROTHIAZIDE		
	/∂/EON LABS/	/50MG;75MG/	/N71366/001/
> DLT >			/DEC/08,/1987/
> DLT >			N73281 001
AB	GENEVA	25MG;37.5MG	APR 30, 1992

HYDROCORTISONE

CREAM; TOPICAL

	HYDROCORTISONE		
/AT/	/BAUSCH AND LOMB/	/1%/	/N87838/001/
			/JUL/28,/1982/
AT	PHARMAFAIR	1%	N87838 001
			JUL 28, 1982

LOTION; TOPICAL

	/CORT-DOME/		
/AT/	/MILES/	/0.5%/	/N09895/003/
/AT/		/1%/	/N09895/001/
	∂ MILES	0.5%	N09895 003
	∂	1%	N09895 001

	HYDROCORTISONE		
/AT/	/THAMES/	/1%/	/N89024/001/
			/FEB/12,/1986/
	∂ THAMES	1%	N89024 001
			FEB 12, 1986

OINTMENT; TOPICAL

	HYDROCORTISONE		
AT	NMC	1%	N87796 001
			OCT 13, 1982
	/HYMAC/		
/AT/	/NMC/	/1%/	/N87796/001/
			/OCT/13,/1982/

SOLUTION; TOPICAL

	TEXACORT		
	GENDERM	2.5%	N81271 001
			APR 17, 1992

TABLET; ORAL

	/HYCORTOLE/		
	/∂/VITARINE/	/20MG/	/N80642/002/
	HYDROCORTISONE		
	∂ EON LABS	20MG	N80642 002

> DLT >	/TABLET;/VAGINAL/		
> DLT >	/CORTRIL/		
> DLT >	/PFIPHARMECS/	/10MG/	/N09796/001/
> ADD >	∂ PFIPHARMECS	10MG	N09796 001

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION; OTIC

>DLT>		OTOBIONE		
>DLT>/AT/	/SCHERING/	/1%;EQ 3.5MG BASE/ML;/		
>DLT>		/10,000 UNITS/ML/	/N61816/001/	
>ADD>	∂ SCHERING	1%;EQ 3.5MG BASE/ML;		
>ADD>		10,000 UNITS/ML	N61816 001	

HYDROCORTISONE ACETATE

CREAM; TOPICAL

	HEMSOL-HC		
AT	ABLE	1%¤	N81274 001 JUN 19, 1992

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE

/CREAM;/TOPICAL/

	/NEO-CORTEF/		
	/UPJOHN/	/1%;EQ/3.5MG/BASE/GM/	/N61049/001/
		/2.5%;EQ/3.5MG/BASE/GM/	/N61049/002/
	∂ UPJOHN	1%;EQ 3.5MG BASE/GM	N61049 001
	∂	2.5%;EQ 3.5MG BASE/GM	N61049 002

SUSPENSION/DROPS; OPHTHALMIC

	COR-OTICIN			
/AT/	/AKORN/	/1.5%;EQ 3.5MG BASE/ML/	/N60188/001/	
	AKORN	1.5%;EQ 3.5MG BASE/ML	N60188 001	
	/NEO-CORTEF/			
/AT/	/UPJOHN/	/0.5%;EQ 3.5MG BASE/ML/	/N60612/002/	
/AT/		/1.5%;EQ 3.5MG BASE/ML/	/N60612/001/	
	∂ UPJOHN	0.5%;EQ 3.5MG BASE/ML	N60612 002	
	∂	1.5%;EQ 3.5MG BASE/ML	N60612 001	

HYDROCORTISONE ACETATE; UREA

CREAM; TOPICAL

/HYDROCORTISONE ACETATE/

/AT/	/THAMES/	/1%;10%/	/N89472/001/ /JUN/13,/1988/
	U-CORT		
AT	THAMES	1%;10%	N89472 001 JUN 13, 1988

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

HYDROCORTISONE SODIUM SUCCINATE

/AP/	/ELKINS/SINN/	/EQ 100MG BASE/VIAL/	/N86619/001/
/AP/		/EQ 250MG BASE/VIAL/	/N87567/001/
/AP/		/EQ 500MG BASE/VIAL/	/N87568/001/
	∂ ELKINS SINN	EQ 100MG BASE/VIAL	N86619 001
	∂	EQ 250MG BASE/VIAL	N87567 001
	∂	EQ 500MG BASE/VIAL	N87568 001

HYDROFLUMETHIAZIDE; RESERPINE

TABLET; ORAL

/HYDROFLUMETHIAZIDE/AND/RESERPINE/

/B¤/	/PHARM/BASICS/	/50MG;0.125MG/	/N88195/001/ /OCT/26,/1983/
	∂ PHARM BASICS	50MG;0.125MG	N88195 001 OCT 26, 1983

HYDROMORPHONE HYDROCHLORIDE

SOLUTION; ORAL

>ADD>	DILAUDID		
>ADD>	KNOLL	5MG/5ML¤	N19891 001 DEC 07, 1992

TABLET; ORAL

>ADD>	DILAUDID		
>ADD>	+ KNOLL	8MG¤	N19892 001 DEC 07, 1992

HYDROXYAMPHETAMINE HYDROBROMIDE; TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC

PAREMYD		
ALLERGAN	1%;0.25%¤	N19261 001 JAN 30, 1992

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

PLAQUENIL		
+ STERLING	200MG /EQ/155MG/BASE/	N09768 001 /N09768/001/

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROXYZINE HCL

> ADD > AP	FUJISAWA	25MG/ML	N87329 001	
> ADD > AP		50MG/ML	N87329 002	
> DLT > /AP/	/LYPHOMED/	/25MG/ML/	/N87329/001/	
> DLT > /AP/		/50MG/ML/	/N87329/002/	
> DLT > /AP/	/SMITH/NEPHEW/SOCOPAK/	/25MG/ML/	/N86822/001/	
> DLT > /AP/		/50MG/ML/	/N87310/001/	
> DLT > /AP/		/50MG/ML/	/N87596/001/	
> ADD > AP	SOLOPAK MEDCL	25MG/ML	N86822 001	
> ADD > AP		50MG/ML	N87310 001	
> ADD > AP		50MG/ML	N87596 001	

TABLET; ORAL

HYDROXYZINE HCL

/AB/	/EON/LABS/	/10MG/	/N87246/001/	
/AB/		/25MG/	/N85247/001/	
/AB/		/50MG/	/N87245/001/	
	∂ EON LABS	10MG	N87246 002	
	∂	25MG	N85247 001	
	∂	50MG	N87245 001	
/B*/	/PHARM/BASICS/	/10MG/	/N89121/001/	
/B*/		/25MG/	/MAR/20,/1986/ /N89122/001/	
/B*/		/50MG/	/MAR/20,/1986/ /N89123/001/	
	∂ PHARM BASICS	10MG	/MAR/20,/1986/ N89121 001 MAR 20, 1986	
	∂	25MG	N89122 001 MAR 20, 1986	
	∂	50MG	N89123 001 MAR 20, 1986	

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HY-PAM

AB	EON LABS	EQ 25MG HCL	N87479 001	
/AB/	/VITARINE/	/EQ 25MG HCL/	/N87479/001/	

HYDROXYZINE PAMOATE

AB	EON LABS	EQ 50MG HCL	N86183 001	
/AB/	/VITARINE/	/EQ 50MG HCL/	/N86183/001/	

IBUPROFEN

TABLET; ORAL

IBUPROFEN

/AB/	/BOOTS/	/600MG/	/N70556/001/	
			/JUN/14,/1985/	
	∂ BOOTS	600MG	N70556 001 JUN 14, 1985	
AB	LEMMON	400MG	N73343 001 JUN 30, 1992	
AB		600MG	N73344 001 JUN 30, 1992	
AB		800MG	N73345 001 JUN 30, 1992	
/AB/	/MEDICOPHARMA/	/400MG/	/N71644/001/ /FEB/01,/1988/	
/AB/	/SUPERPHARM/	/600MG/	/N70709/001/ /APR/25,/1986/	
	∂ SUPERPHARM	600MG	N70709 001 APR 25, 1986	
AB	VINTAGE	400MG	N71644 001 FEB 01, 1988	

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HCL

AB	EON LABS	10MG	N85200 001	
AB		25MG	N84869 002	
AB		50MG	N85133 001	
/AB/	/VITARINE/	/25MG/	/N84869/002/	
/AB/		/50MG/	/N85133/001/	
/AB/		/10MG/	/N85200/001/	

INDOMETHACIN

CAPSULE; ORAL

INDOMETHACIN

> DLT >	/∂/EON/LABS/	/25MG/	/N71711/001/ /JUL/05,/1988/	
> DLT >			/N71712/001/	
> DLT >	/∂/	/50MG/	/JUL/05,/1988/	
> DLT >			/N70813/001/	
/AB/	/PIONEER/PHARMS/	/25MG/	/AUG/11,/1986/	
/AB/		/50MG/	/N70592/001/ /AUG/11,/1986/	
	∂ PIONEER PHARMS	25MG	N70813 001 AUG 11, 1986	
	∂	50MG	N70592 001 AUG 11, 1986	

INDOMETHACIN

CAPSULE, EXTENDED RELEASE; ORAL
INDOMETHACIN

>DLT<	/3/EON/LABS/	/75MG/	/N71531/001/	
>DLT<			/JUL/21,/1987/	

SUPPOSITORY; RECTAL
INDOCIN

AB	+ MERCK	50MG	N17814 001	
			AUG 13, 1984	

INDOMETHEGAN

AB	G AND W	50MG¤	N73314 001	
			AUG 31, 1992	

IOFETAMINE HYDROCHLORIDE I-123

INJECTABLE; INJECTION
SPECTAMINE

	IMP	1 MCI/ML	N19432 001	
			DEC 24, 1987	
	/MEDI/PHYSICS/	/1/MCI/ML/	/N19432/001/	
			/DEC/24,/1987/	

IOPAMIDOL

INJECTABLE; INJECTION
ISOVUE-250

	SQUIBB	51%¤	N18735 007	
			JUL 06, 1992	

IOPHENDYLATE

/INJECTABLE;/INJECTION/
/PANTOPAQUE/

	/LAFAYETTE/	/100%/	/N05319/001/	
ə	ALCON	100%	N05319 001	

IOVERSOL

INJECTABLE; INJECTION
OPTIRAY 300

	MALLINCKRODT	64%¤	N19710 004	
			JAN 22, 1992	

OPTIRAY 350

	MALLINCKRODT	74%¤	N19710 005	
			JAN 22, 1992	

IRON DEXTRAN

INJECTABLE; INJECTION
/INFERON/

/AP/	/FISONS/	/EQ 50MG IRON/ML/	/N10787/002/		
ə	FISONS	EQ 50MG IRON/ML	N10787 002		

IRON DEXTRAN
/STERIS/

BP	STERIS	EQ 50MG IRON/ML	N17441 001	
	PROFERDEX			
BP	/3/FISONS/ LOTUS	/EQ/50MG/IRON/ML/ EQ 50MG IRON/ML	/N17807/001/ N17807 001	

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION
ISOETHARINE HCL

/AN/	/ARMOUR/	/0.125%/	/N87938/001/	
			/NOV/15,/1982/	
/AN/		/0.167%/	/N88470/001/	
			/MAR/14,/1984/	
/AN/		/0.2%/	/N88471/001/	
			/MAR/14,/1984/	
/AN/		/0.25%/	/N88472/001/	
			/MAR/14,/1984/	
		/0.062%/	/N87937/001/	
			/NOV/15,/1982/	
AN	ASTRA	0.125%	N87938 001	
			NOV 15, 1982	
		0.062%	N87937 001	
			NOV 15, 1982	
ə		0.167%	N88470 001	
			MAR 14, 1984	
ə		0.2%	N88471 001	
			MAR 14, 1984	
ə		0.25%	N88472 001	
			MAR 14, 1984	
/AN/	/DEY/	/0.062%/	/N88187/001/	
			/DEC/03,/1982/	
/AN/		/0.1%/	/N87389/001/	
/AN/		/0.17%/	/N87390/001/	
/AN/		/0.25%/	/N88188/001/	
			/DEC/03,/1982/	
/AN/		/1%/	/N86763/001/	
ə	DEY	0.08%	N88187 001	
			DEC 03, 1982	
ə		0.1%	N87389 001	
ə		0.17%	N87390 001	
ə		0.25%	N88188 001	
			DEC 03, 1982	
ə		1%	N86763 001	

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION
ISOETHARINE HCL S/F

AN	DEY	0.17%	N89819 001 NOV 22, 1988
/AN/	/DEY/	/0.17%/	/N89819/001/ /NOV/22,/1988/

ISOETHARINE MESYLATE

AEROSOL, METERED; INHALATION
BRONKOMETER

>DLT>	/BN/+//STERLING/	/0.34MG/INH/	/N12339/001/
>ADD>	+ STERLING	0.34MG/INH	N12339 007

ISOETHARINE MESYLATE

>DLT>	/BN/ /BARRE/	/0.34MG/INH/	/N87858/001/ /AUG/21,/1984/
>DLT>			
>ADD>	∂ BARRE	0.34MG/INH	N87858 001 AUG 21, 1984
>ADD>			

ISONIAZID

TABLET; ORAL
HYZYD

>DLT>	/AA/ /WALLACE/	/100MG/	/N80134/003/
>DLT>	/AA/	/300MG/	/N80134/004/
>ADD>	∂ WALLACE	100MG	N80134 003
>ADD>	∂	300MG	N80134 004
	/AA/ /CIBA/	/100MG/	/N80935/001/
	∂ CIBA	300MG	N80935 001

ISONIAZID

AA	EON LABS	100MG	N08678 002
AA		300MG	N08678 003
/AA/	/LILLY/	/100MG/	/N08499/002/
/AA/		/300MG/	/N08499/003/
	∂ LILLY	100MG	N08499 002
	∂	300MG	N08499 003
/AA/	/VITARINE/	/100MG/	/N08678/002/
/AA/		/300MG/	/N08678/003/

ISOPROTERENOL HYDROCHLORIDE

SOLUTION; INHALATION
ISOPROTERENOL HCL

/AN/	/DEY/	/0.5%/	/N86764/001/ /JAN/04,/1982/
	∂ DEY	0.5%	N86764 001 JAN 04, 1982

ISOSORBIDE DINITRATE

TABLET; ORAL
ISORDIL

AB	WYETH AYERST	40MG	N12093 001 JUL 29, 1988

SORBITRATE

AB	ICI	20MG	N86405 002 AUG 21, 1990
AB		30MG	N88124 001 AUG 21, 1990
AB		40MG	N88125 001 AUG 21, 1990

ISOSORBIDE MONONITRATE

TABLET; ORAL
ISMO

	+ WYETH	20MG	N19091 001 DEC 30, 1991
		/20MG/	/N19091/001/ /DEC/30,/1991/

ITRACONAZOLE

CAPSULE; ORAL
SPORANOX

	+ JANSSEN	100MG✠	N20083 001 SEP 11, 1992

KANAMYCIN SULFATE

INJECTABLE; INJECTION
KANAMYCIN SULFATE

AP	LOCH	EQ 75MG BASE/2ML✠	N63021 001 JUL 31, 1992
AP		EQ 500MG BASE/2ML✠	N63022 001 JUL 31, 1992
AP		EQ 1GM BASE/3ML✠	N63025 001 JUL 31, 1992

KANAMYCIN SULFATE

INJECTABLE; INJECTION
KANAMYCIN SULFATE

/AP/	/LYPHOMED/	/EQ 75MG BASE/2ML/	/N62504/001/ /APR/05,/1984/
/AP/		/EQ 500MG BASE/2ML/	/N62504/002/ /APR/05,/1984/
/AP/		/EQ 1GM BASE/3ML/	/N62504/003/ /APR/05,/1984/
	∂ LYPHOMED	EQ 75MG BASE/2ML	N62504 001 APR 05, 1984
	∂	EQ 500MG BASE/2ML	N62504 002 APR 05, 1984
	∂	EQ 1GM BASE/3ML	N62504 003 APR 05, 1984
> DLT > /AP/	/SMITH/NEPHEW/SOLOPAK	/EQ 75MG BASE/2ML/	/N62605/003/ /FEB/26,/1986/
> DLT >			
> ADD > AP	SOLOPAK	EQ 75MG BASE/2ML	N62605 003 FEB 26, 1986
> ADD >			
> DLT > /AP/	/SMITH/NEPHEW/SOLOPAK	/EQ 500MG BASE/2ML/	/N62605/001/ /FEB/26,/1986/
> DLT >			
> ADD > AP	SOLOPAK	EQ 500MG BASE/2ML	N62605 001 FEB 26, 1986
> ADD >			
> DLT > /AP/	/SMITH/NEPHEW/SOLOPAK	/EQ 1GM BASE/3ML/	/N62605/002/ /FEB/26,/1986/
> DLT >			
> ADD > AP	SOLOPAK	EQ 1GM BASE/3ML	N62605 002 FEB 26, 1986
> ADD >			

KETOPROFEN

CAPSULE; ORAL
KETOPROFEN

> ADD > AB	BIOCRAFT	25MG¤	N73515 001 DEC 22, 1992
> ADD > AB		50MG¤	N73516 001 DEC 22, 1992
> ADD > AB		75MG¤	N73517 001 DEC 22, 1992
	ORUDIS		
> ADD > AB	WYETH AYERST	25MG	N18754 001 JUL 31, 1987
> ADD > AB		50MG	N18754 002 JAN 09, 1986
> ADD > AB +		75MG	N18754 003 JAN 09, 1986

KETOROLAC TROMETHAMINE

SOLUTION/DROPS; OPHTHALMIC
ACULAR

SYNTEX	0.5%¤	N19700 001 NOV 09, 1992

TABLET; ORAL
TORADOL

+ SYNTEX	10MG	N19645 001 DEC 20, 1991
	/10MG/	/N19645/001/ /DEC/20,/1991/

LACTULOSE

SYRUP; ORAL
LACTULOSE

AA	PACO	10GM/15ML¤	N73160 001 AUG 25, 1992
AA	ROXANE	10GM/15ML¤	N73591 001 MAY 29, 1992
AA	UDL	10GM/15ML¤	N74138 001 SEP 30, 1992

SYRUP; ORAL, RECTAL
LACTULOSE

AA	PACO	10GM/15ML¤	N72029 001 AUG 25, 1992
AA	ROXANE	10GM/15ML¤	N73590 001 MAY 29, 1992

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION
LEUCOVORIN CALCIUM

/AP/	/ABIC/	/EQ 3MG BASE/ML/	/N89352/001/ /JUN/01,/1988/
/AP/		/EQ 50MG BASE/VIAL/	/N89353/001/ /JUN/01,/1988/
	∂ ABIC	EQ 3MG BASE/ML	N89352 001 JUN 01, 1988
	∂	EQ 50MG BASE/VIAL	N89353 001 JUN 01, 1988
/AP/	/LYPHOMED/	/EQ 50MG BASE/VIAL/	/N88939/001/ /DEC/01,/1986/
	∂ LYPHOMED	EQ 50MG BASE/VIAL	N88939 001 DEC 01, 1986

LEVOCARNITINE

> ADD > INJECTABLE; INJECTION
> ADD > CARNITOR
> ADD > SIGMA TAU 200MG/ML¤ N20182 001
> ADD > DEC 16, 1992

SOLUTION; ORAL
CARNITOR
AA SIGMA TAU 1GM/10ML N19257 001
APR 10, 1986

/VITACARN/
/AA/ /MCGAW/ /1GM/10ML/ /N19257/001/
/APR/10,/1986/

LEVODOPA

CAPSULE; ORAL
DOPAR
/+//P/AND/G/ /500MG/ /N16913/002/
/100MG/ /N16913/003/
/250MG/ /N16913/001/
+ ROBERTS 500MG N16913 002
100MG N16913 003
250MG N16913 001

LEVORPHANOL TARTRATE

TABLET; ORAL
LEVO-DROMORAN
+ ROCHE 2MG N08720 001
DEC 19, 1991
/2MG/ /N08720/001/
/DEC/19,/1991/

> ADD > LIDOCAINE; PRILOCAINE

> ADD > CREAM; TOPICAL
> ADD > EMLA
> ADD > + ASTRA 2.5%;2.5%¤ N19941 001
> ADD > DEC 30, 1992

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
LIDOCAINE HCL
/INTL/MEDICATION/ /1GM/VIAL/ /N18543/001/
∂ INTL MEDICATION 1GM/VIAL N18543 001
/2GM/VIAL/ /N18543/002/
∂ 2GM/VIAL N18543 002
LIDOCAINE HCL 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER
AP MCGAW 200MG/100ML¤ N19830 002
APR 08, 1992
LIDOCAINE HCL 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER
AP MCGAW 400MG/100ML¤ N19830 003
APR 08, 1992
LIDOCAINE HCL 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER
AP MCGAW 800MG/100ML¤ N19830 004
APR 08, 1992

LIDOCAINE HYDROCHLORIDE; OXYTETRACYCLINE

INJECTABLE; INJECTION
TERRAMYCIN
> DLT > /∂/PFIZER/ /2%;50MG/ML/ /N60567/001/
> ADD > PFIZER 2%;50MG/ML N60567 001
> DLT > /∂/ /2%;125MG/ML/ /N60567/002/
> ADD > 2%;125MG/ML N60567 002

LITHIUM CARBONATE

CAPSULE; ORAL
LITHIUM CARBONATE
/B*/ /PHARM/BASICS/ /300MG/ /N72542/001/
/FEB/01,/1989/
∂ PHARM BASICS 300MG N72542 001
FEB 01, 1989

LOMEFLOXACIN HYDROCHLORIDE

TABLET; ORAL
MAXAQUIN
+ SEARLE EQ 400MG BASE¤ N20013 001
FEB 21, 1992

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL
LOPERAMIDE HCL
AB GENEVA 2MG¤ N72993 001
AUG 28, 1992

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL
LOPERAMIDE HCL
AB LEMMON 2MG N73192 001 APR 30, 1992

LORACARBEF

CAPSULE; ORAL
LORABID
+ LILLY 200MG N50668 001 DEC 31, 1991
/200MG/ /N50668/001/ /DEC/31,/1991/

POWDER FOR RECONSTITUTION; ORAL
LORABID
+ LILLY 200MG/5ML N50667 002 DEC 31, 1991
/200MG/5ML/ /N50667/002/ /DEC/31,/1991/

LORAZEPAM

TABLET; ORAL
LORAZEPAM
/B*/ /PHARM/BASICS/ /1MG/ /N70539/001/ /DEC/22,/1986/
/B*/ /2MG/ /N70540/001/ /DEC/22,/1986/
∂ PHARM BASICS 1MG N70539 001 DEC 22, 1986
∂ 2MG N70540 001 DEC 22, 1986

MANNITOL

INJECTABLE; INJECTION
MANNITOL 25%
> ADD > AP FUJISAWA 12.5GM/50ML N80677 001
> DLT > /AP/ /LYPHOMED/ /12.5GM/50ML/ /N80677/001/ > DLT >
/AP/ /12.5GM/50ML/ /N86754/001/ > DLT >
∂ LYPHOMED 12.5GM/50ML N86754 001

MASOPROCOL

CREAM; TOPICAL
ACTINEX
+ CHEMEX 10% N19940 001 SEP 04, 1992

MECLOFENAMATE SODIUM

CAPSULE; ORAL
MECLOFENAMATE SODIUM
/B*/ /PHARM/BASICS/ /EQ/50MG/BASE/ /N71007/001/ /MAR/25,/1988/
/B*/ /EQ/100MG/BASE/ /N71008/001/ /MAR/25,/1988/
∂ PHARM BASICS EQ 50MG BASE N71007 001 MAR 25, 1988
∂ EQ 100MG BASE N71008 001 MAR 25, 1988

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION
DEPO-PROVERA
UPJOHN 150MG/ML N20246 001 OCT 29, 1992

TABLET; ORAL
CYCRIN
AB WYETH AYERST 2.5MG N81239 001 OCT 30, 1992
AB 5MG N81240 001 OCT 30, 1992
PROVERA
AB UPJOHN 2.5MG N11839 001
AB 5MG N11839 003

MEFENAMIC ACID

CAPSULE; ORAL
MEFENAMIC ACID
> DLT > /∂/EON/LABS/ /250MG/ /N72179/001/ /APR/21,/1988/

MEGESTROL ACETATE

TABLET; ORAL
MEGESTROL ACETATE

/B*/	/PHARM/BASICS/	/20MG/	/N70646/001/	/OCT/02,/1987/
/B*/		/40MG/	/N70647/001/	/OCT/02,/1987/
	∂ PHARM BASICS	20MG	N70646 001	OCT 02, 1987
	∂	40MG	N70647 001	OCT 02, 1987

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION
ALKERAN

	BURROUGHS WELLCOME	EQ 50MG BASE/VIAL*	N20207 001	NOV 18, 1992

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
MEPERIDINE HCL

AP	ABBOTT	10MG/ML	N88432 001	AUG 16, 1984
/AP/	/PARKE/DAVIS/	/50MG/ML/	/N80364/002/	
/AP/		/75MG/ML/	/N80364/003/	
/AP/		/100MG/ML/	/N80364/001/	
	∂ PARKE DAVIS	50MG/ML	N80364 002	
	∂	75MG/ML	N80364 003	
	∂	100MG/ML	N80364 001	
AP	STERIS	10MG/ML*	N73443 001	MAR 17, 1992
AP		50MG/ML*	N73444 001	MAR 17, 1992
AP		100MG/ML*	N73445 001	MAR 17, 1992

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION
/POLOCAINE/

/AP/	/ASTRA/	/1%/	/N89406/001/	/DEC/01,/1986/
/AP/		/1.5%/	/N89408/001/	/DEC/01,/1986/
/AP/		/2%/	/N89409/001/	/DEC/01,/1986/

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION
POLOCAINE-MPF

AP	ASTRA	1%	N89406 001	DEC 01, 1986
AP		1.5%	N89408 001	DEC 01, 1986
AP		2%	N89409 001	DEC 01, 1986

MEPROBAMATE

TABLET; ORAL
MEPROBAMATE

	∂ ELKINS SINN	200MG	N15426 002	
	∂	400MG	N15426 001	
AA	EON LABS	200MG	N14547 002	
AA		400MG	N14547 001	
> DLT > /AA/	/HEATHER/	/400MG/	/N16928/003/	
/AA/		/600MG/	/N84329/001/	
> ADD >	∂ HEATHER	400MG	N16928 003	
	∂	600MG	N84329 001	
/AA/	/ICN/	/200MG/	/N15139/006/	
/AA/		/400MG/	/N15139/005/	
	∂ ICN	200MG	N15139 006	
	∂	400MG	N15139 005	
/AA/	/PARKE/DAVIS/	/200MG/	/N84744/001/	
/AA/		/400MG/	/N84744/002/	
	∂ PARKE DAVIS	200MG	N84744 001	
	∂	400MG	N84744 002	
	/∂/QUANTUM/PHARMICS/	/200MG/	/N15426/002/	
	/∂/	/400MG/	/N15426/001/	
/AA/	/VITARINE/	/200MG/	/N14547/002/	
/AA/		/400MG/	/N14547/001/	
/AA/	/ZENITH/	/200MG/	/N15438/001/	
/AA/		/400MG/	/N15438/002/	
	∂ ZENITH	200MG	N15438 001	
	∂	400MG	N15438 002	

MESALAMINE

TABLET, DELAYED RELEASE; ORAL
ASACOL

+	P AND G	400MG*	N19651 001	JAN 31, 1992

METAPROTERENOL SULFATE

SOLUTION; INHALATION

	METAPROTERENOL SULFATE			
/AN/	/ARMOUR/	/0.4%/	/N71275/001/	
			/JUL/27,/1988/	
/AN/		/0.6%/	/N71018/001/	
			/JUL/27,/1988/	
AN	ASTRA	0.4%	N71275 001	JUL 27, 1988
AN		0.6%	N71018 001	JUL 27, 1988
	/DEY/	/0.33%/	/N71806/001/	
			/AUG/05,/1988/	
	ə DEY	0.33%	N71806 001	AUG 05, 1988
> DLT >		/0.5%/	/N71805/001/	
> DLT >			/AUG/05,/1988/	
> ADD >	ə	0.5%	N71805 001	AUG 05, 1988
> ADD >				
	PROMETA			
AN	MURO	5%¤	N73340 001	MAR 30, 1992

SYRUP; ORAL

	METAPROTERENOL SULFATE			
AA	BIOCRAFT	10MG/5ML¤	N72761 001	FEB 27, 1992
AA	SILARX	10MG/5ML¤	N73632 001	JUL 22, 1992

TABLET; ORAL

	METAPROTERENOL SULFATE			
/B*/	/PHARM/BASICS/	/10MG/	/N71013/001/	
			/JAN/25,/1988/	
/B*/		/20MG/	/N71014/001/	
			/JAN/25,/1988/	
	ə PHARM BASICS	10MG	N71013 001	JAN 25, 1988
	ə	20MG	N71014 001	JAN 25, 1988

METHACYCLINE HYDROCHLORIDE

> DLT >	/CAPSULE;/ORAL/			
> DLT >	/RONDOMYCIN/			
> DLT >	/+//WALLACE/	/EQ/280MG/BASE/	/N60641/002/	
> DLT >		/EQ/140MG/BASE/	/N60641/001/	
> ADD >	ə WALLACE	EQ 140MG BASE	N60641 001	
> ADD >	ə	EQ 280MG BASE	N60641 002	

METHACYCLINE HYDROCHLORIDE

> DLT >	/SYRUP;/ORAL/			
> DLT >	/RONDOMYCIN/			
> DLT >	/+//WALLACE/	/EQ/70MG/BASE/5ML/	/N60641/003/	
> ADD >	ə WALLACE	EQ 70MG BASE/5ML	N60641 003	

METHADONE HYDROCHLORIDE

TABLET, DISPERSIBLE; ORAL

	WESTADONE		
	ə EON LABS	2.5MG	N17108 001
	ə	5MG	N17108 002
	ə	10MG	N17108 003
	ə	40MG	N17108 004
	/ə/VITARINE/	/2.5MG/	/N17108/001/
	/ə/	/5MG/	/N17108/002/
	/ə/	/10MG/	/N17108/003/
	/ə/	/40MG/	/N17108/004/

METHOCARBAMOL

TABLET; ORAL

	METHOCARBAMOL			
AA	EON LABS	500MG	N87283 001	
AA		750MG	N87282 001	
/AA/	/HEATHER/	/500MG/	/N84675/001/	
/AA/		/750MG/	/N84924/001/	
	ə HEATHER	500MG	N84675 001	
	ə	750MG	N84924 001	
/AA/	/VITARINE/	/500MG/	/N87283/001/	
/AA/		/750MG/	/N87282/001/	

METHOTREXATE SODIUM

INJECTABLE; INJECTION
ABITREXATE
/AP/ /ABIC/ /EQ 25MG BASE/ML/ /N89161/001/ /MAR/10/1987/
/AP/ /EQ 50MG BASE/VIAL/ /N89354/001/ /JUL/17/1987/
/AP/ /EQ 100MG BASE/VIAL/ /N89355/001/ /JUL/17/1987/
/AP/ /EQ 250MG BASE/VIAL/ /N89356/001/ /JUL/17/1987/

	∂ ABIC	EQ 25MG BASE/ML	N89161 001 MAR 10, 1987
	∂	EQ 50MG BASE/VIAL	N89354 001 JUL 17, 1987
	∂	EQ 100MG BASE/VIAL	N89355 001 JUL 17, 1987
	∂	EQ 250MG BASE/VIAL	N89356 001 JUL 17, 1987

METHOTREXATE
>DLT >/AP/ /LEDERLE/ /EQ 20MG BASE/VIAL/ /N11719/001/
>ADD > LEDERLE EQ 20MG BASE/VIAL N11719 001
>DLT > /MEXATE/
>DLT >/AP/ /BRISTOL/ /EQ 20MG BASE/VIAL/ /N86358/001/
>DLT >/AP/ /EQ 50MG BASE/VIAL/ /N86358/002/
>DLT >/AP/ /EQ 100MG BASE/VIAL/ /N86358/003/
>DLT >/AP/ /EQ 250MG BASE/VIAL/ /N86358/004/

>ADD >	∂ BRISTOL	EQ 20MG BASE/VIAL	N86358 001
>ADD >	∂	EQ 50MG BASE/VIAL	N86358 002
>ADD >	∂	EQ 100MG BASE/VIAL	N86358 003
>ADD >	∂	EQ 250MG BASE/VIAL	N86358 004

TABLET; ORAL
METHOTREXATE

AB	MYLAN	EQ 2.5MG BASE*	N81235 001 MAY 15, 1992

METHOXYFLURANE

LIQUID; INHALATION
PENTHRANE

	ABBOTT	99.9%	N13056 001

/SOLUTION;INHALATION/
/PENTHRANE/
/ABBOTT/ /99.9%/ /N13056/001/

METHYCLOTHIAZIDE

TABLET; ORAL
METHYCLOTHIAZIDE
/B*/ /PHARM BASICS/ /5MG/ /N88745/001/ /MAR/21/1985/

	∂ PHARM BASICS	5MG	N88745 001 MAR 21, 1985

METHYLDOPA

TABLET; ORAL
METHYLDOPA
/AB/ /PARKE/DAVIS/ /125MG/ /N70331/001/ /APR/15/1986/
/AB/ /250MG/ /N70332/001/ /APR/15/1986/
/AB/ /500MG/ /N70333/001/ /APR/15/1986/

	∂ PARKE DAVIS	125MG	N70331 001 APR 15, 1986
	∂	250MG	N70332 001 APR 15, 1986
	∂	500MG	N70333 001 APR 15, 1986

METHYLPREDNISOLONE

TABLET; ORAL
METHYLPREDNISOLONE

	∂ EON LABS	4MG	N87341 001
>DLT >/AB/	/HEATHER/	/4MG/	/N85650/001/
>ADD >	∂ HEATHER	4MG	N85650 001
	/∂/VITARINE/	/4MG/	/N87341/001/

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION
METHYLPREDNISOLONE
/AP/ /ELKINS/SINN/ /EQ 125MG BASE/VIAL/ /N86906/002/
/AP/ /EQ 500MG BASE/VIAL/ /N86906/003/
/AP/ /EQ 1GM BASE/VIAL/ /N86906/004/

∂ ELKINS SINN	EQ 125MG BASE/VIAL	N86906 002
∂	EQ 500MG BASE/VIAL	N86906 003
∂	EQ 1GM BASE/VIAL	N86906 004

METHYLPREDNISOLONE SODIUM SUCCINATE
/AP/ /ELKINS/SINN/ /EQ 40MG BASE/VIAL/ /N86906/001/

∂ ELKINS SINN	EQ 40MG BASE/VIAL	N86906 001

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION
METHYLPREDNISOLONE SODIUM SUCCINATE

AP	GENSIA	EQ 125MG BASE/VIAL*	N81266 001 NOV 30, 1992
AP		EQ 500MG BASE/VIAL*	N81267 001 NOV 30, 1992
AP		EQ 1GM BASE/VIAL*	N81268 001 NOV 30, 1992

METOCLOPRAMIDE HYDROCHLORIDE

CONCENTRATE; ORAL
METOCLOPRAMIDE INTENSOL

	ROXANE	EQ 10MG BASE/ML*	N72995 001 JAN 30, 1992

INJECTABLE; INJECTION
METOCLOPRAMIDE HCL

AP	CETUS BEN VENUE	EQ 10MG BASE/2ML*	N72155 001 MAR 30, 1992
AP		EQ 10MG BASE/2ML*	N72244 001 MAR 30, 1992
AP		EQ 10MG BASE/2ML*	N72247 001 MAY 18, 1992
> ADD > AP	FUJISAWA	EQ 10MG BASE/2ML	N70293 001 JAN 24, 1986
> ADD > > DLT > /AP/	/LYPHOMED/	/EQ 10MG BASE/2ML/	/N70293/001/ /JAN/24,/1986/
> DLT >			

SOLUTION; ORAL
METOCLOPRAMIDE HCL

AA	SILARX	EQ 5MG BASE/5ML*	N73680 001 OCT 27, 1992

TABLET; ORAL
METOCLOPRAMIDE HCL

/B*/	/INTERPHARM/	/EQ/10MG/BASE/	/N71213/001/ /SEP/24,/1986/
	◑ INTERPHARM	EQ 10MG BASE	N71213 001 SEP 24, 1986
/B*/	/PHARM/BASICS/	/EQ/10MG/BASE/	/N70339/001/ /JUL/29,/1985/
	◑ PHARM BASICS	EQ 10MG BASE	N70339 001 JUL 29, 1985

METOLAZONE

TABLET; ORAL
/DIULO/

/AB/	/SCHIAPPARELLI/SEARLE/	/2.5MG/	/N18535/001/
/AB/		/5MG/	/N18535/002/
/AB/		/10MG/	/N18535/003/
	◑ SCHIAPPARELLI SEARLE	2.5MG	N18535 001
	◑	5MG	N18535 002
	◑	10MG	N18535 003

ZAROXOLYN

/AB/	/FISONS/	/2.5MG/	/N17386/001/
/AB/		/5MG/	/N17386/002/
/AB/		/10MG/	/N17386/003/
/AB/ /+/	+ FISONS	10MG	N17386 003
		2.5MG	N17386 001
		5MG	N17386 002

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL
TOPROL XL

+	HASSLE	EQ 50MG TARTRATE*	N19962 001 JAN 10, 1992
+		EQ 100MG TARTRATE*	N19962 002 JAN 10, 1992
+		EQ 200MG TARTRATE*	N19962 003 JAN 10, 1992

METRONIDAZOLE

GEL; VAGINAL
METROGEL

+	CURATEK	0.75%*	N20208 001 AUG 17, 1992

INJECTABLE; INJECTION
METRONIDAZOLE

/AP/	/LYPHOMED/	/500MG/100ML/	/N70071/001/ /DEC/03,/1984/
	◑ LYPHOMED	500MG/100ML	N70071 001 DEC 03, 1984

METRONIDAZOLE

TABLET; ORAL
METRONIDAZOLE

AB	EON LABS	250MG	N18620 001 MAR 04, 1982
AB		500MG	N18620 002 JUN 02, 1983
/AB/	/VITARINE/	/250MG/	/N18620/001/ /MAR/04,/1982/
/AB/		/500MG/	/N18620/002/ /JUN/02,/1983/

METRONIDAZOLE HYDROCHLORIDE

INJECTABLE; INJECTION
FLAGYL I.V.

/AP/	/SCHIAPPARELLI/SEARLE/ SCHIAPPARELLI SEARLE	/EQ 500MG BASE/VIAL/ EQ 500MG BASE/VIAL	/N18353/001/ N18353 001
/AP/	/METRONIDAZOLE HCL/ /LYPHOMED/	/EQ 500MG BASE/VIAL/	/N70295/001/ /OCT/15,/1985/
	∂ LYPHOMED	EQ 500MG BASE/VIAL	N70295 001 OCT 15, 1985

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL
MINOCYCLINE HCL

AB	BIOCRAFT	EQ 50MG BASE*	N63011 001 MAR 02, 1992
AB		EQ 100MG BASE*	N63009 001 MAR 02, 1992

SUSPENSION; ORAL
MINOCIN

+	LEDERLE	EQ 50MG BASE/5ML	N50445 001
/SYRUP;/ORAL/ /MINOCIN/ /+//LEDERLE/		/EQ/50MG/BASE/5ML/	/N50445/001/

MINOXIDIL

TABLET; ORAL
MINOXIDIL

/B*/	/PHARM/BASICS/	/2.5MG/	/N71537/001/ /DEC/16,/1988/
	∂ PHARM BASICS	2.5MG	N71537 001 DEC 16, 1988
/AB/	/ROYCE/	/2.5MG/	/N71799/001/ /NOV/10,/1987/
/AB/		/10MG/	/N71796/001/ /NOV/10,/1987/
	∂ ROYCE	2.5MG	N71799 001 NOV 10, 1987
	∂	10MG	N71796 001 NOV 10, 1987

MIVACURIUM CHLORIDE

INJECTABLE; INJECTION
MIVACRON

BURROUGHS WELLCOME	EQ 2MG BASE/ML*	N20098 001 JAN 22, 1992
MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER		
BURROUGHS WELLCOME	EQ 0.5MG BASE/ML*	N20098 002 JAN 22, 1992
	EQ 50MG BASE/100ML*	N20098 003 JAN 22, 1992

MONOBENZONE

CREAM; TOPICAL
BENOQUIN

/ELDER/	/20%/	/N08173/003/
ICN	20%	N08173 003

MORPHINE SULFATE

INJECTABLE; INJECTION
MORPHINE SULFATE

AP	ABBOTT	0.5MG/ML*	N19917 001 OCT 30, 1992
AP		0.5MG/ML*	N73509 001 SEP 30, 1992
AP		1MG/ML*	N19916 001 OCT 30, 1992
AP		1MG/ML*	N73510 001 SEP 30, 1992

NABUMETONE

TABLET; ORAL
RELAFEN
+ SMITHKLINE BEECHAM — 750MG — N19583 002 DEC 24, 1991

NAFARELIN ACETATE

SPRAY, METERED; NASAL
SYNAREL
SYNTEX — EQ 0.2MG BASE/INH — N20109 001 FEB 26, 1992

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION
LYPHOMED
AP — 10MG/ML — N70751 001 JUL 02, 1986
AP — 20MG/ML — N70752 001 JUL 02, 1986

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION
NALOXONE HCL
AP FUJISAWA — 0.02MG/ML — N70648 001 NOV 17, 1986
AP — 0.4MG/ML — N70649 001 NOV 17, 1986
AP LYPHOMED — 0.02MG/ML — N70648 001 NOV 17, 1986
AP — 0.4MG/ML — N70649 001 NOV 17, 1986
AP SMITH NEPHEW SOLOPAK — 0.02MG/ML — N71672 001 NOV 17, 1987
AP — 0.4MG/ML — N71683 001 NOV 17, 1987
AP SOLOPAK MEDCL — 0.02MG/ML — N71672 001 NOV 17, 1987
AP — 0.4MG/ML — N71683 001 NOV 17, 1987

NAPROXEN

TABLET; ORAL
NAPROSYN
AB SYNTEX — 250MG — N17581 002
AB — 375MG — N17581 003
AB — 500MG — N17581 004 APR 15, 1982

NAPROXEN
AB HAMILTON — 250MG — N74110 001 OCT 30, 1992
AB — 375MG — N74110 002 OCT 30, 1992
AB — 500MG — N74110 003 OCT 30, 1992

> ADD > NEDOCROMIL SODIUM

> ADD > AEROSOL, METERED; INHALATION
> ADD > TILADE
> ADD > + FISONS — 1.75MG/INH — N19660 001 DEC 30, 1992
> ADD >

NEOMYCIN SULFATE

TABLET; ORAL
NEOMYCIN SULFATE
AA EON LABS — EQ 350MG BASE — N61586 001
AA VITARINE — EQ 350MG BASE — N61586 001

NEOMYCIN SULFATE; PREDNISOLONE ACETATE

SUSPENSION, DROPS; OPHTHALMIC
NEO-DELTA-CORTEF
UPJOHN — EQ 3.5MG BASE/ML; 0.25% — N61037 001
UPJOHN — EQ 3.5MG BASE/ML; 0.25% — N61037 001

NEOMYCIN SULFATE; PREDNISOLONE SODIUM PHOSPHATE

OINTMENT; OPHTHALMIC
NEO-HYDELTRASOL
MSD — EQ 3.5MG BASE/GM; EQ 0.25% PHOSPHATE — N50378 001
MSD — EQ 3.5MG BASE/GM; EQ 0.25% PHOSPHATE — N50378 001

NIACIN

TABLET; ORAL
NIACIN

AA	HOCKHARDT	500MG¤		N81134 001 APR 28, 1992

NICARDIPINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
CARDENE SR

+	SYNTEX	30MG¤		N20005 001 FEB 21, 1992
+		45MG¤		N20005 002 FEB 21, 1992
+		60MG¤		N20005 003 FEB 21, 1992

> ADD >
> ADD >
> DLT >
> DLT >

INJECTABLE; INJECTION
CARDENE

	DUPONT MERCK	2.5MG/ML¤	N19734 001 JAN 30, 1992

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL
NICODERM

/BC/	/MARION/MERRELL/DOW/	/7MG/24HR/	/N20165/001/ /NOV/07,/1991/
BC +	MARION MERRELL DOW	7MG/24HR	N20165 001 NOV 07, 1991
/BC/		/14MG/24HR/	/N20165/002/ /NOV/07,/1991/
BC +		14MG/24HR	N20165 002 NOV 07, 1991
/BC/		/21MG/24HR/	/N20165/003/ /NOV/07,/1991/
BC +		21MG/24HR	N20165 003 NOV 07, 1991

NICOTROL

+	KABI	5MG/16HR¤	N20150 001 APR 22, 1992
+		10MG/16HR¤	N20150 002 APR 22, 1992
+		15MG/16HR¤	N20150 003 APR 22, 1992

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL
PROSTEP

+	ELAN	11MG/24HR¤	N19983 001 JAN 28, 1992
+		22MG/24HR¤	N19983 002 JAN 28, 1992

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL
NICORETTE

+	MERRELL DOW	EQ 2MG BASE	N18612 001 JAN 13, 1984
		/EQ/2MG/BASE/	/N18612/001/ /JAN/13,/1984/

NICORETTE DS

+	MERRELL DOW	EQ 4MG BASE¤	N20066 001 JUN 08, 1992

/GUM;/CHEWING;/ORAL/
/NICORETTE/DS/

/+/	/MERRELL/DOW/	/4MG¤/	/N20066/001/ /JUN/08,/1992/

NIFEDIPINE

CAPSULE; ORAL
NIFEDIPINE

AB	NOVOPHARM	10MG¤	N72651 001 FEB 19, 1992
AB	SCHERER	20MG¤	N74045 001 APR 30, 1992

NITROFURANTOIN

TABLET; ORAL
NITROFURANTOIN

∂	EON LABS	50MG	N80043 001
∂		100MG	N80043 002
/∂/	/VITARINE/	/50MG/	/N80043/001/
/∂/		/100MG/	/N80043/002/

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE, EXTENDED RELEASE; ORAL

MACROBID
+ P AND G — 75MG;25MG — N20064 001 DEC 24, 1991

/75MG;25MG/ /N20064/001/ /DEC/24,/1991/

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

MACRODANTIN
> ADD > AB P AND G — 25MG — N16620 003
> ADD > AB — 50MG — N16620 001
> ADD > AB — 100MG — N16620 002

\+

NITROFURANTOIN
> ADD > AB DANBURY — 25MG* — N73696 001 DEC 31, 1992
> ADD >
> ADD > AB — 50MG* — N73696 002 DEC 31, 1992
> ADD >
> ADD > AB — 100MG* — N73696 003 DEC 31, 1992
> ADD >

NITROFURAZONE

/DRESSING;/TOPICAL/

/AT/ /FURACIN/ /ROBERTS/ /0.2%/ /N05795/001/

/AT/ /NITROFURAZONE/ /THAMES/ /0.2%/ /N86156/001/

OINTMENT; TOPICAL

FURACIN
AT ROBERTS — 0.2% — N05795 001

NITROFURAZONE
AT THAMES — 0.2% — N86156 001

NITROGLYCERIN

INJECTABLE; INJECTION

NITROGLYCERIN
> ADD > AP FUJISAWA — 5MG/ML — N70077 001 DEC 13, 1985
> ADD >

/AP/ /LUITPOLD/ /5MG/ML/ /N71492/001/ /MAY/24,/1988/

@ LUITPOLD — 5MG/ML — N71492 001 MAY 24, 1988

NITROGLYCERIN

INJECTABLE; INJECTION

NITROGLYCERIN
> DLT >/AP/ /LYPHOMED/ /5MG/ML/ /N70077/001/ /DEC/13,/1985/
> DLT >

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL

NORTRIPTYLINE HCL
AB DANBURY — EQ 10MG BASE* — N73553 001 MAR 30, 1992
AB — EQ 25MG BASE* — N73554 001 MAR 30, 1992
AB — EQ 50MG BASE* — N73555 001 MAR 30, 1992
AB — EQ 75MG BASE* — N73556 001 MAR 30, 1992
> ADD > AB GENEVA — EQ 10MG BASE* — N74054 001 DEC 31, 1992
> ADD >
> ADD > AB — EQ 25MG BASE* — N74054 002 DEC 31, 1992
> ADD >
> ADD > AB — EQ 50MG BASE* — N74054 003 DEC 31, 1992
> ADD >
> ADD > AB — EQ 75MG BASE* — N74054 004 DEC 31, 1992
> ADD >

PAMELOR
AB SANDOZ — EQ 10MG BASE — N18013 001
AB — EQ 25MG BASE — N18013 002
AB — EQ 50MG BASE — N18013 004
AB — EQ 75MG BASE — N18013 003

\+

/BD/ /EQ/10MG/BASE/ /N18013/001/
/BD/ /EQ/25MG/BASE/ /N18013/002/

NYSTATIN

LOTION;/TOPICAL/
> DLT > /CANDEX/ MILES — 100,000 UNITS/ML — N50233 001
> DLT >
> DLT >
> ADD > @ MILES

/LOTION;/TOPICAL/ /100,000/UNITS/ML/ /N50233/001/

POWDER; TOPICAL

MYCOSTATIN
> DLT > /SQUIBB/ WESTWOOD SQUIBB — 100,000 UNITS/GM — N60578 001
> ADD >

/100,000/UNITS/GM/ /N60578/001/

NYSTATIN

/SUPPOSITORY;/VAGINAL/
/NYSERT/
/P/AND/G/ /100,000/UNITS/ /N50478/001/
∂ P AND G 100,000 UNITS N50478 001

TABLET; ORAL
NYSTATIN
/AA/ /CHELSEA/ /500,000 UNITS/ /N62402/001/ /DEC/16,/1982/
∂ CHELSEA 500,000 UNITS N62402 001 DEC 16, 1982
AA EON LABS 500,000 UNITS N62065 001
/AA/ /VITARINE/ /500,000 UNITS/ /N62065/001/

TABLET; VAGINAL
NYSTATIN
∂ EON LABS 100,000 UNITS N61965 001
/∂/VITARINE/ /100,000/UNITS/ /N61965/001/

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL
/DERMACOMB/
/AT/ /TARO/ /100,000 UNITS/GM;0.1%/ /N62364/001/ /DEC/22,/1987/

NYSTATIN AND TRIAMCINOLONE ACETONIDE
/AT/ /CLAY/PARK/ /100,000 UNITS/GM;0.1%/ /N62186/002/ /JUN/06,/1985/
B* CLAY PARK 100,000 UNITS/GM;0.1% N62186 002 JUN 06, 1985

NYSTATIN AND TRIAMCINOLONE ACETONIDE
AT TARO 100,000 UNITS/GM;0.1% N62364 001 DEC 22, 1987

NYSTATIN AND TRIAMCINOLONE ACETONIDE
>ADD > AT THAMES 100,000 UNITS/GM;0.1% N62347 001 MAR 30, 1987
>ADD >
>DLT > /NYSTATIN-TRIAMCINOLONE ACETONIDE/
>DLT > /AT/ /THAMES/ /100,000 UNITS/GM;0.1%/ /N62347/001/ /MAR/30,/1987/
>DLT >

OINTMENT; TOPICAL
MYCOLOG-II
>DLT > /AT/ /SQUIBB/ /100,000 UNITS/GM;0.1%/ /N60572/001/ /JUN/28,/1985/
>DLT >
>ADD > AT WESTWOOD SQUIBB 100,000 UNITS/GM;0.1% N60572 001 JUN 28, 1985
>ADD >

OFLOXACIN

INJECTABLE; INJECTION
FLOXIN
JOHNSON RH 20MG/ML* N20087 002 MAR 31, 1992
40MG/ML* N20087 003 MAR 31, 1992

FLOXIN IN DEXTROSE 5%
JOHNSON RH 400MG/100ML* N20087 001 MAR 31, 1992

FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER
JOHNSON RH 4MG/ML* N20087 004 MAR 31, 1992
400MG/100ML* N20087 005 MAR 31, 1992

ONDANSETRON HYDROCHLORIDE

>ADD > TABLET; ORAL
>ADD > ZOFRAN
>ADD > + GLAXO EQ 8MG BASE* N20103 002 DEC 31, 1992
>ADD >
>ADD > EQ 4MG BASE* N20103 001 DEC 31, 1992
>ADD >

OXAPROZIN

TABLET; ORAL
DAYPRO
+ SEARLE 600MG* N18841 004 OCT 29, 1992

OXAZEPAM

CAPSULE; ORAL
OXAZEPAM
/B*/ /CHELSEA/ /10MG/ /N71661/001/ /MAR/02,/1988/
/B*/ /15MG/ /N71662/001/ /MAR/02,/1988/
/B*/ /30MG/ /N71663/001/ /MAR/02,/1988/

OXICONAZOLE NITRATE

LOTION; TOPICAL
OXISTAT
+ GLAXO — EQ 1% BASE* — N20209 001 SEP 30, 1992

OXYBUTYNIN CHLORIDE

TABLET; ORAL
OXYBUTYNIN CHLORIDE
/B*/ /PHARM BASICS/ /5MG/ — /N70746/001/ /MAR 10, 1988/
∂ PHARM BASICS — 5MG — N70746 001 MAR 10, 1988

> ADD > PACLITAXEL

> ADD > INJECTABLE; INJECTION
> ADD > TAXOL
> ADD > BRISTOL MYERS SQUIBB 6MG/ML* — N20262 001 DEC 29, 1992
> ADD >

PARGYLINE HYDROCHLORIDE

> DLT > /TABLET; ORAL/
> DLT > /EUTONYL/
> DLT > /*/ ABBOTT/ /25MG/ /10MG/ — /N13448/003/ /N13448/002/
> DLT >
> ADD > ∂ ABBOTT — 10MG — N13448 002
> ADD > ∂ — 25MG — N13448 003

> ADD > PAROXETINE HYDROCHLORIDE

> ADD > TABLET; ORAL
> ADD > PAXIL
> ADD > + SMITHKLINE BEECHAM — EQ 10MG BASE* — N20031 001 DEC 29, 1992
> ADD >
> ADD > + — EQ 50MG BASE* — N20031 004 DEC 29, 1992
> ADD >
> ADD > — EQ 20MG BASE* — N20031 002 DEC 29, 1992
> ADD >
> ADD > — EQ 30MG BASE* — N20031 003 DEC 29, 1992
> ADD >
> ADD > — EQ 40MG BASE* — N20031 005 DEC 29, 1992
> ADD >

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION
PENICILLIN G POTASSIUM
/AP/ /PARKE/DAVIS/ /1,000,000 UNITS/VIAL/ /N62003/001/
/AP/ /5,000,000 UNITS/VIAL/ /N62003/002/
∂ PARKE DAVIS — 1,000,000 UNITS/VIAL — N62003 001
∂ — 5,000,000 UNITS/VIAL — N62003 002

PENICILLIN V POTASSIUM

POWDER FOR RECONSTITUTION; ORAL
/PENAPAR-VK/
/AA/ /PARKE/DAVIS/ /EQ 125MG BASE/5ML/ /N62002/001/
/AA/ /EQ 250MG BASE/5ML/ /N62002/002/
∂ PARKE DAVIS — EQ 125MG BASE/5ML — N62002 001
∂ — EQ 250MG BASE/5ML — N62002 002

TABLET; ORAL
/PENAPAR-VK/
/AB/ /PARKE/DAVIS/ /EQ 250MG BASE/ /N62001/001/
/AB/ /EQ 500MG BASE/ /N62001/002/
∂ PARKE DAVIS — EQ 250MG BASE — N62001 001
∂ — EQ 500MG BASE — N62001 002

PENTAMIDINE ISETHIONATE

INJECTABLE; INJECTION
PENTAM 300
AP FUJISAWA — 300MG/VIAL — N19264 001 OCT 16, 1984

PENTAMIDINE ISETHIONATE
AP ABBOTT — 300MG/VIAL* — N73479 001 JUN 30, 1992

PERPHENAZINE

TABLET; ORAL
PERPHENAZINE
/B*/ /CHELSEA/ /8MG/ — /N89766/001/ /DEC 23, 1987/

PHENDIMETRAZINE TARTRATE

CAPSULE; ORAL

PHENDIMETRAZINE TARTRATE

AA	EON LABS	35MG	N85633 001
AA		35MG	N85694 001
AA		35MG	N85695 001
AA		35MG	N85702 001
/AA/	/VITARINE/	/35MG/	/N85633/001/
/AA/		/35MG/	/N85694/001/
/AA/		/35MG/	/N85695/001/
/AA/		/35MG/	/N85702/001/

CAPSULE, EXTENDED RELEASE; ORAL

PHENDIMETRAZINE TARTRATE

BC	EON LABS	105MG	N18074 001
/BC/	/VITARINE/	/105MG/	/N18074/001/

TABLET; ORAL

ALPHAZINE

	∂ EON LABS	35MG	N85034 001
	/∂/VITARINE/	/35MG/	/N85034/001/
	/OBEZINE/		
/AA/	/PHARM/BASICS/	/35MG/	/N83805/001/
/AA/		/35MG/	/N84398/001/
/AA/		/35MG/	/N84399/001/

PHENDIMETRAZINE TARTRATE

AA	EON LABS	35MG	N85402 001
AA		35MG	N85497 001
AA		35MG	N85588 001
AA		35MG	N85830 001
	/∂/	/35MG/	/N85830/001/

PHENDIMETRAZINE TARTRATE

AA	PHARM BASICS	35MG	N84399 001
	∂	35MG	N83805 001
	∂	35MG	N84398 001

PHENDIMETRAZINE TARTRATE

/AA/	/VITARINE/	/35MG/	/N85402/001/
/AA/		/35MG/	/N85497/001/
/AA/		/35MG/	/N85588/001/

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENTERMINE HCL

AA	EON LABS	15MG	N87301 001
AA		30MG	N86945 001 JUL 20, 1983
AA		30MG	N87190 001
AA		30MG	N87208 001
AA		30MG	N87223 001
/AA/	/VITARINE/	/15MG/	/N87301/001/
/AA/		/30MG/	/N86945/001/ /JUL/20/1983/
/AA/		/30MG/	/N87190/001/
/AA/		/30MG/	/N87208/001/
/AA/		/30MG/	/N87223/001/

TABLET; ORAL

PHENTERMINE HCL

	∂ EON LABS	8MG	N85671 001
	∂	8MG	N85689 001
	/∂/VITARINE/	/8MG/	/N85671/001/
	/∂/	/8MG/	/N85689/001/

PHENYLBUTAZONE

CAPSULE; ORAL

/AZOLID/

/AB/	/RHONE/POULENC/RORER//100MG/		/N87260/001/
	∂ RHONE POULENC RORER	100MG	N87260 001

TABLET; ORAL

/AZOLID/

/AB/	/RHONE/POULENC/RORER//100MG/		/N87091/001/
	∂ RHONE POULENC RORER	100MG	N87091 001

PHENYTOIN

SUSPENSION; ORAL

DILANTIN-125

AB	+ PARKE DAVIS	125MG/5ML	N08762 001

PHENYTOIN

AB	BARRE	125MG/5ML*	N89892 001 SEP 25, 1992

PHENYTOIN SODIUM

INJECTABLE; INJECTION

PHENYTOIN SODIUM

AP	MARSAM	50MG/ML¤	N89779 001 NOV 27, 1992	
> DLT > /AP/	/SMITH/NEPHEW/SOLOPAK/	50MG/ML/	/N88520/001/ /DEC/17,/1984/	
> DLT >				
> ADD > AP	SOLOPAK MEDCL	50MG/ML	N88520 001 DEC 17, 1984	
> ADD >				

PHENYTOIN SODIUM, PROMPT

CAPSULE; ORAL

/PHENYTOIN/SODIUM/

/BX/	/CHELSEA/	/100MG/	/N85894/001/	
	⊖ CHELSEA	100MG	N85894 001	

PINDOLOL

TABLET; ORAL

PINDOLOL

AB	GENPHARM	5MG¤	N74013 001 SEP 24, 1992	
AB		10MG¤	N74018 001 SEP 24, 1992	
AB	MYLAN	5MG¤	N74019 001 SEP 03, 1992	
AB		10MG¤	N74019 002 SEP 03, 1992	
	VISKEN			
AB	SANDOZ	5MG	N18285 001 SEP 03, 1982	
AB +		10MG	N18285 002 SEP 03, 1982	

PIRBUTEROL ACETATE

AEROSOL, METERED; INHALATION

MAXAIR

3M	EQ 0.2MG BASE/INH¤	N20014 001 NOV 30, 1992	

PIROXICAM

CAPSULE; ORAL

FELDENE

AB	PFIZER	10MG	N18147 002 APR 06, 1982
AB +		20MG	N18147 003 APR 06, 1982
	PIROXICAM		
AB	COPLEY	10MG¤	N74103 001 AUG 28, 1992
AB		20MG¤	N74103 002 AUG 28, 1992
AB	GENPHARM	10MG¤	N74043 001 SEP 22, 1992
AB		20MG¤	N74043 002 SEP 22, 1992
> ADD > AB	LEMMON	10MG¤	N74131 001 DEC 11, 1992
> ADD >			
> ADD > AB		20MG¤	N74131 002 DEC 11, 1992
> ADD >			
AB	MYLAN	10MG¤	N74102 001 JUL 31, 1992
AB		20MG¤	N74102 002 JUL 31, 1992
AB	SCHIAPPARELLI SEARLE	10MG¤	N74036 001 MAY 29, 1992
AB		20MG¤	N74036 002 MAY 29, 1992

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

POWDER FOR RECONSTITUTION; ORAL

CO-LAV

AA	COPLEY	240GM/BOT;2.98GM/BOT;6.72GM/BOT; 5.84GM/BOT;22.72GM/BOT¤	N73428 001 JAN 28, 1992

CO-EVAC

/AA/	/COPLEY/	/236GM/BOT;2.97GM/BOT;6.74GM/BOT; 5.86GM/BOT;22.74GM/BOT¤	/N73433/001/ /APR/28,/1992/
AA	COPLEY	236GM/BOT;2.97GM/BOT;6.74GM/BOT; 5.86GM/BOT;22.74GM/BOT¤	N73433 001 APR 28, 1992

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

K-LEASE

AB	ADRIA	8MEQ*	N73398 001 JAN 28, 1992	

MICRO-K

AB	ROBINS	8MEQ	N18238 001	

INJECTABLE; INJECTION

POTASSIUM CHLORIDE

> ADD > AP	FUJISAWA	2MEQ/ML	N80225 001	
> ADD > AP		3MEQ/ML	N80225 003	
> DLT >/AP/	/LYPHOMED/	/2MEQ/ML/	/N80225/001/	
> DLT >/AP/		/3MEQ/ML/	/N80225/003/	

POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER

AP	ABBOTT	745MG/100ML*	N20161 001 NOV 30, 1992	
AP		14.9MG/ML*	N20161 005 NOV 30, 1992	
AP	BAXTER	746MG/100ML	N19904 005 DEC 17, 1990	
AP		14.9MG/ML	N19904 001 DEC 26, 1989	

POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER

AP	ABBOTT	1.49GM/100ML*	N20161 002 NOV 30, 1992	
AP	BAXTER	1.49GM/100ML	N19904 006 DEC 17, 1990	

TABLET, EXTENDED RELEASE; ORAL

KLOR-CON

AB	UPSHER SMITH	8MEQ	N19123 001 APR 17, 1986	
/BC/		/8MEQ/	/N19123/001/ /APR/17,/1986/	

KLOTRIX

BC	APOTHECON	10MEQ	N17850 001	
/BC/	/MEAD/JOHNSON/	/10MEQ/	/N17850/001/	

PRAZEPAM

CAPSULE; ORAL

CENTRAX

/AB/	/PARKE/DAVIS/	/5MG/	/N18144/001/	
/AB/+/		/10MG/	/N18144/002/	
	+ PARKE DAVIS	10MG	N18144 002	
		5MG	N18144 001	

PRAZEPAM

CAPSULE; ORAL

/PRAZEPAM/

/B*/	/PHARM/BASICS/	/5MG/	/N70427/001/ /NOV/06,/1987/	
/B*/		/10MG/	/N70428/001/ /NOV/06,/1987/	
	∂ PHARM BASICS	5MG	N70427 001 NOV 06, 1987	
	∂	10MG	N70428 001 NOV 06, 1987	

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

MINIPRESS

/AB/	/PFIZER/	/EQ 2MG BASE/	/N17442/003/	
AB	+ PFIZER	EQ 2MG BASE	N17442 003	
/AB/+/		/EQ 5MG BASE/	/N17442/001/	
AB		EQ 5MG BASE	N17442 001	

TABLET, EXTENDED RELEASE; ORAL

MINIPRESS XL

	+ PFIZER	2.5MG*	N19775 001 JAN 29, 1992	
	+	5MG*	N19775 002 JAN 29, 1992	

PREDNISOLONE

TABLET; ORAL

/DELTA-CORTEF/

/BX/+/	/UPJOHN/	/5MG/	/N009987/004/	
	∂ UPJOHN	5MG	N09987 004	

PREDNISOLONE

	∂ EON LABS	5MG	N84773 001	
/BX/	/HEATHER/	/5MG/	/N80326/001/	
	∂ HEATHER	5MG	N80326 001	
	/∂/VITARINE/	/5MG/	/N84773/001/	

PREDNISOLONE ACETATE

INJECTABLE; INJECTION

PREDNISOLONE ACETATE

> DLT >	/BP/	/BEL/MAR/	/50MG/ML/	/N83738/002/	
> DLT >	/BP/		/25MG/ML/	/N83738/001/	
> ADD >		∂ BEL MAR	25MG/ML	N83738 001	
> ADD >		∂	50MG/ML	N83738 002	
> DLT >	/BP/	/STERIS/	/25MG/ML/	/N83398/001/	
> DLT >	/BP/		/25MG/ML/	/N83654/001/	
> DLT >	/BP/		/50MG/ML/	/N83764/001/	
> DLT >	/BP/		/50MG/ML/	/N85781/001/	
> ADD >		STERIS	25MG/ML	N83398 001	
> ADD >			25MG/ML	N83654 001	
> ADD >			50MG/ML	N83764 001	
> ADD >			50MG/ML	N85781 001	

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

SUSPENSION/DROPS; OPHTHALMIC

BLEPHAMIDE

/AT/	/ALLERGAN/	/0.12;10%/	/N12813/002/	
	ALLERGAN	0.2%;10%	N12813 002	

PREDSULFAIR II

/AT/	/PHARMAFAIR/	/0.12;10%/	/N88837/001/	
			/DEC/24,/1985/	
	∂ PHARMAFAIR	0.2%;10%	N88837 001	
			DEC 24, 1985	

PREDNISONE

TABLET; ORAL

FERNISONE

/BX/	/FERNDALE/	/5MG/	/N83364/001/	
	∂ FERNDALE	5MG	N83364 001	

PREDNISONE

	∂ EON LABS	5MG	N84774 001	
AB	RICHLYN	5MG	N80782 001	
/BX/		/5MG/	/N80782/001/	
	/∂/VITARINE/	/5MG/	/N84774/001/	

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINAMIDE HCL

> DLT >	/AP/	/SMITH/NEPHEW/SOLOPAK/	/500MG/ML/	/N88532/001/	
> DLT >				/MAR/04,/1985/	
> ADD >	AP	SOLOPAK MEDCL	500MG/ML	N88532 001	
> ADD >				MAR 04, 1985	

PROCAINAMIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

PROCAINAMIDE HCL

/AB/	/BOLAR/	/250MG/	/N88533/001/	
			/DEC/03,/1984/	
/AB/		/500MG/	/N88534/001/	
			/DEC/03,/1984/	
/AB/		/750MG/	/N88535/001/	
			/NOV/03,/1984/	
	∂ BOLAR	250MG	N88533 001	
			DEC 03, 1984	
	∂	500MG	N88534 001	
			DEC 03, 1984	
	∂	750MG	N88535 001	
			NOV 03, 1984	

PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINE HCL

> ADD >	AP	FUJISAWA	1%	N80384 002
> ADD >	AP		2%	N80384 003
> DLT >	/AP/	/LYPHOMED/	/1%/	/N80384/002/
> DLT >	/AP/		/2%/	/N80384/003/

PROCAINE HYDROCHLORIDE; TETRACYCLINE HYDROCHLORIDE

INJECTABLE; INJECTION

ACHROMYCIN

AP	LEDERLE	40MG/VIAL;100MG/VIAL	N50267 002	
AP		40MG/VIAL;100MG/VIAL	N50276 001	
AP		40MG/VIAL;250MG/VIAL	N50267 003	

TETRACYN

AP	PFIZER	40MG/VIAL;250MG/VIAL	N60285 003
	∂	40MG/VIAL;100MG/VIAL	N60285 002

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION

PROCHLORPERAZINE EDISYLATE

/AP/	/ELKINS/SINN/	/EQ 5MG BASE/ML/	/N89523/001/	
			/MAY/03,/1988/	
	∂ ELKINS SINN	EQ 5MG BASE/ML	N89523 001	
			MAY 03, 1988	

PROCHLORPERAZINE MALEATE

PROPANTHELINE BROMIDE

INJECTABLE; INJECTION

PROCAINAMIDE HCL

> DLT > /AP/	/SMITH/DEHNER/SOLOPAK/	500MG/ML/	/N88532/001/ /MAR/04,/1985/
> DLT >			
> ADD > AP	SOLOPAK MEDCL	500MG/ML	N88532 001 MAR 04, 1985
> ADD >			

PROCHLORPERAZINE MALEATE

TABLET; ORAL

/PROCHLORPERAZINE/MALEATE/

/B#/ /DURAMED/	/EQ/5MG/BASE/	/N89484/001/ /JAN/20,/1987/
/B#/	/EQ/10MG/BASE/	/N89485/001/ /JAN/20,/1987/
/B#/	/EQ/25MG/BASE/	/N89486/001/ /JAN/20,/1987/
∂ DURAMED	EQ 5MG BASE	N89484 001 JAN 20, 1987
∂	EQ 10MG BASE	N89485 001 JAN 20, 1987
∂	EQ 25MG BASE	N89486 001 JAN 20, 1987

PROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROMAZINE HCL

/AP/	/STERIS/	/25MG/ML/	/N84510/001/
	STERIS	25MG/ML	N84510 001

SPARINE

/AP/	/WYETH/AYERST/	/25MG/ML/	/N10349/008/
	∂ WYETH AYERST	25MG/ML	N10349 008

PROMETHAZINE HYDROCHLORIDE

TABLET; ORAL

PROMETHAZINE HCL

∂ EON LABS	25MG	N85146 001
∂	50MG	N85146 002
/∂/VITARINE/	/25MG/	/N85146/001/
/∂/	/50MG/	/N85146/002/

PROPAFENONE HYDROCHLORIDE

TABLET; ORAL

RYTHMOL

KNOLL	225MG	N19151 003 NOV 20, 1992

PROPANTHELINE BROMIDE

TABLET; ORAL

PROPANTHELINE BROMIDE

/AA/	/HEATHER/	/15MG/	/N85780/001/
	∂ HEATHER	15MG	N85780 001

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

OPHTHAINE

/AT/	/SQUIBB/	/5MG/ML/	/N08883/001/
AT	SQUIBB	0.5%	N08883 001

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

PROPOXYPHENE HCL

∂ EON LABS	32MG	N84014 001
∂	65MG	N83688 001
∂	65MG	N83870 002
∂	65MG	N86495 001
/∂/VITARINE/	/32MG/	/N84014/001/
/∂/	/65MG/	/N83688/001/
/∂/	/65MG/	/N83870/002/
/∂/	/65MG/	/N86495/001/

/PROPOXYPHENE HCL 65/

/AA/	/PARKE/DAVIS/	/65MG/	/N83786/001/
	∂ WARNER CHILCOTT	65MG	N83786 001

PROPRANOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

PROPRANOLOL HCL

> DLT > /AP/	/SMITH/DEHNER/SOLOPAK/	1MG/ML/	/N70136/001/ /APR/15,/1986/
> DLT >			
> ADD > AP	SOLOPAK MEDCL	1MG/ML	N70136 001 APR 15, 1986
> ADD >			

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HCL

>DLT >/AB/	/SCHERING/	/10MG/	/N70120/001/	
>DLT >			/AUG/06,/1985/	
>DLT >/AB/		/20MG/	/N70121/001/	
>DLT >			/AUG/06,/1985/	
>DLT >/AB/		/40MG/	/N70122/001/	
>DLT >			/AUG/06,/1985/	
>DLT >/AB/		/60MG/	/N70123/001/	
>DLT >			/OCT/29,/1986/	
>DLT >/AB/		/80MG/	/N70124/001/	
>DLT >			/AUG/06,/1985/	
>ADD >	∂ SCHERING	10MG	N70120 001	
>ADD >			AUG 06, 1985	
>ADD >	∂	20MG	N70121 001	
>ADD >			AUG 06, 1985	
>ADD >	∂	40MG	N70122 001	
>ADD >			AUG 06, 1985	
>ADD >	∂	60MG	N70123 001	
>ADD >			OCT 29, 1986	
>ADD >	∂	80MG	N70124 001	
>ADD >			AUG 06, 1985	
/AB/	/SUPERPHARM/	/10MG/	/N71515/001/	
/AB/		/20MG/	/JUN/08,/1988/	
			/N71516/001/	
	∂ SUPERPHARM	10MG	/JUN/08,/1988/	
			N71515 001	
	∂	20MG	JUN 08, 1988	
			N71516 001	
			JUN 08, 1988	

PROTIRELIN

INJECTABLE; INJECTION

RELEFACT TRH

AP	FERRING	0.5MG/ML	N18087 001
/AP/	/HOECHST/ROUSSEL/	/0.5MG/ML/	/N18087/001/

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

TABLET; ORAL

PSEUDOEPHEDRINE HCL AND TRIPROLIDINE HCL

AA	EON LABS	60MG;2.5MG	N88193 001
			MAY 17, 1983
/AA/	/VITARINE/	/60MG;2.5MG/	/N88193/001/
			/MAY/17,/1983/

PYRAZINAMIDE

TABLET; ORAL

PYRAZINAMIDE

AB	+ LEDERLE	500MG	N80157 001
AB	MIKART	500MG*	N81319 001
			JUN 30, 1992

PYRIDOXINE HYDROCHLORIDE

INJECTABLE; INJECTION

PYRIDOXINE HCL

/AP/	/LUITPOLD/	/100MG/ML/	/N80669/001/
	∂ LUITPOLD	100MG/ML	N80669 001

QUINETHAZONE; RESERPINE

/TABLET;/ORAL/

/HYDROMOX/R/

	/LEDERLE/	/50MG;0.125MG/	/N13927/001/
	∂ LEDERLE	50MG;0.125MG	N13927 001

QUINIDINE SULFATE

TABLET; ORAL

QUINIDINE SULFATE

	∂ ELKINS SINN	200MG	N83622 001
AB	EON LABS	200MG	N84631 001
AB		300MG	N88072 001
			SEP 26, 1983
	/∂/QUANTUM/PHARMICS/	/200MG/	/N83622/001/
/AB/	/VITARINE/	/200MG/	/N84631/001/
/AB/		/300MG/	/N88072/001/
			/SEP/26,/1983/

RAUWOLFIA SERPENTINA

TABLET; ORAL

/RAUVERID/

/BP/	/FOREST/PHARMS/	/50MG/	/N09255/008/
	WOLFINA		
	∂ FOREST PHARMS	50MG	N09255 008

RESERPINE

TABLET; ORAL
RESERPINE

BP	EON LABS	0.1MG	N09838 001	> ADD >	AP
BP		0.25MG	N09838 002	> ADD >	
/BP/	/VITARINE/	/0.1MG/	/N09838/001/	> ADD >	AP
/BP/		/0.25MG/	/N09838/002/	> ADD >	
	/SERPATE/				
/BP/	/VALE/	/0.1MG/	/N09453/001/		
/BP/		/0.25MG/	/N09453/002/		
	ə VALE	0.1MG	N09453 001		
	ə	0.25MG	N09453 002	> DLT >	
				> DLT >	
				> DLT >	
				> DLT >	

> ADD > **RIFABUTIN**

> ADD > CAPSULE; ORAL
> ADD > MYCOBUTIN
> ADD > + ADRIA 150MG¤ N50689 001 DEC 23, 1992
> ADD >

RITODRINE HYDROCHLORIDE

INJECTABLE; INJECTION
RITODRINE HCL

/AP/	/LYPHOMED/	/10MG/ML/	/N71188/001/	> ADD >	AP
			/JUL/23/1987/	> ADD >	
/AP/		/15MG/ML/	/N71189/001/	> ADD >	AP
			/JUL/23/1987/	> ADD >	
	ə LYPHOMED	10MG/ML	N71188 001 JUL 23, 1987		
	ə	15MG/ML	N71189 001 JUL 23, 1987		

SELENIUM SULFIDE

LOTION/SHAMPOO; TOPICAL
SELENIUM SULFIDE

> DLT >/AT/	/THAMES/	/2.5%/	/N86209/001/	
> ADD >	ə THAMES	2.5%	N86209 001	

SODIUM BICARBONATE; TARTARIC ACID

GRANULE, EFFERVESCENT; ORAL
BAROS

/E/Z/EM/	/460MG/GM;420MG/GM/	/N18509/001/	
		/AUG/07/1985/	
LAFAYETTE	460MG/GM;420MG/GM	N18509 001 AUG 07, 1985	

SODIUM CHLORIDE

INJECTABLE; INJECTION
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	ABBOTT	9MG/ML	N18800 001 OCT 29, 1982		
	LYPHOMED	9MG/ML	N88911 001 FEB 07, 1985		
		/9MG/ML/	/N88909/001/		
			/FEB/07/1985/		
	ə	9MG/ML	N88909 001 FEB 07, 1985		
		/9MG/ML/	/N88911/001/		
	/ABBOTT/	/9MG/ML/	/FEB/07/1985/		
			/N18800/001/		
			/OCT/29/1982/		

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	BAXTER	900MG/100ML¤	N20178 001 DEC 07, 1992	> ADD >	AP
		9MG/ML¤	N20178 002 DEC 07, 1992	> ADD >	
		/SODIUM/CHLORIDE/23.4%/IN/PLASTIC/CONTAINER/		> ADD >	AP
	/LYPHOMED/	/234MG/ML/	/N19329/001/	> ADD >	
			/APR/22/1987/		
	ə LYPHOMED	234MG/ML	N19329 001 APR 22, 1987		

SODIUM LACTATE

INJECTABLE; INJECTION
SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER

AP	MCGAW	1.87GM/100ML¤	N20004 001 APR 21, 1992

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION
NITROPRESS

AP	ABBOTT	25MG/ML	N71961 001 AUG 01, 1988

SODIUM NITROPRUSSIDE

AP	GENSIA	25MG/ML¤	N73465 001 MAR 30, 1992

SODIUM POLYSTYRENE SULFONATE

SUSPENSION; ORAL, RECTAL

	SODIUM POLYSTYRENE SULFONATE			
/AA/	/ROXANE/	/15GM/60ML/	/N88453/001/	
			/NOV/17,/1983/	
	ə ROXANE	15GM/60ML	N88453 001	
			NOV 17, 1983	

SODIUM THIOSULFATE

INJECTABLE; INJECTION

SODIUM THIOSULFATE			
US ARMY	250MG/ML‡	N20166 001	
		FEB 14, 1992	

SOTALOL HYDROCHLORIDE

TABLET; ORAL

BETAPACE			
+ BERLEX	240MG‡	N19865 003	
		OCT 30, 1992	
	80MG‡	N19865 001	
		OCT 30, 1992	
	160MG‡	N19865 002	
		OCT 30, 1992	
ə	320MG‡	N19865 004	
		OCT 30, 1992	

SPIRONOLACTONE

TABLE; ORAL

	SPIRONOLACTONE			
/AA/	/PARKE/DAVIS/	/25MG/	/N87952/001/	
			/NOV/18,/1982/	
	ə WARNER CHILCOTT	25MG	N87952 001	
			NOV 18, 1982	

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION

	SUCCINYLCHOLINE CHLORIDE			
	/INTL/MEDICATION/	/100MG/VIAL/	/N85400/001/	
			/FEB/04,/1982/	
	ə INTL MEDICATION	100MG/VIAL	N85400 001	
			FEB 04, 1982	

/SULFABENZAMIDE;/SULFACETAMIDE;/SULFATHIAZOLE/

/CREAM;/VAGINAL/

/SULTRIN/			
/JOHNSON/RW/	/3.72;2.862;3.422/	/N85794/001/	

/TABLET;/VAGINAL/

/SULTRIN/			
/JOHNSON/RW/	/184MG;143.75MG;172.5MG/	/N85794/002/	
/TRIPLE/SULFA/			
/ə/FOUGERA/	/184MG;143.75MG;172.5MG/	/N88463/001/	
		/JAN/03,/1985/	
/ə/PHARMADERM/	/184MG;143.75MG;172.5MG/	/N88462/001/	
		/JAN/03,/1985/	

/SULFABENZAMIDE;/SULFACETAMIDE;/SULFATHIAZOLE;/UREA/

/CREAM;/VAGINAL/

	/GYNE-SULF/			
/AT/	/G/AND/W/	/3.72;2.862;3.422;0.642/	/N88607/001/	
			/JUN/09,/1986/	
	/TRIPLE SULFA/			
/AT/	/CLAY/PARK/	/3.72;2.862;3.422;0.642/	/N87285/001/	
			/NOV/15,/1982/	
/AT/	/FOUGERA/	/3.72;2.862;3.422;0.642/	/N86424/001/	
/AT/	/NMC/	/3.72;2.862;3.422;0.642/	/N87864/001/	
			/SEP/01,/1982/	
/AT/	/PHARMADERM/	/3.72;2.862;3.422;0.642/	/N87887/001/	
			/JUL/23,/1982/	
	/VAGILIA/			
/AT/	/LEMMON/	/3.72;2.862;3.422;0.642/	/N88821/001/	
			/NOV/09,/1987/	

SULFAMETHIZOLE

TABLET; ORAL

	/PROKLAR/			
/AB/	/FOREST/PHARMS/	/500MG/	/N80273/001/	
	ə FOREST PHARMS	500MG	N80273 001	
	THIOSULFIL			
/AB/	/WYETH/AYERST/	/500MG/	/N08565/004/	
	+ WYETH AYERST	500MG	N08565 004	

SULFAMETHOXAZOLE

TABLET; ORAL

SULFAMETHOXAZOLE

>DLT>	/AB/	/HEATHER/	/500MG/	/N66163/001/
>ADD>		∂ HEATHER	500MG	N86163 001
		/UROBAK/		
	/AB/	/SHIONOGI/	/500MG/	/N87307/001/
		∂ SHIONOGI	500MG	N87307 001

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

SULFAMETHOXAZOLE AND TRIMETHOPRIM

	AP	CETUS BEN VENUE	80MG/ML;16MG/ML*	N72383 001 APR 29, 1992
>ADD>	AP	FUJISAWA	80MG/ML;16MG/ML	N70223 001 JAN 16, 1987
>ADD>				
>DLT>	/AP/	/LYPHOMED/	/80MG/ML;16MG/ML/	/N70223/001/ /JAN/16,/1987/
>DLT>				
	AP	STERLING WINTHROP	80MG/ML;16MG/ML*	N73199 001 SEP 11, 1992

TABLET; ORAL

>DLT> /SULFAMETHOXAZOLE & TRIMETHOPRIM/

>DLT>	/AB/	/HEATHER/	/400MG;80MG/	/N18946/001/ /AUG/10,/1984/
>DLT>				
>DLT>	/AB/		/800MG;160MG/	/N18946/002/ /AUG/10,/1984/
>DLT>				
>ADD>		∂ HEATHER	400MG;80MG	N18946 001 AUG 10, 1984
>ADD>				
>ADD>		∂	800MG;160MG	N18946 002 AUG 10, 1984
>ADD>				

SULFAMETHOXAZOLE AND TRIMETHOPRIM

	AB	EON LABS	400MG;80MG	N18598 001 MAY 19, 1982
	/AB/	/INTERPHARM/	/400MG;80MG/	/N71299/001/ /OCT/27,/1987/
	/AB/		/800MG;160MG/	/N71300/001/ /OCT/27,/1987/
	B*	INTERPHARM	400MG;80MG	N71299 001 OCT 27, 1987
	B*		800MG;160MG	N71300 001 OCT 27, 1987
	/AB/	/MARTEC/	/400MG;80MG/	/N72408/001/ /DEC/07,/1988/
		∂ MARTEC	400MG;80MG	N72408 001 DEC 07, 1988

SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

/B*/	/PHARM BASICS/	/400MG;80MG/	/N70203/001/ /NOV/08,/1985/
/B*/		/800MG;160MG/	/N70204/001/ /NOV/08,/1985/
	∂ PHARM BASICS	400MG;80MG	N70203 001 NOV 08, 1985
	∂	800MG;160MG	N70204 001 NOV 08, 1985
/AB/	/VITARINE/	/400MG;80MG/	/N18598/001/ /MAY/19,/1982/

SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH

AB	EON LABS	800MG;160MG	N18598 004 MAY 19, 1982
/AB/	/MARTEC/	/800MG;160MG/	/N72417/001/ /DEC/07,/1988/
	∂ MARTEC	800MG;160MG	N72417 001 DEC 07, 1988
/AB/	/VITARINE/	/800MG;160MG/	/N18598/004/ /MAY/19,/1982/

SULFASALAZINE

TABLET; ORAL

SULFASALAZINE

∂ EON LABS	500MG	N86184 001
/∂/VITARINE/	/500MG/	/N86184/001/

SULFISOXAZOLE

TABLET; ORAL

/SULFALAR/

/AB/	/PARKE/DAVIS/	/500MG/	/N84955/001/
	∂ PARKE DAVIS	500MG	N84955 001

SULFISOXAZOLE

/AB/	/WEST/WARD/	/500MG/	/N80379/001/
	∂ WEST WARD	500MG	N80379 001

SULINDAC

TABLET; ORAL

SULINDAC

AB	LEMMON	150MG*	N72972 001 FEB 28, 1992
AB		200MG*	N72973 001 FEB 28, 1992

> ADD > SUMATRIPTAN SUCCINATE

> ADD > INJECTABLE; INJECTION
> ADD > IMITREX
> ADD > GLAXO — EQ 6MG BASE/0.5ML — N20080 001 DEC 28, 1992
> ADD >
> ADD >

TALBUTAL

/TABLET; ORAL/
/LOTUSATE/
/STERLING/ — /120MG/ — /N09410/005/
@ STERLING — 120MG — N09410 005

TECHNETIUM TC-99M ETIDRONATE KIT

INJECTABLE; INJECTION
OSTEOSCAN
/MALLINCKRODT/ — /N/A/ — /N17454/001/
@ MALLINCKRODT — N/A — N17454 001

TECHNETIUM TC-99M RED BLOOD CELL KIT

INJECTABLE; INJECTION
RBC-SCAN
CADEMA — N/A* — N20063 001 JUN 11, 1992

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE; INJECTION
CARDIOLITE
/DUPONT/ — /N/A/ — /N19785/001/ /DEC/21,/1990/
DUPONT MERCK — N/A — N19785 001 DEC 21, 1990

TEMAFLOXACIN HYDROCHLORIDE

TABLET; ORAL
OMNIFLOX
/#//ABBOTT/ — /EQ/600MG/BASE#/ — /N20043/004/ /JAN/30,/1992/
/EQ/400MG/BASE#/ — /N20043/003/ /JAN/30,/1992/

TEMAFLOXACIN HYDROCHLORIDE

TABLET; ORAL
OMNIFLOX
@ ABBOTT — EQ 400MG BASE* — N20043 003 JAN 30, 1992
@ — EQ 600MG BASE* — N20043 004 JAN 30, 1992

TEMAZEPAM

CAPSULE; ORAL
TEMAZEPAM
/B*/ /PHARM/BASICS/ — /15MG/ — /N70489/001/ /JUL/07,/1986/
/B*/ — /30MG/ — /N70490/001/ /JUL/07,/1986/
@ PHARM BASICS — 15MG — N70489 001 JUL 07, 1986
@ — 30MG — N70490 001 JUL 07, 1986

TENIPOSIDE

INJECTABLE; INJECTION
VUMON
BRISTOL MYERS SQUIBB — 10MG/ML* — N20119 001 JUL 14, 1992

TERAZOSIN HYDROCHLORIDE

TABLET; ORAL
HYTRIN
+ ABBOTT — 2MG — N19057 002 AUG 07, 1987
/#/ — /10MG/ — /N19057/004/ /AUG/07,/1987/
/2MG/ — /N19057/002/ /AUG/07,/1987/
10MG — N19057 004 AUG 07, 1987

> ADD > TERBINAFINE HYDROCHLORIDE

> ADD > CREAM; TOPICAL
> ADD > LAMISIL
> ADD > + SANDOZ — 1%* — N20192 001 DEC 30, 1992
> ADD >

TERBUTALINE SULFATE

INJECTABLE; INJECTION

		BRETHINE		
> DLT >	/AP/	/GEIGY/	/1MG/ML/	/N18571/001/
> ADD >	AP	+ GEIGY	1MG/ML	N18571 001

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION

		DELATESTRYL		
	AO	GYNEX	200MG/ML	N09165 003
	ə		200MG/ML	N09165 001
	/AO/	/SQUIBB/	/200MG/ML/	/N09165/003/
	/ə/		/200MG/ML/	/N09165/001/

TETRACYCLINE

SYRUP; ORAL

		/ETHOCYCLINE/		
	/AA/	/BARRE/	/EQ 125MG HCL/5ML/	/N60633/001/
		TETRACYCLINE		
	AB	BARRE	EQ 125MG HCL/5ML	N60633 001

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

		/CYCLOPAR/		
	/AB/	/PARKE/DAVIS/	/250MG/	/N61725/001/
	/AB/		/250MG/	/N62175/001/
	/AB/		/250MG/	/N62332/001/
	/AB/		/500MG/	/N61725/002/
	/AB/		/500MG/	/N62332/002/
		ə WARNER CHILCOTT	250MG	N61725 001
		ə	250MG	N62175 001
		ə	250MG	N62332 001
		ə	500MG	N61725 002
		ə	500MG	N62332 002
		ROBITET		
	/AB/	/ROBINS/	/250MG/	/N61734/001/
	/AB/		/500MG/	/N61734/002/
	AB	WYETH AYERST	250MG	N61734 001
	AB		500MG	N61734 002
		SUMYCIN		
> ADD >	AB	APOTHECON	250MG	N60429 001
> ADD >	AB		500MG	N60429 003
		ə	100MG	N60429 002
		ə	125MG	N60429 004

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

		SUMYCIN		
	/AB/	/SQUIBB/	/100MG/	/N60429/002/
	/AB/		/125MG/	/N60429/004/
> DLT >	/AB/		/250MG/	/N60429/001/
> DLT >	/AB/		/500MG/	/N60429/003/
		TETRACYCLINE HCL		
	/AB/	/VITARINE/	/250MG/	/N61471/001/
	AB	EON LABS	250MG	N61471 001
> DLT >	/ə/		/500MG/	/N61471/002/
> DLT >				/SEP/06,/1988/
> DLT >	/AB/	/HEATHER/	/250MG/	/N61148/001/
> DLT >	/AB/		/500MG/	/N61148/002/
> ADD >		ə HEATHER	250MG	N61148 001
> ADD >		ə	500MG	N61148 002
	/AB/	/MK/	/125MG/	/N60173/001/
		MK	125MG	N60173 001
	/AB/	/PARKE/DAVIS/	/250MG/	/N62300/001/
	/AB/		/500MG/	/N62300/002/
	/AB/	/RICHLYN/	/100MG/	/N60469/002/
		RICHLYN	100MG	N60469 002
	AB	WARNER CHILCOTT	250MG	N62300 001
	AB		500MG	N62300 002

/INJECTABLE;/INJECTION/

		/ACHROMYCIN/		
	/AP/	/LEDERLE/	/100MG/VIAL/	/N50267/002/
	/AP/		/100MG/VIAL/	/N50276/001/
	/AP/		/250MG/VIAL/	/N50267/003/
		/TETRACYN/		
	/AP/	/PFIZER/	/250MG/VIAL/	/N60285/003/
	/ə/		/100MG/VIAL/	/N60285/002/

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

		SOMOPHYLLIN-CRT		
	/BC/	/FISONS/	/50MG/	/N87763/001/
				/FEB/27,/1985/
	/BC/		/100MG/	/N87194/001/
	/BC/		/200MG/	/N88382/001/
				/FEB/27,/1985/
	/BC/		/250MG/	/N87193/001/
	/BC/		/300MG/	/N88383/001/
				/FEB/27,/1985/

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

	SOMOPHYLLIN-CRT			
BC	GRAHAM LABS	50MG	N87763 001	FEB 27, 1985
BC		100MG	N87194 001	
BC		200MG	N88382 001	FEB 27, 1985
BC		250MG	N87193 001	
BC		300MG	N88383 001	FEB 27, 1985
	THEO-24			
/BC/	/SEARLE/	/100MG/	/N87942/001/	/AUG/22,/1983/
/BC/		/200MG/	/N87943/001/	/AUG/22,/1983/
/BC/		/300MG/	/N87944/001/	/AUG/22,/1983/
		/400MG¤/	/N81034/001/	/FEB/28,/1992/
BC	WHITBY	100MG	N87942 001	AUG 22, 1983
BC		200MG	N87943 001	AUG 22, 1983
BC		300MG	N87944 001	AUG 22, 1983
		400MG¤	N81034 001	FEB 28, 1992
	THEOPHYLLINE			
	∂ EON LABS	260MG	N87462 001	MAY 11, 1982
/∂/	/VITARINE/	/260MG/	/N87462/001/	/MAY/11,/1982/

INJECTABLE; INJECTION

	THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER			
AP	MCGAW	40MG/100ML¤	N19826 001	AUG 14, 1992
	THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER			
AP	MCGAW	80MG/100ML¤	N19826 002	AUG 14, 1992
	THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER			
AP	MCGAW	160MG/100ML¤	N19826 003	AUG 14, 1992
	THEOPHYLLINE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER			
AP	MCGAW	200MG/100ML¤	N19826 004	AUG 14, 1992
	THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER			
AP	MCGAW	320MG/100ML¤	N19826 006	AUG 14, 1992

THEOPHYLLINE

INJECTABLE; INJECTION

	THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER			
AP	MCGAW	400MG/100ML¤	N19826 005	AUG 14, 1992

TABLET, EXTENDED RELEASE; ORAL

	T-PHYL			
BC	PURDUE FREDERICK	200MG	N88253 001	AUG 17, 1983
	THEO-DUR			
AB	+ KEY PHARMS	450MG	N89131 001	JUN 25, 1986
	/THEOCONTIN/			
/BC/	/PURDUE/FREDERICK/	/200MG/	/N88253/001/	/AUG/17,/1983/
	THEOPHYLLINE			
AB	SIDMAK	450MG¤	N81236 001	NOV 09, 1992

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

	THIAMINE HCL			
/AP/	/LUITPOLD/	/100MG/ML/	/N80667/001/	
	∂ LUITPOLD	100MG/ML	N80667 001	
/AP/	/PARKE/DAVIS/	/100MG/ML/	/N80770/001/	
	∂ PARKE DAVIS	100MG/ML	N80770 001	

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

	THIORIDAZINE HCL			
/AB/	/PAR/	/150MG/	/N89764/001/	/FEB/09,/1988/
/AB/		/200MG/	/N89765/001/	/FEB/09,/1988/
	∂ PAR	150MG	N89764 001	FEB 09, 1988
	∂	200MG	N89765 001	FEB 09, 1988

THIOTHIXENE HYDROCHLORIDE

CONCENTRATE; ORAL
THIOTHIXENE HCL INTENSOL

AA	ROXANE	EQ 5MG BASE/ML*	N73494 001 JUN 30, 1992

TIMOLOL MALEATE

TABLET; ORAL
TIMOLOL MALEATE

/B*/	/PHARM/BASICS/	/5MG/	/N72001/001/ /JAN/10,/1989/
/B*/		/10MG/	/N72002/001/ /JAN/10,/1989/
/B*/		/20MG/	/N72003/001/ /JAN/10,/1989/
	ə PHARM BASICS	5MG	N72001 001 JAN 10, 1989
	ə	10MG	N72002 001 JAN 10, 1989
	ə	20MG	N72003 001 JAN 10, 1989

TIOCONAZOLE

OINTMENT; VAGINAL
VAGISTAT-1

>DLT>	/BRISTOL/MYERS/	/6.5%/	/N19355/001/ /DEC/30,/1986/
>DLT>			
>ADD>	BRISTOL MYERS SQUIBB	6.5%	N19355 001 DEC 30, 1986
>ADD>			

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION
TOBRAMYCIN SULFATE

AP	ABBOTT	EQ 40MG BASE/ML*	N63116 001 MAY 18, 1992
AP	GENSIA	EQ 40MG BASE/ML*	N63100 001 JAN 30, 1992

TOLAZAMIDE

TABLET; ORAL
TOLAZAMIDE

/AB/	/INTERPHARM/	/250MG/	/N71270/001/ /SEP/23,/1986/
/AB/		/500MG/	/N71271/001/ /SEP/23,/1986/
B*	INTERPHARM	250MG	N71270 001 SEP 23, 1986
B*		500MG	N71271 001 SEP 23, 1986
/B*/	/PHARM/BASICS/	/100MG/	/N71355/001/ /JAN/11,/1988/
/B*/		/250MG/	/N70168/001/ /APR/02,/1986/
/B*/		/500MG/	/N70169/001/ /APR/02,/1986/
	ə PHARM BASICS	100MG	N71355 001 JAN 11, 1988
	ə	250MG	N70168 001 APR 02, 1986
	ə	500MG	N70169 001 APR 02, 1986

TOLBUTAMIDE

TABLET; ORAL
TOLBUTAMIDE

AB	EON LABS	500MG	N12678 001
/AB/	/PARKE/DAVIS/	/500MG/	/N86047/001/
	ə PARKE DAVIS	500MG	N86047 001
/AB/	/VITARINE/	/500MG/	/N12678/001/

TOLMETIN SODIUM

CAPSULE; ORAL
TOLMETIN SODIUM

AB	BAKER CUMMINS	EQ 400MG BASE*	N73392 001 JAN 24, 1992
AB	GENEVA	EQ 400MG BASE*	N73462 001 APR 30, 1992
AB	LEMMON	EQ 400MG BASE*	N73519 001 MAY 29, 1992
AB	PUREPAC	EQ 400MG BASE*	N73308 001 JAN 24, 1992

TOLMETIN SODIUM

TABLET; ORAL

TOLECTIN 600

AB	+ JOHNSON RW	EQ 600MG BASE	N17628 002	MAR 08, 1989

TOLMETIN SODIUM

AB	GENEVA	EQ 200MG BASE*	N73588 001	JUL 31, 1992
AB	PUREPAC	EQ 600MG BASE*	N73527 001	JUN 30, 1992

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

TRAZODONE HCL

/B*/	/PHARM/BASICS/	/50MG/	/N70491/001/	/APR/29,/1987/
/B*/		/100MG/	/N70492/001/	/APR/29,/1987/
	∂ PHARM BASICS	50MG	N70491 001	APR 29, 1987
	∂	100MG	N70492 001	APR 29, 1987

TRICHLORMETHIAZIDE

TABLET; ORAL

TRICHLORMETHIAZIDE

	∂ EON LABS	4MG	N86171 001	
/∂/	/VITARINE/	/4MG/	/N86171/001/	

TRIDIHEXETHYL CHLORIDE

/TABLET;/ORAL/

/PATHILON/

/LEDERLE/	/25MG/	/N09489/005/	
∂ LEDERLE	25MG	N09489 005	

TRIHEXYPHENIDYL HYDROCHLORIDE

TABLET; ORAL

/TRIHEXIN/

>DLT>				
>DLT>/AA/	/SCHERING/	/2MG/	/N80381/001/	
>DLT>/AA/		/5MG/	/N80381/003/	
>ADD>	∂ SCHERING	2MG	N80381 001	
>ADD>	∂	5MG	N80381 003	

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

TRIMETHOBENZAMIDE HCL

>DLT>/AP/	/SMITH/NEPHEW/SOLOPAK/	/100MG/ML/	/N89094/001/	/APR/04,/1986/
>DLT>				
>ADD> AP	SOLOPAK MEDCL	100MG/ML	N89094 001	APR 04, 1986
>ADD>				

TRIMIPRAMINE MALEATE

CAPSULE; ORAL

SURMONTIL

/AB/	/WYETH/AYERST/	/EQ 25MG BASE/	/N16792/001/	
/AB/		/EQ 50MG BASE/	/N16792/002/	
/AB//+/		/EQ 100MG BASE/	/N16792/003/	/SEP/15,/1982/
	+ WYETH AYERST	EQ 100MG BASE	N16792 003	SEP 15, 1982
		EQ 25MG BASE	N16792 001	
		EQ 50MG BASE	N16792 002	

/TRIMIPRAMINE/MALEATE/

/B*/	/PHARM/BASICS/	/EQ/25MG/BASE/	/N71283/001/	/DEC/08,/1987/
/B*/		/EQ/50MG/BASE/	/N71284/001/	/DEC/08,/1987/
/B*/		/EQ/100MG/BASE/	/N71285/001/	/DEC/08,/1987/

TRIMIPRAMINE MALEATE

>DLT>	/∂/EON/LABS/	/EQ/25MG/BASE/	/N71832/001/	
>DLT>				/SEP/10,/1987/
>DLT>	/∂/	/EQ/50MG/BASE/	/N71833/001/	
>DLT>				/SEP/10,/1987/
>DLT>	/∂/	/EQ/100MG/BASE/	/N71834/001/	
>DLT>				/SEP/10,/1987/
	∂ PHARM BASICS	EQ 25MG BASE	N71283 001	DEC 08, 1987
	∂	EQ 50MG BASE	N71284 001	DEC 08, 1987
	∂	EQ 100MG BASE	N71285 001	DEC 08, 1987

TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE)

CREAM; VAGINAL

GYNE-SULF

AT	G AND W	3.7%;2.86%;3.42%	N88607 001

SULTRIN

AT	JOHNSON RW	3.7%;2.86%;3.42%	N05794 001

TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE)

CREAM; VAGINAL
TRIPLE SULFA

AT	CLAY PARK	3.7%;2.86%;3.42%	N87285 001 NOV 15, 1982
AT	FOUGERA	3.7%;2.86%;3.42%	N86424 001
AT	NMC	3.7%;2.86%;3.42%	N87864 001 SEP 01, 1982

TRYSUL

AT	SAVAGE	3.7%;2.86%;3.42%	N87887 001 JUL 23, 1982

VAGILIA

∂	LEMMON	3.7%;2.86%;3.42%	N88821 001 NOV 09, 1987

TABLET; VAGINAL
SULTRIN

	JOHNSON RW	184MG;143.75MG;172.5MG	N05794 002

TRIPLE SULFA

∂	FOUGERA	184MG;143.75MG;172.5MG	N88463 001 JAN 03, 1985
∂	PHARMADERM	184MG;143.75MG;172.5MG	N88462 001 JAN 03, 1985

TRISULFAPYRIMIDINES

SUSPENSION; ORAL
/SULFALOID/

/AB/	/FOREST PHARMS/	/500MG/5ML/	/N80100 001/
∂	FOREST PHARMS	500MG/5ML	N80100 001

URACIL MUSTARD

CAPSULE; ORAL
URACIL MUSTARD

	ROBERTS	1MG	N12892 001
	/UPJOHN/	/1MG/	/N12892 001/

VALPROIC ACID

SYRUP; ORAL
VALPROIC ACID

AA	COPLEY	250MG/5ML¤	N73178 001 AUG 25, 1992

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION
VANCOMYCIN HCL

AP	ABBOTT	EQ 500MG BASE/VIAL¤	N62931 001 OCT 29, 1992
AP		EQ 1GM BASE/VIAL¤	N62933 001 OCT 29, 1992

> DLT > /VANCOR/
> DLT >/AP/ /ADRIA/ /EQ 500MG BASE/VIAL/ /N62956/001/ /AUG/01,/1988/
> DLT >
> DLT >/AP/ /EQ 1GM BASE/VIAL/ /N62956/002/ /AUG/01,/1988/
> DLT >
> ADD > ∂ ADRIA EQ 500MG BASE/VIAL N62956 001 AUG 01, 1988
> ADD >
> ADD > ∂ EQ 1GM BASE/VIAL N62956 002 AUG 01, 1988
> ADD >

VECURONIUM BROMIDE

INJECTABLE; INJECTION
NORCURON

	ORGANON	20MG/VIAL¤	N18776 003 JAN 03, 1992

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
VERELAN

+	ELAN	180MG¤	N19614 003 JAN 09, 1992

INJECTABLE; INJECTION
VERAPAMIL HCL

> DLT >/AP/ /SMITH/DEBHEW/SOCOPAK/ 2.5MG/ML/ /N70695/001/ /JUL/31,/1987/
> DLT >
> ADD > AP SOLOPAK MEDCL 2.5MG/ML N70695 001 JUL 31, 1987
> ADD >

TABLET; ORAL
VERAPAMIL HCL

/BX/	/CHELSEA/	/80MG/	/N70421/001/ /SEP/17,/1986/
/BX/		/120MG/	/N70422/001/ /SEP/17,/1986/
AB	GENEVA	40MG¤	N73168 001 JUL 31, 1992

VERAPAMIL HYDROCHLORIDE

TABLET; ORAL
VERAPAMIL HCL
> DLT > /∂/PARKE/DAVIS/ /80MG/ /N70340/001/ /AUG/20,/1986/
> DLT > /∂/ /120MG/ /N70341/001/ /AUG/20,/1986/
> DLT >
> ADD > ∂ WARNER CHILCOTT 80MG N70340 001 AUG 20, 1986
> ADD >
> ADD > ∂ 120MG N70341 001 AUG 20, 1986
> ADD >

TABLET, EXTENDED RELEASE; ORAL
ISOPTIN SR
AB + KNOLL 240MG N19152 001 DEC 16, 1986

VERAPAMIL HCL
AB BAKER CUMMINS 240MG N73568 001 JUL 31, 1992

VINBLASTINE SULFATE

INJECTABLE; INJECTION
/VELSAR/
/AP/ /BULL/ /10MG/VIAL/ /N89565/001/ /AUG/18,/1987/

VINBLASTINE SULFATE
AP BULL 10MG/VIAL N89565 001 AUG 18, 1987

VINCRISTINE SULFATE

INJECTABLE; INJECTION
VINCRISTINE SULFATE
/AP/ /ABIC/ /1MG/ML/ /N70873/001/ /FEB/19,/1987/
∂ ABIC 1MG/ML N70873 001 FEB 19, 1987

VITAMIN A

CAPSULE; ORAL
AQUASOL A
AA ASTRA 50,000 USP UNITS N83080 001
25,000 USP UNITS N83080 002
/AA/ /USV/ /50,000 USP UNITS/ /N83080/001/
/25,000/USP/UNITS/ /N83080/002/

VITAMIN A PALMITATE

CAPSULE; ORAL
VITAMIN A
∂ ELKINS SINN EQ 50,000 UNITS BASE N85479 001
/∂/QUANTUM/PHARMICS/ /EQ/50,000/UNITS/BASE/ /N85479/001/
VITAMIN A PALMITATE
> DLT >/AA/ /BANNER/GELATIN/ /EQ 50,000 UNITS BASE/ /N83981/001/
> ADD > ∂ BANNER GELATIN EQ 50,000 UNITS BASE N83981 001

WARFARIN SODIUM

TABLET; ORAL
/WARFARIN/SODIUM/
/B*/ /PHARM/BASICS/ /2MG/ /N88719/001/ /JUN/27,/1985/
/B*/ /2.5MG/ /N88720/001/ /AUG/06,/1985/
/B*/ /5MG/ /N88721/001/ /JUL/02,/1985/
∂ PHARM BASICS 2MG N88719 001 JUN 27, 1985
∂ 2.5MG N88720 001 AUG 06, 1985
∂ 5MG N88721 001 JUL 02, 1985

XENON, XE-133

> DLT > /SOLUTION;/INHALATION;/INJECTION/
> DLT > /XENESOL/
> DLT > /MALLINCKRODT/ /18-25MCI/AMP/ /N17262/002/
> ADD > ∂ MALLINCKRODT 18-25MCI/AMP N17262 002

ZALCITABINE

TABLET; ORAL
HIVID
+ ROCHE 0.75MG N20199 002 JUN 19, 1992
0.375MG N20199 001 JUN 19, 1992

>_ADD_> ZOLPIDEM TARTRATE

>_ADD_>	TABLET; ORAL		
>_ADD_>	AMBIEN		
>_ADD_>	+ LOREX	10MG	N19908 002
>_ADD_>			DEC 16, 1992
>_ADD_>		5MG	N19908 001
>_ADD_>			DEC 16, 1992

ACETAMINOPHEN

SUPPOSITORY; RECTAL

ACEPHEN

>ADD>	+	G AND W	120MG	N18060 001
>ADD>	+		325MG	N18060 003
>ADD>				DEC 18, 1986
>ADD>	+		650MG	N18060 002
>DLT>			/120MG/	/N18060/001/
			120MG¤	N72218 001
				MAR 27, 1992
>DLT>			/325MG/	/N18060/003/
>DLT>				/DEC/18,/1986/
			325MG¤	N72344 001
				MAR 27, 1992
>DLT>			/650MG/	/N18060/002/
			650MG¤	N72237 001
				MAR 27, 1992

>ADD> AVOBENZONE; OCTYL METHOXYCINNAMATE; OXYBENZONE

>ADD> LOTION; TOPICAL

>ADD> SHADE UVAGUARD

>ADD> PLOUGH 3%;7.5%;3%¤ N20045 001

>ADD> DEC 07, 1992

BACITRACIN ZINC; LIDOCAINE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

/OINTMENT;TOPICAL/

/ANABIOTIC/

/COMBE/ /400/UNITS/GM;40MG/GM;EQ/5MG/BASE/GM/ /5,000/UNITS/GM/ /N62499/001/ /JUN/03,/1985/

@ COMBE 400 UNITS/GM;40MG/GM;EQ 5MG BASE/GM 5,000 UNITS/GM N62499 001 JUN 03, 1985

CHLORHEXIDINE GLUCONATE

SOLUTION; TOPICAL

MICROCOL

JOHNSON AND JOHNSON 0.5%¤ N72292 001 JAN 28, 1992

STERI-STAT

MATRIX MEDCL 4% N70104 001 JUL 24, 1986

/MEDCL/SYSTEMS/ /4%/ /N70104/001/ /JUL/24,/1986/

CLEMASTINE FUMARATE

TABLET; ORAL

>ADD> CLEMASTINE FUMARATE

>ADD> LEMMON 1.34MG¤ N73282 002 DEC 03, 1992

>ADD>

TAVIST-1

SANDOZ 1.34MG¤ N17661 003 AUG 21, 1992

CLEMASTINE FUMARATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

TAVIST-D

SANDOZ 1.34MG;75MG¤ N18298 002 AUG 21, 1992

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

/RESPORAL/

/PIONEER/PHARMS/ /6MG;120MG/ /N89139/001/ /JUN/16,/1988/

@ PIONEER PHARMS 6MG;120MG N89139 001 JUN 16, 1988

DIPHENHYDRAMINE HYDROCHLORIDE

SYRUP; ORAL

DIPHENHYDRAMINE HCL

CUMBERLAND SWAN 12.5MG/5ML¤ N73611 001 AUG 20, 1992

SILPHEN

SILARX 12.5MG/5ML¤ N72646 001 FEB 27, 1992

DOXYLAMINE SUCCINATE

>DLT> /CAPSULE;ORAL/

>DLT> /UNISOM/

>DLT> /PFIZER/ /25MG/ /N19440/001/ /FEB/05,/1986/

>DLT>

>ADD> @ PFIZER 25MG N19440 001 FEB 05, 1986

>ADD>

IBUPROFEN

TABLET; ORAL
IBUPROFEN

>DLT>	/CHELSEA/	/200MG/	/N70605/001/	
>DLT>			/MAY/07,/1986/	
	/MEDICOPHARMA/	/200MG/	/N71639/001/	
			/FEB/02,/1988/	
	TAG	200MG	N73141 001	
			MAY 29, 1992	
	VINTAGE	200MG	N71639 001	
			FEB 02, 1988	

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET; ORAL
SINE-AID IB

>ADD>	MCNEIL	200MG;30MG	N19899 001
>ADD>			DEC 31, 1992

INSULIN BIOSYNTHETIC HUMAN; INSULIN SUSP ISOPHANE BIOSYNTHETIC HUMAN

INJECTABLE; INJECTION
HUMULIN 50/50

	LILLY	50 UNITS/ML;50 UNITS/ML	N20100 001
			APR 29, 1992

LOPERAMIDE HYDROCHLORIDE

SOLUTION; ORAL
LOPERAMIDE HCL

	BARRE	1MG/5ML	N73187 001
			SEP 15, 1992
	PERRIGO	1MG/5ML	N73243 001
			JAN 21, 1992
	ROXANE	1MG/5ML	N73079 001
			APR 30, 1992

TABLET; ORAL
LOPERAMIDE HCL

>ADD>	OHM	2MG	N74091 001
>ADD>			DEC 10, 1992
	PERRIGO	2MG	N74194 001
			OCT 30, 1992

MICONAZOLE NITRATE

CREAM; VAGINAL
MICONAZOLE NITRATE

	COPLEY	2%	N74030 001
			OCT 30, 1992

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
PSEUDOEPHEDRINE HCL

>ADD>	ALZA	240MG	N20021 002
>ADD>			DEC 15, 1992

SODIUM CHLORIDE

AEROSOL, METERED; INHALATION
BRONCHO SALINE

	BLAIREX	0.9%	N19912 001
			SEP 03, 1992

SODIUM MONOFLUOROPHOSPHATE

PASTE; DENTAL
EXTRA-STRENGTH AIM

	/A/CHESEBROUGH/PONDS/	/1.2%/	/N19518/001/
			/JUN/03,/1987/
	CHESEBROUGH PONDS	1.2%	N19518 001
			JUN 03, 1987

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST
CUMULATIVE SUPPLEMENT NUMBER 12 / JAN '92 - DEC '92

DEXTRAN 40, 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
LMD IN PLASTIC CONTAINER

ABBOTT LABS	10GM/100ML;0.9GM/100ML	N72562 OCT 30, 1992

DEXTRAN 40, 10% IN DEXTROSE 5%

INJECTABLE; INJECTION
LMD IN PLASTIC CONTAINER

ABBOTT LABS	10GM/100ML;5GM/100ML	N72563 OCT 30, 1992

DEXTRAN 75 6% INVERTED SUGAR 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
6% GENTRAN 75 AND 10% TRAVERT

TRAVENOL LABS	6GM/100ML;10GM/100ML; 0.9GM/100ML	N08788

UROKINASE

INJECTABLE; INJECTION
BREOKINASE

STERLING DRUG	250,000 IU/VIAL	N17873

ORPHAN DRUG PRODUCT DESIGNATIONS

ORPHAN DRUG PRODUCT DESIGNATIONS

SECTION 526 OF THE FEDERAL FOOD, DRUG, AND COSMETIC ACT CONTAINS PROVISIONS WHEREBY FDA MAY DESIGNATE A SPONSOR'S DRUG, ANTIBIOTIC, OR BIOLOGICAL PRODUCT AS A "DESIGNATED ORPHAN DRUG." SECTION 527 OF THE ACT ESTABLISHES A PROCESS WHEREBY A SPONSOR MAY RECEIVE SEVEN YEARS OF EXCLUSIVE APPROVAL STATUS IF THAT SPONSOR IS THE FIRST TO ACHIEVE NEW DRUG, ANTIBIOTIC, OR BIOLOGICAL PRODUCT APPROVAL FOR A DESIGNATED ORPHAN DRUG FOR THE DESIGNATED INDICATION(S). THE EXCLUSIVE APPROVAL MAY BE REVOKED BY WRITTEN CONSENT OF THE SPONSOR OR BY FDA ACTION AFTER FINDING THAT THE SPONSOR HOLDING EXCLUSIVE APPROVAL CANNOT ASSURE THE AVAILABILITY OF SUFFICIENT QUANTITIES OF THE DRUG TO MEET THE NEEDS OF PATIENTS WITH THE DESIGNATED ORPHAN INDICATION(S).

WHEN A PRODUCT IS GRANTED ORPHAN DRUG DESIGNATION, IT WILL APPEAR IN THIS SECTION. ONCE A BIOLOGICAL OR DRUG PRODUCT IS LICENSED/APPROVED FOR MARKETING, IT WILL BE LISTED IN THIS SECTION AND ASTERISKED, AS APPROPRIATE, TO DENOTE MARKETING/EXCLUSIVE APPROVAL STATUS. IN ADDITION, THE EXCLUSIVITY EXPIRATION DATE WILL BE DISPLAYED FOLLOWING THE APPROVED DESIGNATED INDICATION(S).

THE FOLLOWING DRUGS AND BIOLOGICALS HAVE BEEN GRANTED ORPHAN DRUG DESIGNATION PURSUANT TO SECTION 526 OF THE FOOD, DRUG, AND COSMETIC ACT AS AMENDED BY THE ORPHAN DRUG ACT [PUBLIC LAW 97-414].

ORPHAN DRUG PRODUCT DESIGNATIONS

BIOLOGICAL DESIGNATIONS
[Approved for Marketing*]
[Exclusive Approval**]

NAME OF BIOLOGICAL	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: AI-RSA TRADE: NOT ESTABLISHED	TREATMENT OF AUTOIMMUNE UVEITIS.	AUTOIMMUNE, INC
GENERIC: ALDESLEUKIN TRADE: PROLEUKIN*/**	TREATMENT OF PRIMARY IMMUNODEFICIENCY DISEASE ASSOCIATED WITH T-CELL DEFECTS.*/** [MAY 05, 1999]	CETUS
GENERIC: ANANAIN, COMOSAIN TRADE: VIANAIN	FOR THE ENZYMATIC DEBRIDEMENT OF SEVERE BURNS.	GENZYME CORPORATION
GENERIC: ANTIHEMOPHILIC FACTOR, HUMAN TRADE: HUMATE P	TREATMENT OF PATIENTS WITH VON WILLEBRAND'S DISEASE.	BEHRINGWERKE AKTIENGESELLSCHAFT
GENERIC: ANTITHROMBIN III TRADE: THROMBATE III*/**	USE AS REPLACEMENT THERAPY IN CONGENITAL DEFICIENCY OF ANTITHROMBIN-III FOR PREVENTION AND TREATMENT OF OF THROMBOSIS AND PULMONARY EMBOLI. [DEC 13, 1996]	CUTTER BIOLOGICAL

ORPHAN DRUG PRODUCT DESIGNATIONS

BIOLOGICAL DESIGNATIONS

NAME OF BIOLOGICAL	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: BOTULINUM TOXIN TYPE A TRADE: NOT ESTABLISHED	TREATMENT OF SYNKINETIC CLOSURE OF THE EYELID ASSOCIATED WITH VII CRANIAL NERVE ABERRANT REGENERATION.	BIOPURE CORPORATION
GENERIC: BOTULINUM TOXIN TYPE B TRADE: NOT ESTABLISHED	TREATMENT OF CERVICAL DYSTONIA.	ATHENA NEUROSCIENCES, INC
GENERIC: CILIARY NEUROTROPHIC FACTOR TRADE: NOT ESTABLISHED	TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS.	ROGENERON PHARMACEUTICALS, INC
GENERIC: CILIARY NEUROTROPHIC FACTOR, RECOMBINANT HUMAN TRADE: NOT ESTABLISHED	TREATMENT OF SPINAL MUSCULAR ATROPHIES. TREATMENT OF MOTOR NEURON DISEASE (INCLUDING AMYOTROPHIC LATERAL SCLEROSIS, PROGRESSIVE MUSCULAR ATROPHY, PROGRESSIVE BULBAR PALSY, AND PRIMARY LATERAL SCLEROSIS).	SYNTEX-SYNERGEN NEUROSCIENCE
GENERIC: COAGULATION FACTOR IX TRADE: MONONINE*/**	REPLACEMENT TREATMENT AND PROPHYLAXIS OF THE HEMORRHAGIC COMPLICATIONS OF HEMOPHILIA B. [AUG 20, 1999]	ARMOUR PHARMACEUTICAL
GENERIC: CYSTIC FIBROSIS GENE THERAPY TRADE: NOT ESTABLISHED	TREATMENT OF CYSTIC FIBROSIS.	GENZYME CORPORATION
GENERIC: CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR TRADE: NOT ESTABLISHED	FOR CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN REPLACEMENT THERAPY IN CYSTIC FIBROSIS PATIENTS.	GENZYME CORPORATION
GENERIC: C1-ESTERASE INHIBITOR, HUMAN, PASTEURIZED TRADE: NOT ESTABLISHED	PREVENTION AND/OR TREATMENT OF ACUTE ATTACKS OF HEREDITARY ANGIOEDEMA.	BEHRINGWERKE AKTIENGESELLSCHAFT

ORPHAN DRUG PRODUCT DESIGNATIONS

BIOLOGICAL DESIGNATIONS

ORPHAN DRUG PRODUCT DESIGNATIONS

BIOLOGICAL DESIGNATIONS

NAME OF BIOLOGICAL	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: HERPES SIMPLEX VIRUS GENE TRADE: NOT ESTABLISHED	TREATMENT OF PRIMARY AND METASTATIC BRAIN TUMORS.	GENETIC THERAPY, INC
GENERIC: HIV NEUTRALIZING ANTIBODIES TRADE: IMMUPATH	TREATMENT OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS).	HEMACARE CORPORATION
GENERIC: HUMAN IMMUNODEFICIENCY VIRUS IMMUNE GLOBULIN TRADE: NOT ESTABLISHED	TREATMENT OF HIV-INFECTED PREGNANT WOMEN AND INFANTS OF HIV-INFECTED MOTHERS.	NORTH AMERICAN BIOLOGICALS
GENERIC: IMMUNE GLOBULIN INTRAVENOUS, HUMAN TRADE: IVEEGAM, IMMUNO	TREATMENT OF POLYMYOSITIS/DERMATOMYOSITIS. TREATMENT OF JUVENILE RHEUMATOID ARTHRITIS.	IMMUNO CLINICAL RESEARCH CORPORATION
GENERIC: IMPORTED FIRE ANT VENOM, ALLERGENIC EXTRACT TRADE: NOT ESTABLISHED	FOR SKIN TESTING OF VICTIMS OF FIRE ANT STINGS TO CONFIRM FIRE ANT SENSITIVITY AND IF POSITIVE, FOR USE AS IMMUNOTHERAPY FOR THE PREVENTION OF IgE-MEDIATED ANAPHYLACTIC REACTIONS.	ALK LABORATORIES, INC
GENERIC: INTERFERON (RECOMBINANT HUMAN, BETA) TRADE: NOT ESTABLISHED	TREATMENT OF ACUTE NON-A, NON-B HEPATITIS.	BIOGEN, INC
GENERIC: INTERFERON BETA (RECOMBINANT) TRADE: R-FRONE	TREATMENT OF SYMPTOMATIC PATIENTS WITH ACQUIRED IMMUNODEFICIENCY SYNDROME INCLUDING ALL PATIENTS WITH CD4 T-CELL COUNTS LESS THAN 200 CELLS PER MM^3.	SERONO LABORATORIES, INC
GENERIC: INTERLEUKIN-1 RECEPTOR ANTAGONIST, HUMAN RECOMBINANT TRADE: ANTRIL	PREVENTION AND TREATMENT OF GRAFT VERSUS HOST DISEASE IN TRANSPLANT RECIPIENTS.	SYNERGEN, INC
GENERIC: PROTEIN C CONCENTRATE TRADE: PROTEIN C CONCENTRATE (HUMAN) VAPOR HEATED, IMMUNO	FOR REPLACEMENT THERAPY IN PATIENTS WITH CONGENITAL OR ACQUIRED PROTEIN C DEFICIENCY FOR THE PREVENTION AND TREATMENT OF WARFARIN-INDUCED SKIN NECROSIS DURING ORAL ANTICOAGULATION. FOR REPLACEMENT THERAPY IN CONGENITAL PROTEIN C DEFICIENCY FOR THE PREVENTION AND TREATMENT OF THROMBOSIS, PULMONARY EMBOLI, AND PURPURA FULMINANS.	IMMUNO CLINICAL RESEARCH CORPORATION

ORPHAN DRUG PRODUCT DESIGNATIONS

BIOLOGICAL DESIGNATIONS

NAME OF BIOLOGICAL	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: SARGRAMOSTIM TRADE: LEUKINE*/**	TREATMENT OF NEUTROPENIA ASSOCIATED WITH BONE MARROW TRANSPLANT, FOR THE PROMOTION OF EARLY ENGRAFTMENT, AND FOR THE TREATMENT OF GRAFT FAILURE AND DELAY OF ENGRAFTMENT.*/** [DEC 31, 1998] TREATMENT OF NEUTROPENIA ASSOCIATED WITH BONE MARROW TRANSPLANTS IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA, HODGKIN'S DISEASE AND ACUTE LYMPHOBLASTIC LEUKEMIA.*/** [MAR 05, 1998]	IMMUNEX
GENERIC: SECRETORY LEUKOCYTE PROTEASE INHIBITOR TRADE: NOT ESTABLISHED	TREATMENT OF BRONCHOPULMONARY DYSPLASIA.	SYNERGEN, INC
GENERIC: TECHNETIUM TC99M MURINE MONOCLONAL ANTIBODY (IGG2A) TO BCE TRADE: IMMURAID-LL-2[99mTc]	DIAGNOSTIC IMAGING IN THE EVALUATION OF THE EXTENT OF DISEASE IN PATIENTS WITH HISTOLOGICALLY CONFIRMED DIAGNOSIS OF NON-HODGKIN'S B-CELL LYMPHOMA, ACUTE B-CELL LYMPHOBLASTIC LEUKEMIA (IN CHILDREN AND ADULTS), AND CHRONIC B-CELL LYMPHOCYTIC LEUKEMIA.	IMMUNOMEDICS, INC
GENERIC: TRANSFORMING GROWTH FACTOR-BETA 2 TRADE: NOT ESTABLISHED	TREATMENT OF FULL THICKNESS MACULAR HOLES.	CELTRIX PHARMACEUTICALS, INC

ORPHAN DRUG PRODUCT DESIGNATIONS

DRUG DESIGNATIONS
[Approved for Marketing*]
[Exclusive Approval**]

NAME OF DRUG	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: ALLOPURINOL SODIUM TRADE: ZYLOPRIM FOR INJECTION	MANAGEMENT OF PATIENTS WITH LEUKEMIA, LYMPHOMA, AND SOLID TUMOR MALIGNANCIES WHO ARE RECEIVING CANCER THERAPY WHICH CAUSES ELEVATIONS OF SERUM AND URINARY URIC ACID LEVELS AND WHO CANNOT TOLERATE ORAL THERAPY.	BURROUGHS WELLCOME COMPANY
GENERIC: ANARITIDE ACETATE TRADE: AURICULIN	IMPROVEMENT OF EARLY RENAL ALLOGRAFT FUNCTION FOLLOWING RENAL TRANSPLANTATION. TREATMENT OF PATIENTS WITH ACUTE RENAL FAILURE.	SCIOS, INC
GENERIC: ARGININE BUTYRATE TRADE: NOT ESTABLISHED	TREATMENT OF BETA-HEMOGLOBINOPATHIES AND BETA-THALASSEMIA.	SUSAN P. PERRINE, M.D.
GENERIC: BACLOFEN (INTRATHECAL) TRADE: LIORESAL	TREATMENT OF INTRACTABLE SPASTICITY CAUSED BY SPINAL CORD INJURY, MULTIPLE SCLEROSIS, AND OTHER SPINAL DISEASES (INCLUDING SPINAL ISCHEMIA, SPINAL TUMOR, TRANSVERSE MYELITIS, CERVICAL SPONDYLOSIS, AND DEGENERATIVE MYELOPATHY.	MEDTRONIC, INC
GENERIC: BUTYRYLCHOLINESTERASE TRADE: NOT ESTABLISHED	FOR THE REDUCTION AND CLEARANCE OF TOXIC BLOOD LEVELS OF COCAINE ENCOUNTERED DURING A DRUG OVERDOSE. TREATMENT OF POST-SURGICAL APNEA.	PHARMAVENE, INCORPORATED
GENERIC: DAPSONE TRADE: DAPSONE	FOR THE COMBINATION TREATMENT OF PNEUMOCYSTIS CARINII PNEUMONIA IN CONJUNCTION WITH TRIMETHOPRIM.	JACOBUS PHARMACEUTICAL COMPANY
GENERIC: DIANEAL PD-2 PERITONEAL DIALYSIS SOLN WITH 1.1% AMINO ACIDS TRADE: NUTRINEAL PD-2 PERITONEAL DIALYSIS SOLN WITH 1.1% AMINO ACIDS	FOR USE AS A NUTRITIONAL SUPPLEMENT FOR THE TREATMENT OF MALNOURISHMENT IN PATIENTS UNDERGOING CONTINUOUS AMBULATORY PERITONEAL DIALYSIS.	BAXTER HEALTHCARE CORPORATION
GENERIC: DIAZEPAM VISCOUS SOLUTION FOR RECTAL ADMINISTRATION TRADE: DIASTAT	TREATMENT OF ACUTE REPETITIVE SEIZURES.	UPSHER SMITH LABORATORIES, INC
GENERIC: FIAU TRADE: NOT ESTABLISHED	ADJUNCTIVE TREATMENT OF CHRONIC ACTIVE HEPATITIS B.	OCLASSEN PHARMACEUTICALS, INC

ORPHAN DRUG PRODUCT DESIGNATIONS

DRUG DESIGNATIONS

NAME OF DRUG	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: HALOFANTRINE HCL TRADE: HALFAN*/**	TREATMENT OF MILD TO MODERATE ACUTE MALARIA CAUSED BY SUSCEPTIBLE STRAINS OF P. FALCIPARUM AND P. VIVAX. [JUL 24, 1999]	SMITHKLINE BEECHAM
GENERIC: HUMAN THYROID STIMULATING HORMONE (TSH) TRADE: THYROGEN	AS AN ADJUNCT IN THE DIAGNOSIS OF THYROID CANCER.	GENZYME CORPORATION
GENERIC: IDARUBICIN TRADE: IDAMYCIN	TREATMENT OF MYELODYSPLASTIC SYNDROMES. TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA.	ADRIA LABORATORIES
GENERIC: ISOBUTYRAMIDE TRADE: ISOBUTYRAMIDE ORAL SOLUTION	TREATMENT OF BETA-HEMOGLOBINOPATHIES AND BETA THALASSEMIA SYNDROMES.	SUSAN PERRINE OAKLAND, CA
GENERIC: L-BACLOFEN TRADE: NEURALGON	TREATMENT OF INTRACTABLE SPASTICITY IN CHILDREN WITH CEREBRAL PALSY.	WTD, INC
GENERIC: L-THREONINE TRADE: NOT ESTABLISHED	TREATMENT OF SPASTICITY ASSOCIATED WITH FAMILIAL SPASTIC PARAPARESIS.	INTERNEURON PHARMACEUTICALS, INC
GENERIC: LEVOCARNITINE TRADE: CARNITOR*/**	GENETIC CARNITINE DEFICIENCY.* TREATMENT OF MANIFESTATIONS OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE (ESRD) WHO REQUIRE DIALYSIS. PREVENTION OF SECONDARY CARNITINE DEFICIENCY IN VALPROIC ACID TOXICITY. TREATMENT OF SECONDARY CARNITINE DEFICIENCY IN VALPROIC ACID TOXICITY.	SIGMA TAU
GENERIC: LEVOCARNITINE TRADE: CARNITOR*/**	TREATMENT OF PRIMARY AND SECONDARY CARNITINE DEFICIENCY OF GENETIC ORIGIN.*/** [DEC 27, 1992] */** [DEC 16, 1999 - SECONDARY CARNITINE DEFICIENCY].	SIGMA TAU
GENERIC: LIOTHYRONINE SODIUM TRADE: TRIOSTAT*/**	TREATMENT OF MYXEDEMA COMA/PRE-COMA. [DEC 31, 1998]	SMITHKLINE BEECHAM
GENERIC: LOXORIBINE TRADE: NOT ESTABLISHED	TREATMENT OF COMMON VARIABLE IMMUNODEFICIENCY.	R.W. JOHNSON RESEARCH INSTITUTE

ORPHAN DRUG PRODUCT DESIGNATIONS

DRUG DESIGNATIONS

NAME OF DRUG	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: MELPHALAN*/** TRADE: ALKERAN FOR INJECTION	TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA FOR WHOM ORAL THERAPY IS INAPPROPRIATE.*/** [NOV 18, 1999] FOR USE IN HYPERTHERMIC REGIONAL LIMB PERFUSION TO TREAT METASTATIC MELANOMA OF THE EXTREMITY.	BURROUGHS WELLCOME
GENERIC: MINOCYCLINE HCL TRADE: MINOCIN	TREATMENT OF CHRONIC MALIGNANT PLEURAL EFFUSION.	LEDERLE LABORATORIES
GENERIC: OXALIPLATIN TRADE: NOT ESTABLISHED	TREATMENT OF OVARIAN CANCER.	AXION PHARMACEUTICALS
GENERIC: PAPAVERINE (TOPICAL GEL) TRADE: NOT ESTABLISHED	TREATMENT OF SEXUAL DYSFUNCTION IN SPINAL CORD INJURY PATIENTS.	PHARMEDIC COMPANY
GENERIC: PARA-AMINOSALICYLIC ACID TRADE: NOT ESTABLISHED	TREATMENT OF TUBERCULOSIS INFECTIONS.	JACOBUS PHARMACEUTICAL COMPANY
GENERIC: PEG-GLUCOCEREBROSIDASE TRADE: NOT ESTABLISHED	CHRONIC ENZYME REPLACEMENT THERAPY IN PATIENTS WITH GAUCHER'S DISEASE WHO ARE DEFICIENT IN GLUCOCEREBROSIDASE.	ENZON, INCORPORATED
GENERIC: PILOCARPINE HCL TRADE: NOT ESTABLISHED	TREATMENT OF XEROSTOMIA AND KERATOCONJUNCTIVITIS SICCA IN SJOGREN'S SYNDROME PATIENTS.	MGI PHARMA, INC
GENERIC: POLYMERIC OXYGEN TRADE: NOT ESTABLISHED	TREATMENT OF SICKLE CELL ANEMIA.	CAPMED, USA
GENERIC: PPI-002 TRADE: NOT ESTABLISHED	TREATMENT OF MALIGNANT MESOTHELIOMA.	PLEXUS PHARMACEUTICALS, INC
GENERIC: SODIUM MONOMERCAPTOUNDECAHYDRO-CLOSODODECABORATE TRADE: BOROCELL	FOR USE IN BORON NEUTRON CAPTURE THERAPY IN THE TREATMENT OF GLIOBLASTOMA MULTIFORME.	NEUTRON TECHNOLOGY CORPORATION
GENERIC: SODIUM PHENYLBUTYRATE TRADE: NOT ESTABLISHED	TREATMENT OF SICKLING DISORDERS, WHICH INCLUDE S-S HEMOGLOBINOPATHY, S-C HEMOGLOBINOPATHY, AND S-THALASSEMIA HEMOGLOBINOPATHY.	JOHNS HOPKINS MEDICAL INSTITUTIONS

ORPHAN DRUG PRODUCT DESIGNATIONS

DRUG DESIGNATIONS

NAME OF DRUG	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: SOTALOL HCL TRADE: BETAPACE*/**	TREATMENT OF LIFE-THREATENING VENTRICULAR TACHYARRHYTHMIAS. [OCT 30, 1999]	BRISTOL-MYERS SQUIBB
GENERIC: TENIPOSIDE TRADE: VUMON*/**	TREATMENT OF REFRACTORY CHILDHOOD ACUTE LYMPHOCYTIC LEUKEMIA (ALL). [JUL 14, 1999]	BRISTOL MYERS SQUIBB
GENERIC: TOPIRAMATE TRADE: TOPIMAX	TREATMENT OF LENNOX-GASTAUT SYNDROME.	R. W. JOHNSON RESEARCH INSTITUTE
GENERIC: ZALCITABINE TRADE: HIVID	TREATMENT OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS). [JUN 19, 1999]	ROCHE
GENERIC: 9-CIS RETINOIC ACID TRADE: NOT ESTABLISHED	TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA.	LIGAND PHARMACUETICALS, INC

DRUG PRODUCTS WHICH MUST DEMONSTRATE IN VIVO BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO DECEMBER 1992 ADDITIONS

BIOPHARMACEUTIC GUIDANCE AVAILABILITY

THE FOLLOWING IS A LIST OF GUIDANCES AVAILABLE FOR IN VIVO BIOEQUIVALENCE STUDIES AND IN VITRO DISSOLUTION TESTING AVAILABLE FROM THE DIVISION OF BIOEQUIVALENCE, HFD-650, MPN-2 ROOM 279, 5600 FISHERS LANE, ROCKVILLE, MD 20857. COMMENTS AND SUGGESTIONS CONCERNING THESE GUIDANCES ARE ENCOURAGED AND SHOULD BE SENT TO THE DIVISION OF BIOEQUIVALENCE.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 12TH EDITION FOR A FULL LISTING OF BIOPHARMACEUTIC GUIDANCE AVAILABILITY DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

DRUG NAME (DOSAGE FORM)	DATE	REVISED DATE
ALPRAZOLAM (TABLET)	NOV 27, 1992	
CARBIDOPA AND LEVODOPA (TABLET)	JUN 19, 1992	
CIMETIDINE (TABLET)	JUN 12, 1992	
CORTICOSTEROID *IN VITRO* AND *IN VIVO* INTERIM (TOPICAL)	JUL 01, 1992	
DICLOFENAC SODIUM (TABLET)	DEC 24, 1992	
DIFLUNISAL (TABLET)	MAY 16, 1992	
DILTIAZEM HYDROCHLORIDE (TABLET)	MAY 16, 1992	
ESTROPIPATE (TABLET)	AUG 26, 1992	
FLURBIPROFEN (TABLET)	DEC 24, 1992	
GEMFIBROZIL (CAPSULE AND TABLET)	JUN 23, 1989	JUN 15, 1992
METOPROLOL TARTRATE (TABLET)	JUN 12, 1992	
NADOLOL (TABLET)	MAY 16, 1992	
NAPROXEN (TABLET)	JUN 12, 1992	
NORTRIPTYLINE HYDROCHLORIDE (CAPSULE)	JUN 15, 1992	
PIROXICAM (CAPSULE)	JUN 15, 1992	
STATISTICAL PROCEDURE FOR BIOEQUIVALENCE STUDIES USING A STANDARD TWO-TREATMENT CROSSOVER DESIGN	JUL 01, 1992	
TERFENADINE (TABLET)	JUN 12, 1992	

ANDA SUITABILITY PETITIONS

THE FOLLOWING ARE TWO LISTS OF PETITIONS FILED UNDER SECTION 505(j)(2)(C) OF THE ACT WHERE THE AGENCY HAS DETERMINED THAT THE REFERENCED PRODUCT: (1) IS SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS APPROVED) OR (2) IS NOT SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS DENIED). THE DETERMINATION THAT AN ANDA WILL BE APPROVED IS NOT MADE UNTIL THE ANDA ITSELF IS SUBMITTED AND REVIEWED BY THE AGENCY. A COPY OF EACH PETITION IS LISTED BY DOCKET NUMBER ON PUBLIC DISPLAY IN FDA'S DOCKETS MANAGEMENT BRANCH, HFA-305, ROOM 4-62, 5600 FISHERS LANE, ROCKVILLE, MD 20857.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 12TH EDITION FOR A FULL LISTING OF ANDA SUITABILITY PETITIONS DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

PETITIONS APPROVED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
ACETAMINOPHEN; CODEINE PHOSPHATE TABLET; ORAL	500MG 7.5MG	91 P-0514/ CP1	SOFTAN	NEW STRENGTH	APPROVED JUN 03, 1992
ACETAMINOPHEN; HYDROCODONE BITARTRATE TABLET; ORAL	660MG 10MG	91 P-0004/ CP1	KNOLL	NEW STRENGTH	APPROVED OCT 27, 1992
ALBUTEROL SULFATE CAPSULE, EXTENDED RELEASE; ORAL	EQ 4MG BASE	91 P-0348/ CP1	HAMER	NEW DOSAGE FORM	APPROVED MAR 17, 1992
ALPRAZOLAM CONCENTRATE; ORAL	1MG/ML	92 P-0050/ CP1	ROXANE	NEW DOSAGE FORM	APPROVED DEC 15, 1992
ALPRAZOLAM SOLUTION; ORAL	0.5MG/5ML	92 P-0050/ CP2	ROXANE	NEW DOSAGE FORM	APPROVED DEC 15, 1992
CHLORZOXAZONE TABLET; ORAL	750MG	91 P-0153/ CP1	MIKART	NEW STRENGTH	APPROVED JUN 03, 1992

ANDA SUITABILITY PETITIONS

PETITIONS APPROVED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
CIMETIDINE HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER INJECTABLE; INJECTION	EQ 90MG BASE/100ML EQ 120MG BASE/100ML EQ 180MG BASE/100ML EQ 240MG BASE/100ML EQ 360MG BASE/100ML EQ 480MG BASE/100ML	92 P-0337/ CP1	ABBOTT	NEW STRENGTH	APPROVED OCT 26, 1992
HYDROCORTISONE ACETATE AEROSOL; TOPICAL	2.5%	92 P-0101/ CP1	HOGAN & HARTSON	NEW DOSAGE FORM	APPROVED JUL 08, 1992
NALBUPHINE HYDROCHLORIDE INJECTABLE; INJECTION	10MG/ML (2ML/CONTAINER)	92 P-0224/CP	STERLING	NEW STRENGTH	APPROVED SEP 11, 1992
NITROGLYCERIN IN DEXTROSE 5% INJECTABLE; INJECTION	5MG/ML (50ML/CONTAINER)	91 P-0387/ CP1	ABBOTT	NEW STRENGTH	APPROVED FEB 18, 1992
NITROGLYCERIN IN DEXTROSE 5% INJECTABLE; INJECTION	10MG/ML (100ML/CONTAINER)	91 P-0387/ CP1	ABBOTT	NEW STRENGTH	APPROVED FEB 18, 1992
PROPRANOLOL HYDROCHLORIDE TABLET, EFFERVESCENT; ORAL	40MG	92 P-0332/ CP1	FLEMINGTON PHARM	NEW DOSAGE FORM	APPROVED NOV 25, 1992
TAMOXIFEN CITRATE TABLET; ORAL	EQ 20MG BASE	92 P-0269/ CP1	KROSS	NEW STRENGTH	APPROVED OCT 26, 1992
TRIAZOLAM SOLUTION; ORAL	0.125MG/5ML	92 P-0048/ CP2	ROXANE	NEW DOSAGE FORM	APPROVED SEP 11, 1992

ANDA SUITABILITY PETITIONS

ANDA SUITABILITY PETITIONS

PETITIONS DENIED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
ETOPOSIDE INJECTABLE; INJECTION	20MG/ML (50ML/VIAL)	91 P-0076/ CP1	ADRIA	NEW STRENGTH	DENIED FEB 19, 1992

EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE EXCLUSIVITY COLUMN, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 12TH EDITION FOR A FULL LISTING OF EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). ONLY NEW CODES WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

REFERENCES
NEW DOSING SCHEDULE

D-18	LOWER RECOMMENDED STARTING DOSE GUIDELINES
D-19	BOLUS DOSING GUIDELINES

REFERENCES
NEW INDICATION

I-67	TREATMENT OF ACUTE ASTHMATIC ATTACKS IN CHILDREN SIX YEARS OF AGE AND OLDER
I-68	CENTRAL PRECOCIOUS PUBERTY
I-69	SHORT TERM TREATMENT OF PATIENTS WITH SYMPTOMS OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), AND FOR THE SHORT TERM TREATMENT OF ESOPHAGITIS DUE TO GERD INCLUDING ULCERATIVE DISEASE DIAGNOSED BY ENDOSCOPY
I-70	USE IN COMBINATION WITH 5-FLUOROURACIL TO PROLONG SURVIVAL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER
I-71	VARICELLA INFECTIONS (CHICKENPOX)
I-72	PREVENTION OF CMV DISEASE IN TRANSPLANT PATIENTS AT RISK FOR CMV DISEASE
I-73	INITIATE AND MAINTAIN MONITORED ANESTHESIA CARE (MAC) SEDATION DURING DIAGNOSTIC PROCEDURES
I-74	INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY
I-75	TREATMENT OF ENDOSCOPICALLY DIAGNOSED EROSIVE ESOPHAGITIS
I-76	PREVENTION OF OSTEOPOROSIS
I-77	DERMAL INFECTIONS-TINEA PEDIS, TINEA CORPORIS, TINEA CRURIS DUE TO EPIDERMOPHYTON FLOCCOSUM
I-78	CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY AND INTRAVENOUS EXCRETORY UROGRAPHY
I-79	MANAGEMENT OF CHRONIC STABLE ANGINA AND ANGINA DUE TO CORONARY ARTERY SPASM
I-80	DIAGNOSIS AND LOCALIZATION OF ISCHEMIA AND CORONARY HEART DISEASE
I-81	PROPHYLAXIS IN DESIGNATED IMMUNOCOMPROMISED CONDITIONS TO REDUCE THE INCIDENCE OF OROPHARYNGEAL CANDIDIASIS
I-82	TREATMENT OF TRAVELERS' DIARRHEA
I-83	ANGIOCARDIOGRAPHY, CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY IN CHILDREN
I-84	INTRAOPERATIVE AND POSTOPERATIVE TACHYCARDIA AND/OR HYPERTENSION
I-85	TREATMENT OF ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS
I-86	TREATMENT OF SECONDARY CARNITINE DEFICIENCY

EXCLUSIVITY TERMS

REFERENCES
PATENT USE CODE

U-57	OPHTHALMIC USE OF NORFLOXACIN
U-58	METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASES
U-59	METHOD OF TREATING HYPERCHOLESTEROLEMIA
U-60	NASAL ADMINISTRATION OF BUTORPHANOL
U-61	CEREBRAL AND PERIPHERAL ARTERIOGRAPHY AND CT IMAGING OF THE HEAD
U-62	CORONARY ARTERIOGRAPHY, LEFT VENTRICULOGRAPHY, CT IMAGING OF THE BODY, INTRAVENOUS EXCRETORY UROGRAPHY, INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY AND VENOGRAPHY
U-63	ISOPRENALINE ANTAGONISM ON THE HEART RATE OR BLOOD PRESSURE
U-64	TREATMENT OF VIRAL INFECTIONS
U-65	METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV
U-66	TRIPHASIC REGIMEN
U-67	METHOD OF INDUCING ANESTHESIA IN A WARM BLOODED ANIMAL
U-68	TREATMENT OF ACTINIC KERATOSIS
U-69	TREATMENT OF PNEUMOCYSTIS CARINII INFECTIONS
U-70	TREATMENT OF TRANSIENT INSOMNIA
U-71	METHOD OF TREATMENT OF HEART FAILURE
U-72	TREATMENT OF MIGRAINES
U-73	METHOD OF TREATING DISEASES OR INFECTIONS CAUSED BY MYCETES

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20232 001	ACETAMINOPHEN; FIORICET W/ CODEINE				NC	OCT 26, 1993
	18828 001	ACYCLOVIR; ZOVIRAX				I-71	FEB 26, 1995
	19909 001	ACYCLOVIR; ZOVIRAX				I-71	FEB 26, 1995
	20089 001	ACYCLOVIR; ZOVIRAX				I-71	FEB 26, 1995
	20089 002	ACYCLOVIR; ZOVIRAX				I-71	FEB 26, 1995
>ADD>	19604 002	ALBUTEROL SULFATE; VOLMAX				NS	DEC 23, 1995
	19729 001	AMCINONIDE; CYCLOCORT	4158055	JUN 12, 1996	U-19		
>DLT>	~~16949 001~~	~~AMITRIPTYLINE HYDROCHLORIDE; LIMBITROL~~	~~4316897~~	~~FEB 23, 1999~~			
>DLT>	~~16949 002~~	~~AMITRIPTYLINE HYDROCHLORIDE; LIMBITROL~~	~~4316897~~	~~FEB 23, 1999~~			
	19787 001	AMLODIPINE BESYLATE; NORVASC	4879303	NOV 07, 2006			
			4572909	FEB 25, 2003		NCE	JUL 31, 1997
	19787 002	AMLODIPINE BESYLATE; NORVASC	4879303	NOV 07, 2006			
			4572909	FEB 25, 2003		NCE	JUL 31, 1997
	19787 003	AMLODIPINE BESYLATE; NORVASC	4879303	NOV 07, 2006			
			4572909	FEB 25, 2003		NCE	JUL 31, 1997
>ADD>	20259 001	ATOVAQUONE; MEPRON	5053432	OCT 01, 2008		ODE	NOV 25, 1999
			4981874	JAN 01, 2008	U-69	NCE	NOV 25, 1997
>ADD>	20045 001	AVOBENZONE; SHADE UVAGUARD	4387089	JUN 07, 2000			
	20075 001	BACLOFEN; LIORESAL				ODE	JUN 17, 1999
						NDF	JUN 17, 1995
	20075 002	BACLOFEN; LIORESAL				ODE	JUN 17, 1999
						NDF	JUN 17, 1995
	19851 001	BENAZEPRIL HYDROCHLORIDE; LOTENSIN	4410520	OCT 18, 2002		NCE	JUN 25, 1996
	19851 002	BENAZEPRIL HYDROCHLORIDE; LOTENSIN	4410520	OCT 18, 2002		NCE	JUN 25, 1996
	19851 003	BENAZEPRIL HYDROCHLORIDE; LOTENSIN	4410520	OCT 18, 2002		NCE	JUN 25, 1996
	19851 004	BENAZEPRIL HYDROCHLORIDE; LOTENSIN	4410520	OCT 18, 2002		NCE	JUN 25, 1996
	20033 001	BENAZEPRIL HYDROCHLORIDE; LOTENSIN HCT	4410520	OCT 18, 2002		NCE	JUN 25, 1996
						NC	MAY 19, 1995
	20033 002	BENAZEPRIL HYDROCHLORIDE; LOTENSIN HCT	4410520	OCT 18, 2002		NCE	JUN 25, 1996
						NC	MAY 19, 1995
	20033 003	BENAZEPRIL HYDROCHLORIDE; LOTENSIN HCT	4410520	OCT 18, 2002		NCE	JUN 25, 1996
						NC	MAY 19, 1995
	20033 004	BENAZEPRIL HYDROCHLORIDE; LOTENSIN HCT	4410520	OCT 18, 2002		NCE	JUN 25, 1996
						NC	MAY 19, 1995
	19001 001	BEPRIDIL HYDROCHLORIDE; BEPADIN	RE30577	JUN 08, 1995		NCE	DEC 28, 1995
	19001 002	BEPRIDIL HYDROCHLORIDE; BEPADIN	RE30577	JUN 08, 1995		NCE	DEC 28, 1995
	19001 003	BEPRIDIL HYDROCHLORIDE; BEPADIN	RE30577	JUN 08, 1995		NCE	DEC 28, 1995

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
19002 001	BEPRIDIL HYDROCHLORIDE; VASCOR	RE30577	JUN 08, 1995		NCE	DEC 28, 1995
19002 002	BEPRIDIL HYDROCHLORIDE; VASCOR	RE30577	JUN 08, 1995		NCE	DEC 28, 1995
19002 003	BEPRIDIL HYDROCHLORIDE; VASCOR	RE30577	JUN 08, 1995		NCE	DEC 28, 1995
19807 001	BETAXOLOL HYDROCHLORIDE; KERLEDEX	4311708	JAN 19, 1999	U-3	NC	OCT 30, 1995
		4252984	FEB 24, 1998			
19807 002	BETAXOLOL HYDROCHLORIDE; KERLEDEX	4311708	JAN 19, 1999	U-3	NC	OCT 30, 1995
		4252984	FEB 24, 1998			
19982 001	BISOPROLOL FUMARATE; ZEBETA	4258062	MAR 24, 1998	U-63	NCE	JUL 31, 1997
19982 002	BISOPROLOL FUMARATE; ZEBETA	4258062	MAR 24, 1998	U-63	NCE	JUL 31, 1997
19548 001	BITOLTEROL MESYLATE; TORNALATE	4336400	JUN 22, 1999	U-5		
		4138581	FEB 06, 1998		NDF	FEB 19, 1995
19890 001	BUTORPHANOL TARTRATE; STADOL	4464378	AUG 07, 2001	U-60	NDF	DEC 12, 1994
>DLT> ~~13071 007~~	~~CHLORDIAZEPOXIDE; LIBRITABS~~	~~4316897~~	~~FEB 23, 1999~~			
>DLT> ~~13071 008~~	~~CHLORDIAZEPOXIDE; LIBRITABS~~	~~4316897~~	~~FEB 23, 1999~~			
>DLT> ~~13071 009~~	~~CHLORDIAZEPOXIDE; LIBRITABS~~	~~4316897~~	~~FEB 23, 1999~~			
>DLT> ~~14740 002~~	~~CHLORDIAZEPOXIDE; MENRIUM 5-2~~	~~4316897~~	~~FEB 23, 1999~~			
>DLT> ~~14740 004~~	~~CHLORDIAZEPOXIDE; MENRIUM 5-4~~	~~4316897~~	~~FEB 23, 1999~~			
>DLT> ~~14740 006~~	~~CHLORDIAZEPOXIDE; MENRIUM 10-4~~	~~4316897~~	~~FEB 23, 1999~~			
>DLT> ~~17813 001~~	~~CHLORDIAZEPOXIDE; LIBRELEASE~~	~~4316897~~	~~FEB 23, 1999~~			
>DLT> ~~12249 001~~	~~CHLORDIAZEPOXIDE HYDROCHLORIDE; LIBRIUM~~	~~4316897~~	~~FEB 23, 1999~~			
>DLT> ~~12249 002~~	~~CHLORDIAZEPOXIDE HYDROCHLORIDE; LIBRIUM~~	~~4316897~~	~~FEB 23, 1999~~			
>DLT> ~~12249 003~~	~~CHLORDIAZEPOXIDE HYDROCHLORIDE; LIBRIUM~~	~~4316897~~	~~FEB 23, 1999~~			
>DLT> ~~12301 001~~	~~CHLORDIAZEPOXIDE HYDROCHLORIDE; LIBRIUM~~	~~4316897~~	~~FEB 23, 1999~~			
>DLT> ~~12750 001~~	~~CHLORDIAZEPOXIDE HYDROCHLORIDE; LIBRAX~~	~~4316897~~	~~FEB 23, 1999~~			
19847 001	CIPROFLOXACIN; CIPRO	4808583	FEB 28, 2006			
		4705789	NOV 10, 2004			
19857 001	CIPROFLOXACIN; CIPRO IN DEXTROSE 5%	4670444	OCT 01, 2002		NCE	OCT 22, 1992
		4957922	SEP 18, 2007			
		4808583	FEB 28, 2006			
		4705789	NOV 10, 2004			
19858 001	CIPROFLOXACIN; CIPRO IN SODIUM CHLORIDE 0.9%	4670444	OCT 01, 2002		NCE	OCT 22, 1992
		4957922	SEP 18, 2007			
		4808583	FEB 28, 2006			
		4705789	NOV 10, 2004			
		4670444	OCT 01, 2002		NCE	OCT 22, 1992

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	19537 002	CIPROFLOXACIN HYDROCHLORIDE; CIPRO	4670444	OCT 01, 2002	U-36	NCE	OCT 22, 1992
	19537 003	CIPROFLOXACIN HYDROCHLORIDE; CIPRO	4670444	OCT 01, 2002	U-36	NCE	OCT 22, 1992
	19537 004	CIPROFLOXACIN HYDROCHLORIDE; CIPRO	4670444	OCT 01, 2002	U-36	NCE	OCT 22, 1992
	19992 001	CIPROFLOXACIN HYDROCHLORIDE; CILOXAN	4670444	OCT 01, 2002		NDF	DEC 31, 1993
>DLT>	~~17533 001~~	~~CLONAZEPAM; KLONOPIN~~	~~4316897~~	~~FEB 23, 1999~~			
>DLT>	~~17533 002~~	~~CLONAZEPAM; KLONOPIN~~	~~4316897~~	~~FEB 23, 1999~~			
>DLT>	~~17533 003~~	~~CLONAZEPAM; KLONOPIN~~	~~4316897~~	~~FEB 23, 1999~~			
	18713 001	CLOTRIMAZOLE; MYCELEX				I-81	SEP 29, 1995
	20118 001	DESFLURANE; SUPRANE	4762856	AUG 09, 2005	U-67	NCE	SEP 18, 1997
>ADD>	20071 001	DESOGESTREL; DESOGEN				NC	DEC 10, 1995
>ADD>	20071 002	DESOGESTREL; DESOGEN				NC	DEC 10, 1995
>ADD>	20301 001	DESOGESTREL; ORTHO-CEPT				NC	DEC 10, 1995
>ADD>	20301 002	DESOGESTREL; ORTHO-CEPT				NC	DEC 10, 1995
>DLT>	~~13263 002~~	~~DIAZEPAM; VALIUM~~	~~4316897~~	~~FEB 23, 1999~~			
>DLT>	~~13263 004~~	~~DIAZEPAM; VALIUM~~	~~4316897~~	~~FEB 23, 1999~~			
>DLT>	~~13263 006~~	~~DIAZEPAM; VALIUM~~	~~4316897~~	~~FEB 23, 1999~~			
>DLT>	~~16087 001~~	~~DIAZEPAM; VALIUM~~	~~4316897~~	~~FEB 23, 1999~~			
>DLT>	~~18179 001~~	~~DIAZEPAM; VALRELEASE~~	~~4316897~~	~~FEB 23, 1999~~			
	20037 001	DICLOFENAC SODIUM; VOLTAREN	4960799	OCT 02, 2007		NDF	MAR 28, 1994
	20154 002	DIDANOSINE; VIDEX				D-18	SEP 25, 1995
	20154 003	DIDANOSINE; VIDEX				D-18	SEP 25, 1995
	20154 004	DIDANOSINE; VIDEX				D-18	SEP 25, 1995
	20154 005	DIDANOSINE; VIDEX				D-18	SEP 25, 1995
	20155 003	DIDANOSINE; VIDEX				D-18	SEP 25, 1995
	20155 004	DIDANOSINE; VIDEX				D-18	SEP 25, 1995
	20155 005	DIDANOSINE; VIDEX				D-18	SEP 25, 1995
	20155 006	DIDANOSINE; VIDEX				D-18	SEP 25, 1995
	20156 001	DIDANOSINE; VIDEX				D-18	SEP 25, 1995
	20027 001	DILTIAZEM HYDROCHLORIDE; CARDIZEM				NCE	NOV 05, 1992
	20027 002	DILTIAZEM HYDROCHLORIDE; CARDIZEM				NCE	NOV 05, 1992

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20062 001	DILTIAZEM HYDROCHLORIDE; CARDIZEM CD	5002776	MAR 26, 2008		NCE	NOV 05, 1992
			4894240	JAN 16, 2007		NS	MAY 29, 1995
						I-79	OCT 15, 1995
	20062 002	DILTIAZEM HYDROCHLORIDE; CARDIZEM CD	5002776	MAR 26, 2008		NCE	NOV 05, 1992
			4894240	JAN 16, 2007		NP	DEC 27, 1994
						I-79	OCT 15, 1995
	20062 003	DILTIAZEM HYDROCHLORIDE; CARDIZEM CD	5002776	MAR 26, 2008		NCE	NOV 05, 1992
			4894240	JAN 16, 2007		NP	DEC 27, 1994
						I-79	OCT 15, 1995
	20062 004	DILTIAZEM HYDROCHLORIDE; CARDIZEM CD	5002776	MAR 26, 2008		NCE	NOV 05, 1992
			4894240	JAN 16, 2007		NP	DEC 27, 1994
						I-79	OCT 15, 1995
	20092 001	DILTIAZEM HYDROCHLORIDE; DILACOR XR	4839177	JUN 13, 2006		NS	MAY 29, 1995
						NCE	NOV 05, 1992
	20092 002	DILTIAZEM HYDROCHLORIDE; DILACOR XR	4839177	JUN 13, 2006		NP	DEC 27, 1994
						NCE	NOV 05, 1992
	20092 003	DILTIAZEM HYDROCHLORIDE; DILACOR XR	4839177	JUN 13, 2006		NP	DEC 27, 1994
						NCE	NOV 05, 1992
>ADD>	19617 001	DINOPROSTONE; PREPIDIL	4680312	JUL 14, 2004		NDF	DEC 09, 1995
>ADD>			3966962	JUN 29, 1993			
	19946 001	DOXACURIUM CHLORIDE; NUROMAX	4701460	MAR 06, 2005		NCE	MAR 07, 1996
>ADD>	18651 001	DRONABINOL; MARINOL				I-85	DEC 22, 1995
>ADD>	18651 002	DRONABINOL; MARINOL				I-85	DEC 22, 1995
>ADD>	18651 003	DRONABINOL; MARINOL				I-85	DEC 22, 1995
>ADD>	19386 001	ESMOLOL HYDROCHLORIDE; BREVIBLOC	4593119	JUN 03, 2003		I-84	DEC 18, 1995
>ADD>			4387103	JUN 07, 2000	U-11	D-19	DEC 18, 1995
>ADD>	19386 002	ESMOLOL HYDROCHLORIDE; BREVIBLOC	4593119	JUN 03, 2003		I-84	DEC 18, 1995
>ADD>			4387103	JUN 07, 2000	U-11	D-19	DEC 18, 1995
	84499 001	ESTRADIOL; ESTRACE				I-76	SEP 08, 1995
	84500 001	ESTRADIOL; ESTRACE				I-76	SEP 08, 1995
	83220 001	ESTROPIPATE; OGEN .625				I-76	NOV 10, 1995
	83220 002	ESTROPIPATE; OGEN 1.25				I-76	NOV 10, 1995
	83220 003	ESTROPIPATE; OGEN 2.5				I-76	NOV 10, 1995
	83220 004	ESTROPIPATE; OGEN 5				I-76	NOV 10, 1995

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	19697 001	ETHINYL ESTRADIOL; ORTHO TRI-CYCLEN	4628051	OCT 01, 2002	U-66		
			4616006	OCT 07, 2003	U-66		
			4544554	JUL 23, 2002	U-66		
			4027019	MAY 31, 1996		NP	JUL 03, 1995
	19697 002	ETHINYL ESTRADIOL; ORTHO TRI-CYCLEN	4628051	OCT 01, 2002	U-66		
			4616006	OCT 07, 2003	U-66		
			4544554	JUL 23, 2002	U-66		
			4027019	MAY 31, 1996		NP	JUL 03, 1995
	19462 001	FAMOTIDINE; PEPCID	4283408	AUG 11, 2000		I-69	DEC 10, 1994
	19462 002	FAMOTIDINE; PEPCID	4283408	AUG 11, 2000		I-69	DEC 10, 1994
	19527 001	FAMOTIDINE; PEPCID	4283408	AUG 11, 2000		I-69	DEC 10, 1994
	19834 001	FELODIPINE; PLENDIL	4264611	APR 28, 1998		NCE	JUL 25, 1996
	19834 002	FELODIPINE; PLENDIL	4264611	APR 28, 1998		NCE	JUL 25, 1996
	20180 001	FINASTERIDE; PROSCAR	4760071	JUL 26, 2005			
			4377584	MAR 22, 2000		NCE	JUN 19, 1997
>ADD>	19960 001	FLOSEQUINAN; MANOPLAX	4552884	NOV 12, 2002	U-71		
>ADD>			4302460	NOV 24, 1998		NCE	DEC 30, 1997
>ADD>	19960 002	FLOSEQUINAN; MANOPLAX	4552884	NOV 12, 2002	U-71		
>ADD>			4302460	NOV 24, 1998		NCE	DEC 30, 1997
>ADD>	19960 003	FLOSEQUINAN; MANOPLAX	4552884	NOV 12, 2002	U-71		
>ADD>			4302460	NOV 24, 1998		NCE	DEC 30, 1997
>ADD>	19960 004	FLOSEQUINAN; MANOPLAX	4552884	NOV 12, 2002	U-71		
>ADD>			4302460	NOV 24, 1998		NCE	DEC 30, 1997
	20038 001	FLUDARABINE PHOSPHATE; FLUDARA	4357324	NOV 02, 2001		NCE	APR 18, 1996
	20101 001	FLUOXETINE HYDROCHLORIDE; PROZAC	4626549	DEC 02, 2003			
			4194009	APR 19, 1994			
			4018895	APR 19, 1994	U-12		
>DLT>	~~16721 001~~	~~FLURAZEPAM HYDROCHLORIDE; DALMANE~~	~~4316897~~	~~FEB 23, 1999~~			
>DLT>	~~16721 002~~	~~FLURAZEPAM HYDROCHLORIDE; DALMANE~~	~~4316897~~	~~FEB 23, 1999~~			
	20068 001	FOSCARNET SODIUM; FOSCAVIR	4771041	JUL 29, 1997			
			4665062	JUL 29, 1997			
			4339445	JUL 29, 1997	U-64		
			4215113	JUL 29, 1997	U-64	NCE	SEP 27, 1996
	19915 002	FOSINOPRIL SODIUM; MONOPRIL	4337201	JUN 29, 2001		NCE	MAY 16, 1996
	19915 003	FOSINOPRIL SODIUM; MONOPRIL	4337201	JUN 29, 2001		NCE	MAY 16, 1996
	20131 001	GADOTERIDOL; PROHANCE	4885363	DEC 05, 2006		NCE	NOV 16, 1997
	19661 001	GANCICLOVIR SODIUM; CYTOVENE	4507305	OCT 19, 1999	U-35	I-72	MAY 15, 1995

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20051 001	GLYBURIDE; GLYNASE	4916163	APR 10, 2007			
			4735805	APR 05, 2005		NCE	MAY 01, 1994
			3507961	APR 21, 1992		NP	MAR 04, 1995
			3507954	APR 21, 1992			
			3454635	APR 21, 1992			
			3426067	APR 21, 1992			
	20051 002	GLYBURIDE; GLYNASE	4916163	APR 10, 2007			
			4735805	APR 05, 2005		NCE	MAY 01, 1994
			3507961	APR 21, 1992		NP	MAR 04, 1995
			3507954	APR 21, 1992			
			3454635	APR 21, 1992			
			3426067	APR 21, 1992			
	20055 001	GLYBURIDE; GLUBATE				NP	MAR 04, 1995
						NCE	MAY 01, 1994
	20055 002	GLYBURIDE; GLUBATE				NP	MAR 04, 1995
						NCE	MAY 01, 1994
	19967 001	HALOBETASOL PROPIONATE; ULTRAVATE				D-1	DEC 31, 1994
	19968 001	HALOBETASOL PROPIONATE; ULTRAVATE				D-1	DEC 31, 1994
	20250 001	HALOFANTRINE HYDROCHLORIDE; HALFAN				NCE	JUL 24, 1997
						ODE	JUL 24, 1999
	19046 001	HYDROCHLOROTHIAZIDE; NORMOZIDE	4012444	MAR 15, 1994		NCE	AUG 01, 1994
	19046 002	HYDROCHLOROTHIAZIDE; NORMOZIDE	4012444	MAR 15, 1994		NCE	AUG 01, 1994
	19046 003	HYDROCHLOROTHIAZIDE; NORMOZIDE	4012444	MAR 15, 1994		NCE	AUG 01, 1994
	19046 004	HYDROCHLOROTHIAZIDE; NORMOZIDE	4012444	MAR 15, 1994		NCE	AUG 01, 1994
	19174 001	HYDROCHLOROTHIAZIDE; TRANDATE HCT	4012444	MAR 15, 1994		NCE	AUG 01, 1994
	19174 002	HYDROCHLOROTHIAZIDE; TRANDATE HCT	4012444	MAR 15, 1994		NCE	AUG 01, 1994
	19174 003	HYDROCHLOROTHIAZIDE; TRANDATE HCT	4012444	MAR 15, 1994		NCE	AUG 01, 1994
	19174 004	HYDROCHLOROTHIAZIDE; TRANDATE HCT	4012444	MAR 15, 1994		NCE	AUG 01, 1994
	19261 001	HYDROXYAMPHETAMINE HYDROBROMIDE; PAREMYD				NC	JAN 30, 1995
	20100 001	INSULIN BIOSYNTHETIC HUMAN; HUMULIN 50/50				NP	APR 29, 1995
	18735 007	IOPAMIDOL; ISOVUE-250	4001323	JAN 04, 1996		NS	JUL 06, 1995
>ADD>	19710 001	IOVERSOL; OPTIRAY 320	4396598	OCT 26, 2002	U-29	I-83	DEC 11, 1995
	19710 002	IOVERSOL; OPTIRAY 240				I-78	JUL 09, 1995
	19710 004	IOVERSOL; OPTIRAY 300	4396598	OCT 26, 2002	U-61	NS	JAN 22, 1995
	19710 005	IOVERSOL; OPTIRAY 350	4396598	OCT 26, 2002	U-62	NS	JAN 22, 1995
						I-74	JAN 22, 1995
	20083 001	ITRACONAZOLE; SPORANOX	4267179	MAY 12, 1998		NCE	SEP 11, 1997

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	19645 001	KETOROLAC TROMETHAMINE; TORADOL	4089969	MAY 16, 1997	U-55	NDF	DEC 20, 1994
						NCE	NOV 30, 1994
	19700 001	KETOROLAC TROMETHAMINE; ACULAR	4089969	MAY 16, 1997			
	08107 001	LEUCOVORIN CALCIUM; LEUCOVORIN CALCIUM				I-70	DEC 12, 1994
	08107 002	LEUCOVORIN CALCIUM; LEUCOVORIN CALCIUM				I-70	DEC 12, 1994
	08107 004	LEUCOVORIN CALCIUM; LEUCOVORIN CALCIUM				I-70	DEC 12, 1994
	08107 005	LEUCOVORIN CALCIUM; LEUCOVORIN CALCIUM				I-70	DEC 12, 1994
	19732 001	LEUPROLIDE ACETATE; LUPRON DEPOT	4917893	MAR 24, 2004			
			4849228	JUL 18, 2006			
			4728721	MAR 01, 2005			
			4677191	JUN 30, 2004			
			4652441	MAR 24, 2004			
	20011 001	LEUPROLIDE ACETATE; LUPRON DEPOT	4917893	MAR 24, 2004			
			4849228	JUL 18, 2006			
			4728721	MAR 01, 2005			
			4677191	JUN 30, 2004			
			4652441	MAR 24, 2004			
>ADD>	20182 001	LEVOCARNITINE; CARNITOR				I-86	DEC 16, 1995
>ADD>						ODE	DEC 16, 1999
>ADD>	19941 001	LIDOCAINE; EMLA	4562060	DEC 31, 2002			
>ADD>			4529601	JUL 16, 2002		NC	DEC 30, 1995
						ODE	DEC 31, 1998
	20105 001	LIOTHYRONINE SODIUM; TRIOSTAT					
	20013 001	LOMEFLOXACIN HYDROCHLORIDE; MAXAQUIN	4528287	JUL 09, 2002	U-36	NCE	FEB 21, 1997
	19487 001	LOPERAMIDE HYDROCHLORIDE; IMODIUM A-D				I-82	NOV 23, 1995
	19860 001	LOPERAMIDE HYDROCHLORIDE; IMODIUM A-D				I-82	NOV 23, 1995
	19940 001	MASOPROCOL; ACTINEX	5008294	APR 15, 2008	U-68		
			4695590	SEP 22, 2004		NCE	SEP 04, 1997
	20246 001	MEDROXYPROGESTERONE ACETATE; DEPO-PROVERA				NP	OCT 29, 1995
>ADD>	20207 001	MELPHALAN HYDROCHLORIDE; ALKERAN	4997651	MAR 05, 2008		ODE	NOV 18, 1999
	19651 001	MESALAMINE; ASACOL				NCE	DEC 24, 1992
						NDF	JAN 31, 1995
	17659 001	METAPROTERENOL SULFATE; ALUPENT				I-67	NOV 14, 1994

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	19962 001	METOPROLOL SUCCINATE; TOPROL XL	3998790	APR 08, 1992		NE	JAN 10, 1995
			3876802	APR 08, 1992			
	19962 002	METOPROLOL SUCCINATE; TOPROL XL	3998790	APR 08, 1992		NE	JAN 10, 1995
			3876802	APR 08, 1992			
	19962 003	METOPROLOL SUCCINATE; TOPROL XL	3998790	APR 08, 1992		NE	JAN 10, 1995
			3876802	APR 08, 1992			
	20208 001	METRONIDAZOLE; METROGEL				NDF	AUG 17, 1995
	20098 001	MIVACURIUM CHLORIDE; MIVACRON	4761418	AUG 02, 2005		NCE	JAN 22, 1997
	20098 002	MIVACURIUM CHLORIDE; MIVACRON IN DEXTROSE 5%	4761418	AUG 02, 2005		NCE	JAN 22, 1997
	19583 001	NABUMETONE; RELAFEN	4420639	DEC 13, 2000		NCE	DEC 24, 1996
			4061779	DEC 06, 1994	U-19		
	19583 002	NABUMETONE; RELAFEN	4420639	DEC 13, 2000		NCE	DEC 24, 1996
			4061779	DEC 06, 1994	U-19		
	19886 001	NAFARELIN ACETATE; SYNAREL				I-68	FEB 26, 1995
	20109 001	NAFARELIN ACETATE; SYNAREL	4234571	NOV 18, 1997		NCE	FEB 13, 1995
						I-68	FEB 26, 1995
>ADD>	19660 001	NEDOCROMIL SODIUM; TILADE	4760072	JUL 26, 2005			
>ADD>			4474787	OCT 02, 2001		NCE	DEC 30, 1997
	19734 001	NICARDIPINE HYDROCHLORIDE; CARDENE	3985758	OCT 12, 1995		NDF	JAN 30, 1995
						NCE	DEC 21, 1993
	20005 001	NICARDIPINE HYDROCHLORIDE; CARDENE SR	3985758	OCT 12, 1995		NDF	FEB 21, 1995
						NCE	DEC 21, 1993
	20005 002	NICARDIPINE HYDROCHLORIDE; CARDENE SR	3985758	OCT 12, 1995		NDF	FEB 21, 1995
						NCE	DEC 21, 1993
	20005 003	NICARDIPINE HYDROCHLORIDE; CARDENE SR	3985758	OCT 12, 1995		NDF	FEB 21, 1995
						NCE	DEC 21, 1993
	19983 001	NICOTINE; PROSTEP	4946853	AUG 07, 2007	U-56	NS	JAN 28, 1995
	19983 002	NICOTINE; PROSTEP	4946853	AUG 07, 2007	U-56	NS	JAN 28, 1995
	20076 001	NICOTINE; HABITROL	5016652	MAY 21, 2008		NDF	NOV 07, 1994
	20076 002	NICOTINE; HABITROL	5016652	MAY 21, 2008		NDF	NOV 07, 1994
	20076 003	NICOTINE; HABITROL	5016652	MAY 21, 2008		NDF	NOV 07, 1994
	20150 001	NICOTINE; NICOTROL				NP	APR 22, 1995
	20150 002	NICOTINE; NICOTROL				NP	APR 22, 1995
	20150 003	NICOTINE; NICOTROL				NP	APR 22, 1995

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20165 001	NICOTINE; NICODERM	5004610	APR 02, 2008			
			4144317	SEP 09, 1992		NDF	NOV 07, 1994
	20165 002	NICOTINE; NICODERM	5004610	APR 02, 2008			
			4144317	SEP 09, 1992		NDF	NOV 07, 1994
	20165 003	NICOTINE; NICODERM	5004610	APR 02, 2008			
			4144317	SEP 09, 1992		NDF	NOV 07, 1994
	20066 001	NICOTINE POLACRILEX; NICORETTE DS				NP	JUN 08, 1995
	20064 001	NITROFURANTOIN; MACROBID	4798725	JAN 17, 2006			
			4772473	SEP 20, 2005		NDF	DEC 24, 1994
	19757 001	NORFLOXACIN; CHIBROXIN	4551456	NOV 05, 2002	U-57		
	20087 001	OFLOXACIN; FLOXIN IN DEXTROSE 5%	4382892	MAY 10, 2000		NCE	DEC 28, 1995
	20087 002	OFLOXACIN; FLOXIN	4382892	MAY 10, 2000		NCE	DEC 28, 1995
	20087 003	OFLOXACIN; FLOXIN	4382892	MAY 10, 2000		NCE	DEC 28, 1995
	20087 004	OFLOXACIN; FLOXIN IN DEXTROSE 5%	4382892	MAY 10, 2000		NCE	DEC 28, 1995
	20087 005	OFLOXACIN; FLOXIN IN DEXTROSE 5%	4382892	MAY 10, 2000		NCE	DEC 28, 1995
	19715 001	OLSALAZINE SODIUM; DIPENTUM	4559330	AUG 04, 2004	U-58	NCE	JUL 31, 1995
>ADD>	20103 001	ONDANSETRON HYDROCHLORIDE; ZOFRAN	4753789	JUN 28, 2005	U-44	NDF	DEC 31, 1995
>ADD>			4695578	SEP 22, 2004			
>ADD>	20103 002	ONDANSETRON HYDROCHLORIDE; ZOFRAN	4753789	JUN 28, 2005	U-44	NDF	DEC 31, 1995
>ADD>			4695578	SEP 22, 2004			
	18841 004	OXAPROZIN; DAYPRO				NCE	OCT 29, 1997
	19828 001	OXICONAZOLE NITRATE; OXISTAT				NCE	DEC 30, 1993
						I-77	SEP 30, 1995
	20209 001	OXICONAZOLE NITRATE; OXISTAT				NP	SEP 30, 1995
						NCE	DEC 30, 1993
>ADD>	20262 001	PACLITAXEL; TAXOL				NCE	DEC 29, 1997
>ADD>	20031 001	PAROXETINE HYDROCHLORIDE; PAXIL				NCE	DEC 29, 1997
>ADD>	20031 002	PAROXETINE HYDROCHLORIDE; PAXIL				NCE	DEC 29, 1997
>ADD>	20031 003	PAROXETINE HYDROCHLORIDE; PAXIL				NCE	DEC 29, 1997
>ADD>	20031 004	PAROXETINE HYDROCHLORIDE; PAXIL				NCE	DEC 29, 1997
>ADD>	20031 005	PAROXETINE HYDROCHLORIDE; PAXIL				NCE	DEC 29, 1997

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	19775 001	PRAZOSIN HYDROCHLORIDE; MINIPRESS XL	5082668	SEP 16, 2003			
			4783337	SEP 16, 2003			
			4765989	SEP 16, 2003			
			4612008	SEP 16, 2003			
			4327725	MAY 04, 1999			
			4092315	MAY 30, 1995		NDF	JAN 29, 1995
	19775 002	PRAZOSIN HYDROCHLORIDE; MINIPRESS XL	5082668	SEP 16, 2003			
			4783337	SEP 16, 2003			
			4765989	SEP 16, 2003			
			4612008	SEP 16, 2003			
			4327725	MAY 04, 1999			
			4092315	MAY 30, 1995		NDF	JAN 29, 1995
	19157 001	PREDNISOLONE SODIUM PHOSPHATE; PEDIAPRED	4448774	MAY 15, 2001			
	19627 001	PROPOFOL; DIPRIVAN	4798846	NOV 01, 1996		I-73	DEC 31, 1994
>ADD>	20021 002	PSEUDOEPHEDRINE HYDROCHLORIDE; PSEUDOEPHEDRINE HCL	4801461	MAY 05, 2004			
>ADD>			4576604	MAR 18, 2003			
	18703 001	RANITIDINE HYDROCHLORIDE; ZANTAC 150	4521431	JUN 04, 2002		I-75	MAY 19, 1995
	18703 002	RANITIDINE HYDROCHLORIDE; ZANTAC 300	4521431	JUN 04, 2002		I-75	MAY 19, 1995
	19675 001	RANITIDINE HYDROCHLORIDE; ZANTAC	4128658	DEC 05, 1995		I-75	MAY 19, 1995
	19766 001	SIMVASTATIN; ZOCOR	4444784	APR 24, 2001	U-59	NCE	DEC 23, 1997
	19766 002	SIMVASTATIN; ZOCOR	4444784	APR 24, 2001	U-59	NCE	DEC 23, 1997
	19766 003	SIMVASTATIN; ZOCOR	4444784	APR 24, 2001	U-59	NCE	DEC 23, 1997
	19766 004	SIMVASTATIN; ZOCOR	4444784	APR 24, 2001	U-59	NCE	DEC 23, 1997
	20166 001	SODIUM THIOSULFATE; SODIUM THIOSULFATE				NCE	FEB 14, 1997
	19865 001	SOTALOL HYDROCHLORIDE; BETAPACE				NCE	OCT 30, 1997
						ODE	OCT 30, 1999
	19865 002	SOTALOL HYDROCHLORIDE; BETAPACE				NCE	OCT 30, 1997
						ODE	OCT 30, 1999
	19865 003	SOTALOL HYDROCHLORIDE; BETAPACE				NCE	OCT 30, 1997
						ODE	OCT 30, 1999
	19865 004	SOTALOL HYDROCHLORIDE; BETAPACE				NCE	OCT 30, 1997
						ODE	OCT 30, 1999
>ADD>	20080 001	SUMATRIPTAN SUCCINATE; IMITREX	5037845	AUG 06, 2008	U-72	NCE	DEC 28, 1997
	20063 001	TECHNETIUM TC-99M RED BLOOD CELL KIT; RBC-SCAN				NP	JUN 11, 1995
	19785 001	TECHNETIUM TC-99M SESTAMIBI KIT; CARDIOLITE				I-80	SEP 09, 1995
	20043 003	TEMAFLOXACIN HYDROCHLORIDE; OMNIFLOX	4730000	MAR 08, 2005	U-36	NCE	JAN 30, 1997
	20043 004	TEMAFLOXACIN HYDROCHLORIDE; OMNIFLOX	4730000	MAR 08, 2005	U-36	NCE	JAN 30, 1997

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20119 001	TENIPOSIDE; VUMON				NCE	JUL 14, 1997
						ODE	JUL 14, 1999
>ADD>	20192 001	TERBINAFINE HYDROCHLORIDE; LAMISIL	4775534	JUL 05, 2005	U-73	NCE	DEC 30, 1999
	19614 003	VERAPAMIL HYDROCHLORIDE; VERELAN	4863742	SEP 05, 2006	U-3	NDF	MAY 29, 1993
	20199 001	ZALCITABINE; HIVID	5028595	JUL 02, 2008	U-65	NCE	JUN 19, 1997
			4879277	NOV 07, 2006	U-65	ODE	JUN 19, 1999
	20199 002	ZALCITABINE; HIVID	5028595	JUL 02, 2008	U-65	NCE	JUN 19, 1997
			4879277	NOV 07, 2006	U-65	ODE	JUN 19, 1999
	19655 001	ZIDOVUDINE; RETROVIR	4837208	FEB 09, 2005			
			4833130	FEB 09, 2005		I-47	MAY 02, 1993
			4828838	FEB 09, 2005		ODE	MAR 19, 1994
			4724232	FEB 09, 2005		NCE	MAR 19, 1992
	19910 001	ZIDOVUDINE; RETROVIR	4837208	FEB 09, 2005			
			4833130	FEB 09, 2005		ODE	MAR 19, 1994
			4818538	FEB 09, 2005		I-47	MAY 02, 1993
			4724232	FEB 09, 2005		NCE	MAR 19, 1992
	19951 001	ZIDOVUDINE; RETROVIR	4837208	FEB 09, 2005			
			4833130	FEB 09, 2005		NCE	MAR 19, 1992
			4818538	FEB 09, 2005			
			4724232	FEB 09, 2005		ODE	MAR 19, 1994
>ADD>	19908 001	ZOLPIDEM TARTRATE; AMBIEN				NCE	DEC 16, 1997
>ADD>	19908 002	ZOLPIDEM TARTRATE; AMBIEN				NCE	DEC 16, 1997

*U.S. Government Printing Office: 1993 — 342-345/60006

New 13th Edition

APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

13TH EDITION

Superintendent of Documents Subscription Order Form

Order Processing Code
* 7023

Charge your order. It's easy!

MasterCard VISA

☐ **Yes,** please send me the following indicated subscriptions:

__ subscriptions of **APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS**, ADP, and the monthly Cumulative Supplements, for $55.00 per year.

1. The total cost of my order is $_____. All prices include regular domestic postage and handling and are subject to change. International customers please add 25%.

Please Type or Print

2. _____
(Company or personal name)

_____
(Additional address/attention line)

_____
(Street address)

_____
(City, State, ZIP Code)

(_____) _____
(Daytime phone including area code)

3. **Please choose method of payment.**

☐ Check payable to Superintendent of Documents
☐ GPO Deposit Account ☐☐☐☐☐☐☐☐ – ☐☐
☐ VISA or MasterCard
☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐

_____
(Credit card expiration date)

Thank you for your order!

_____
(Signature) (11/92)

4. **Mail To:** Superintendent of Documents, Government Printing Office, Washington, DC 20402-9371.
To **FAX** your charge order, call (202) 512-0019.
To charge your subscription call (202) 783-3238.